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Abstract 
This thesis explored the uptake into the freshwater shrimp (Gammarus pulex) and 
the water boatman (Notonecta glauca) of key pharmaceuticals drawn from different 
therapeutic classes and covering a range of physico-chemical properties. For one 
compound, uptake was also assessed using the freshwater snail Planobarius 
corneus. In G. pulex, bioconcentration factors (BCFs) ranged from 4.6 – 185900 and 
increased in the order moclobemide < 5-fluoruracil < carbamazepine < diazepam < 
carvedilol < fluoxetine. In N. glauca BCFs ranged from 0.1 – 1.6 and increased in 
the order 5-fluorouracil < carbamazepine < moclobemide < diazepam < fluoxetine < 
carvedilol. For P. corneus, the BCF for carvedilol was 57.3.  
The metabolism of the study pharmaceuticals in the shrimp was investigated. 
Diazepam was found to be metabolized by G. pulex and a metabolite was detected 
and tentatively identified as nordiazepam. For the other five study compounds no 
metabolites were observed and it was inferred that metabolism in G. pulex may not 
influence the BCF.  
The influence of dietary uptake was explored in the test organisms with carvedilol 
and fluoxetine. It was found that uptake from water was the predominant route of 
exposure for G. pulex but the data for N. glauca was contrasting and the exposure 
from the food was predominant. In both organisms a combination of food and water 
exposure resulted in a higher uptake of the compounds. The differences in degree 
of uptake from water across the organisms may be due to differences in mode of 
respiration, behaviour and the pH of the test system. The differences in degree of 
uptake from food across the organisms may be due to differences in feeding 
strategies. The degree of uptake of pharmaceuticals within an organism was related 
to the hydrophobicity of the pharmaceuticals.  
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Chapter 1 Uptake of pharmaceuticals in the 
environment: An introduction 
 
1.1 Introduction 
Pharmaceuticals are used extensively worldwide in therapeutics in human and 
veterinary medicine. They are a large and diverse group of chemicals with over 
3000 active ingredients being used today with different physico-chemical properties 
and modes of action (Ayscough et al., 2000, Beausse, 2004, Richman and 
Castensson, 2008). Pharmaceutical substances can be used for treating or 
preventing disease and include antibiotics, anti-inflammatories, anti-epileptics, 
cardiovascular drugs, contraceptive hormones, lipid regulators and painkillers. Due 
to their extensive use, human and animal pharmaceuticals have been frequently 
detected in the natural environment and over the past two decades have become an 
important issue for environmental scientists and regulatory agencies (Kolpin et al., 
2002, Kolpin et al., 2004, Crane et al., 2006, Kümmerer, 2010). This chapter 
provides an overview of the current published literature regarding the inputs to and 
fate of pharmaceuticals in the environment and discusses the available information 
on the uptake of pharmaceuticals in aquatic and terrestrial organisms and the 
factors and processes that influence uptake and accumulation. The Chapter also 
identifies major knowledge gaps for future research. 
Human-use pharmaceuticals are released into the environment in emissions from 
the processes involved in manufacturing, in Sewage Treatment Works (STW) 
effluent and sewage sludge and by the disposal of expired or unwanted 
pharmaceuticals in household waste or down drains (Kümmerer, 2004; Figure 1.1). 
Veterinary pharmaceuticals enter the environment directly from excretion of faeces 
or urine onto pasture, the application of manure to agricultural land or from the 
waste water and surface run-off from farming facilities (Boxall et al., 2006, Sarmah 
et al., 2006, Fisher and Scott, 2008, Cunningham et al., 2010). 
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Figure 1.1 Pathways of human pharmaceuticals into the aquatic environment 
 
STWs are thought to be an important source of pharmaceutical input into both the 
aquatic and terrestrial environments. STWs treat the wastewater from both the 
community and medical centres such as hospitals; which are thought to be a 
continual source of high concentrations of pharmaceuticals (Wilkinson, 2001, 
Kümmerer and Schuster, 2008). Many pharmaceuticals entering STWs may be 
largely removed from the effluent by microbial degradation or sorption to sludge and 
later transferred to fields as fertilizer. For example amoxicillin can be removed by up 
to 75 – 100 % depending on the season (Castiglioni et al., 2005). By contrast 
pharmaceuticals such as carbamazepine and diclofenac are removed to a lesser 
extent (< 10 % and 17 % removal respectively; Heberer, 2002). Removal by the 
STW may depend on the physicochemical properties of the pharmaceutical and may 
not be fully removed by the STW. Some of the more soluble substances may remain 
in STW effluents and sorptive pharmaceuticals may become associated with 
sewage sludge (Khan and Ongerth, 2002, Díaz-Cruz and Barceló, 2005, Jones-
Lepp and Stevens, 2007, Radjenović et al., 2009, McClellan and Halden, 2010). 
Reported STW removal efficiencies can vary greatly (Carballa et al., 2004, Choi et 
 
Humans exposed to pharmaceuticals 
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al., 2008, Ying et al., 2009, Monteiro and Boxall, 2010, Plósz et al., 2010) and the 
removal efficiency of the STW is reflected in the concentration that can be found in 
the sewage effluent which is released into fresh water. For a summary of the 
maximum concentrations in fresh waters near sewage effluent outflows the reader is 
referred to figure 1.2. The range of concentrations can be found in the original 
publication Monteiro and Boxall (2010). 
 
 
Figure 1.2 Maximum measured concentrations of pharmaceuticals; analgesics 
and anti-inflammatories (AA), antibacterials (AB), anti-depressants (AD) anti-
epileptics (AE) anti-cancer (AC) beta-blockers (BB), hormones (H) and lipid 
regulators (LR) reported in fresh waters globally between 1985 and 2005 (n=3-
43); for further information refer to Monteiro and Boxall (2010) 
 
Appreciable amounts of wastewater from STWs are applied to land during irrigation 
and as a result pharmaceuticals can be deposited into the soil environment. A study 
in Germany showed that there were substantial amounts of pharmaceuticals, 
including antibiotics, beta-blockers and anti-epileptics released onto fields during 
irrigation with STW effluent (Ternes et al., 2007, Durán-Alvarez et al., 2009). Once 
applied to land, pharmaceuticals can penetrate soils to a depth of 30 cm and 
pharmaceuticals such as carbamazepine, acetaminophen and warfarin can 
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accumulate in the soil over time (Kinney et al., 2006, Xu et al., 2009). 
Pharmaceuticals such as ibuprofen have the potential to move down the soil profile 
with percolating water and therefore have the potential to impact ground water (Xu 
et al., 2009). The more hydrophobic pharmaceutical compounds such as the 
hormone 17α-ethinylestradiol tend to be absorbed into lipid fractions of the soil 
particles or associate with the organic matter via non-ionic van der Waals 
interactions (Ternes et al., 2004). Sorptive pharmaceuticals can enter the soil 
environment from the land application of manure from treated animals, the irrigation 
of land with STW effluent or from the inappropriate disposal of expired or unwanted 
pharmaceuticals to landfill (Holm et al., 1995, Boxall et al., 2002, Carlsson et al., 
2006, Ternes et al., 2007, Schmitt and Römbke, 2008, Topp et al., 2008). Antibiotics 
residues have been detected in the soil environment at concentrations in the range 
of µg up to g kg-1 corresponding to concentrations found for pesticides (Thiele-
Bruhn, 2003). Pharmaceuticals deposited in the soil compartment can be 
transported to fresh waters after rainfall events in surface runoff (e.g. Topp et al., 
2008). 
There is now a large body of data available that show significant environmental 
concentrations of pharmaceuticals in soils and fresh waters. This may be due to the 
recent development of sensitive and powerful analytical techniques has enabled 
detection and monitoring of pharmaceuticals in environmental systems (Ankley et 
al., 2007, Quinn et al., 2008). Several monitoring studies have taken place and 
pharmaceuticals have been observed in STW effluents, fresh waters (both 
freshwater and marine), groundwaters and in drinking water (Ternes, 1998, Zuccato 
et al., 2000, Kolpin et al., 2002, Ferrari et al., 2003, Ashton et al., 2004). 
Concentrations in the aquatic environment are reported to be in the nanogram to 
microgram per litre range in STW effluent, fresh waters and groundwater (Daughton 
and Ternes, 1999, Jørgensen and Halling-Sørensen, 2000, Kümmerer, 2001). 
Concentrations in the terrestrial environment are reported to be in the microgram to 
the milligram per kilogram range in soils (Monteiro and Boxall, 2010). 
Pharmaceuticals detected in soils include antibiotics, anti-epileptics, anti-rheumatics, 
analgesics, anti-inflammatories, cardiovascular drugs, hormones, lipid regulators, 
sedatives, stimulants used for both human and animal medicines at concentrations 
in the range of 0.0006 – 2.9 mg kg−1 (Golet et al., 2002, Golet et al., 2003, Thiele-
Bruhn, 2003, Pérez-Carrera et al., 2010, Vazquez-Roig et al., 2010, Wu et al., 
2010a, Carr et al., 2011). Most pharmaceuticals found in monitoring studies were in 
soils amended with sludge from STWs or manure. However, 2.9 mg kg-1 of the 
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analgesic propyphenazone was found in soil beneath a landfill site in Croatia. Under 
these circumstances it would be expected that leaching to groundwater would occur 
depending on the soil and compounds properties (Ahel et al., 1998).  
Monitoring studies completed for the aquatic environment give information about 
specific drugs. Analysis shows detections of pharmaceuticals in fresh waters, 
groundwater, seawater and potable water (Magnér et al., 2010, Prasse et al., 2010, 
Kleywegt et al., 2011). Compounds such as the analgesic acetaminophen have 
been detected at concentrations of 10 µg L−1 in the USA (Kolpin et al., 2002), 
however pharmaceuticals have generally been detected at lower concentrations. 
Pharmaceuticals such as caffeine, metoprolol, oxazepam and carbamazepine have 
been quantified, at concentrations ranging from 4 to 210 ng L−1 in seawater 
(Magnér et al., 2010). Following on from the detection of pharmaceuticals in the 
environment, exposure of non-target organisms to these bioactive compounds is an 
area of growing concern. 
Even though pharmaceuticals are found at such low concentrations they are of 
environmental concern because they are continually released into the environment 
and their distribution is widespread, which may lead to biologically active 
concentrations in non-target species. They are designed specifically to be bio-
available, readily transported across lipid membranes and to initiate a biological 
response to achieve a therapeutic effect at low exposure concentrations (Kümmerer, 
2010). Pharmaceuticals have specific physico-chemical properties so that they 
withstand degradation in the body and perform their function; these very properties 
may lead to persistence in the environment (Kolpin et al., 2002, Ankley et al., 2007, 
Quinn et al., 2008). Genomic similarities and functionally equivalent mechanistic 
systems (for which the pharmaceutical is targeted) between organisms in the 
environment and humans and farm animals may lead to unwanted effects in non-
target organisms (Huggett et al., 2005). 
There are many studies reporting the ecotoxicological effects of pharmaceuticals, 
their metabolites and pharmaceutical mixtures in non-target organisms in the 
environment. The potency of pharmaceuticals in acute toxicity studies (e.g. Daphnia 
48 h EC50 and fish 96 h EC50 studies) is generally low and acute effects are 
generally seen at concentrations many orders of magnitude higher than the low 
concentrations found in the environment (Cunningham et al., 2006). However, due 
to the chronic nature of the exposure, there is greater concern over longer-term 
chronic effects. Effects of pharmaceuticals on endpoints such as reproductive 
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function, growth, behaviour and immunological response have been demonstrated 
in plants, invertebrates, fish and birds (Brooks et al., 2003, Cleuvers, 2004, Flaherty 
and Dodson, 2005, Brain et al., 2006, Zurita et al., 2007, Markman et al., 2008, 
Quinn et al., 2008). Pharmaceuticals that are more likely to be of concern to the 
environment are 1) those used in the greatest quantities (e.g. anti-inflammatory 
pharmaceuticals), 2) those that are the most potent to humans and animals (e.g. 
hormones like ethinylestradiol) 3) that have clear toxic effects on taxonomic groups 
that occur in the environment (e.g. antibiotics), 4) those that could act through 
similar modes of action leading to possible additive effects (e.g. serotonin reuptake 
inhibitors) and 5) those that bioconcentrate or bioaccumulate (e.g. ethinylestradiol, 
Daughton and Brooks, 2011). 
In the aquatic environment, several laboratory and field-based studies have 
demonstrated the oestrogenic effects of synthetic oestrogens, such as 
ethinylestradiol, at or below environmentally relevant concentrations (Jobling et al., 
2002, Carlsson et al., 2006, Jobling et al., 2006, Ankley et al., 2007, Ji et al., 2010). 
Research has shown that ethinylestradiol can interact with vertebrate and 
invertebrate oestrogen receptors, which can influence several endpoints such as 
reproductive behaviour, physiology and morphology, possibly leading to 
reproductive impairment (Jobling et al., 2002, Scott and Sloman, 2004, Harris et al., 
2011, Reyhanian et al., 2011). A notable example of this is a whole-lake experiment 
that showed that the addition of ethinylestradiol at environmentally relevant 
concentrations led to reproductive failure and a population level collapse of fathead 
minnow, Pimephales promelas (Kidd et al., 2007). 
Other effects arising from pharmaceutical exposure in the terrestrial environment 
have also been observed. The non-steroidal anti-inflammatory drug (NSAID), 
diclofenac, can cause renal abnormalities and kidney failure in non-target 
organisms. It was responsible for the population crash of several species of the 
Oriental White Backed vulture in the Indian subcontinent (Oaks et al., 2004). The 
impact of diclofenac on vultures arose from an unusual route of exposure: dead 
livestock, formerly treated with diclofenac, which were left for scavengers to remove, 
which introduced a toxic amount of diclofenac into the diet of the vultures (Green et 
al., 2004, Oaks et al., 2004, Shultz et al., 2004, Swan et al., 2006). In a more recent 
study on ethinylestradiol, immunological changes in birds were attributed to 
exposure as a result of feeding on contaminated invertebrates inhabiting STW filter-
beds (Markman et al., 2008). This particular study highlights that species at different 
trophic levels in the food-chain may be at risk from exposure to pharmaceuticals via 
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dietary uptake. However, while the toxic effects of some pharmaceuticals have now 
been studied, our understanding of the processes and factors influencing the 
uptake, distribution, metabolism and excretion of pharmaceuticals in organisms is 
relatively less developed. The uptake and bioaccumulation and or bioconcentration 
of pharmaceuticals has been previously reported in some aquatic organisms and 
agricultural crops (Mimeault et al., 2005, Nakamura et al., 2008, Paterson and 
Metcalfe, 2008, Redshaw et al., 2008, Boonsaner and Hawker, 2010, Fick et al., 
2010, Karnjanapiboonwong et al., 2011). The potential transfer of pharmaceuticals 
through food-chains is of concern but largely unknown (Kolpin et al., 2002, Carlsson 
et al., 2006). 
In the past five years there have been reports concentrations of pharmaceutical in 
the biological tissues of non-target organisms in the field. Laboratory research has 
shown the uptake, bioconcentration and elimination of pharmaceuticals in aquatic 
organisms. These data represent a limited number of pharmaceuticals in a limited 
number of organisms. The duration and frequency of exposure of non-target 
organisms to most pharmaceuticals is largely unknown (Daughton and Brooks, 
2011). The following section reviews the current knowledge of the uptake of 
pharmaceuticals in non-target organisms. The section will also draw on knowledge 
gained from other chemical classes to discuss the factors and processes that are 
likely to affect the uptake of pharmaceuticals into organisms and within food chains. 
 
1.2 Uptake and accumulation of pharmaceutical in non-target organisms 
Due to the continual input of pharmaceuticals into the environment, non-target 
organisms are thought to be exposed to pharmaceuticals for the duration of their 
life-cycles (Kümmerer, 2004). Pharmaceuticals are more water soluble compared to 
some of the traditional environmental pollutants such as polycyclic aromatic 
hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs), and as a consequence 
it has been assumed that they will not have the tendency to accumulate or 
biomagnify (Daughton and Brooks, 2011). However, during field monitoring and 
laboratory studies, pharmaceutical residues have been detected in biological 
tissues. While uptake of pharmaceuticals into terrestrial organisms has been 
demonstrated (Boxall et al., 2006, Redshaw et al., 2008, Boonsaner and Hawker, 
2010, Herklotz et al., Wu et al., 2010a), uptake data available for aquatic organisms 
are mostly for fish (Brown et al., 2007, Fick et al., Kallio et al., 2010, Mehinto et al., 
2010, Brozinski et al., 2011, Gomez et al.) with a few studies with aquatic plants 
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(Migliore et al., 2000, Pouliquen et al., 2009) and invertebrates (Lydy et al., 1994, 
Gomes et al., 2004). Several therapeutic groups have been detected in fish tissue, 
including anti-inflammatories and analgesics, anti-histamines and lipid regulators 
(Brooks et al., 2005, Ramirez et al., 2007, Ramirez et al., 2009, Fick et al., 2010). 
Measured concentrations in the fish body are often higher than the concentration 
found in the surrounding aquatic environment indicating that pharmaceutical 
compounds may have the potential to bioconcentrate (figure 1.3). 
The bioconcentration of pharmaceutical residues in tissue is the net result of the 
rates of uptake, biotransformation and elimination of these substances by an 
organism (Nichols et al., 2009). Uptake of compounds into an organism can occur 
by a number of processes including filtration, passive or facilitated diffusion, active 
transport or phago/pinocytosis (Table 1.1; Timbrell, 2002). There are two major 
routes of uptake namely the exchange of substance between the surrounding 
environment (e.g. water for aquatic organisms and air for terrestrial organisms) and 
the respiratory surface and possibly dermal exchange or the uptake from an 
organism’s food (McKim and Goeden, 1982, Barber, 2003, Barber, 2008, Powell et 
al., 2009). Organisms eliminate substances through biological processes such as 
respiratory exchange, metabolism and excretion via the faeces and the urine and 
growth dilution (Powell et al., 2009).  
The degree of uptake of a compound can be described by the bioconcentration 
factor or the bioaccumulation factor. The bioconcentration factor (BCF) is the ratio 
between the concentration of contaminant in the tissue of the organism and the 
concentration in the water (Barber, 2003). BCF applies when the exposure is by 
water alone but the bioaccumulation factor (BAF) applies where exposure is from 
the food and the respired media (Barber, 2008, Powell et al., 2009). Due to the 
general physicochemical properties of pharmaceuticals such as their high water 
solubility and low hydrophobicity it is interesting that some have shown a tendency 
to bioconcentrate in tissue, however, for those substances where BCFs have been 
calculated, most have a BCF of less than 1000. According to REACH (Registration, 
Evaluation and Authorization of Chemicals) the regulatory framework for chemicals 
in the European Union (EU, 2006), a chemical is considered ‘bioaccumulative’ if the 
BCF is greater than 2000, and ‘very bioaccumulative’ if the BCF if greater than 
5000. Therefore, only ibuprofen and the synthetic hormones; 17 α-ethinylestradiol 
and Levonorgestrel would be classed under REACH as bioaccumulative (Länge et 
al., 2001, Brown et al., 2007, Fick et al., 2010). 
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BCFs and tissue residue concentrations in specific tissues provide better information 
on the concentration of the contaminant at the target site compared water 
concentrations. They may give an indication of whether an adverse effect is likely to 
occur in the organism (Walker, 1990, Daughton and Brooks, 2011). In the following 
section the current information on the tissue concentrations of pharmaceuticals in 
aquatic organisms will be reviewed. The processes and factors involved in uptake, 
bioconcentration and elimination are discussed and knowledge gaps highlighted. 
 
 
Figure 1.3 Mean concentration (µg kg-1) of pharmaceuticals; analgesics and 
anti-inflammatories (AA), antidepressants (AD), lipid regulators (LR), anti-
epileptics (AE), hormones (H), anti-hypertensives (AHP) anti-psychotic (AP) 
and anti-histamines (AHS) reported in wild fish tissues (bars with standard 
deviation; n=4-51) and reported concentrations (µgL-1) in effluent and fresh 
waters (×)(Larsson et al., 1999, Brooks et al., 2005, Brown et al., 2007, Chu and 
Metcalfe, 2007, Ramirez et al., 2007, Kwon et al., 2008, Nakamura et al., 2008, 
Zhou et al., 2008, Gelsleichter, 2009, Ramirez et al., 2009, Al-Ansari et al., 2010) 
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Table 1.1 Mechanisms through which uptake across membranes can occur 
(adapted from Timbrell (2002)) 
Uptake mechanism 
Filtration Small molecules may pass through pores in membranes formed by 
protein molecules. Movement is down a concentration gradient 
Passive diffusion A first order process that describes movement of lipophilic 
compounds across a membrane down a concentration gradient. 
Factors influencing passive diffusion are described by Ficks Law: 
 
                            
 
Where K is the constant, A is the surface area, C2 is the 
concentration outside and C1 the concentration inside the 
membrane. Lipid solubility, distance, temperature and ionization 
potential and hence pH are factor in passive diffusion 
Active transport A mechanism generally for endogenous compounds such as 
nutrients that involves transport by a specific membrane carrier for 
which metabolic energy is required. This process occurs against 
concentration gradients but maybe saturated at high concentrations 
and analogue compounds may compete carriers 
Facilitated diffusion Unlike active transport no energy is required for this mechanism as it 
occurs across a concentration gradient. It is a carrier mediated 
transport and maybe saturated by high compound concentrations 
Phagocytosis / pinocytosis Invagination of the membrane to engulf compounds, droplets or 
particles, a mechanism where insoluble compounds can be 
absorbed 
 
 
1.3 Occurrence of Pharmaceuticals in Aquatic Organisms 
Table 1.2 (page 52) syntheses of the current knowledge of pharmaceutical residues 
in aquatic organisms, which will be discussed in the following sections by 
pharmaceutical class. 
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1.3.1 Analgesics and anti – inflammatory 
Major analgesics such as aspirin and paracetamol are non-opioid analgesics used 
to control pain resulting from conditions such as headaches, toothaches, and mild 
rheumatism. Opioid analgesics, sometimes known as narcotic analgesics include 
codeine and more potent pharmaceuticals such as morphine and pethidine. The 
non-steroidal anti-inflammatory drugs are a large group of analgesics (NSAIDs) 
widely used for treating rheumatic conditions and include pharmaceuticals such as 
diclofenac and naproxen (BNF, 2011). They are one of the most frequently detected 
groups of pharmaceuticals in the aquatic environment (Mehinto et al. 2010). 
In the field, Brown et al (2007), surveyed the concentrations of several NSAIDs 
including ibuprofen, diclofenac naproxen and ketoprofen in the plasma of rainbow 
trout, Oncorhynchus mykiss at three STWs. The steady state plasma concentrations 
were highest for ibuprofen (84 ng mL-1) followed by naproxen (14 ng mL-1) and 
diclofenac (12 ng mL-1) but ketoprofen was not detected. Steady state 
concentrations in the plasma were reached after 2 days following exposure to 
0.0045 ng mL-1 ibuprofen, 0.25 ng mL-1 naproxen and 2.32 ng mL-1 diclofenac. The 
main finding of this study was that the BCFs calculated for these pharmaceuticals in 
fish varied between sites despite the exposure scenarios being similar (ibuprofen 
BCF <63 – 18667, naproxen <2 – 35, diclofenac <5 - <11). Variations in 
environmental factors including temperature, dissolved organic material and the 
presence of surfactants were suggested to be responsible for the differences.  
Fick et al (2010) exposed O. mykiss to effluent from three STWs in a semi-field 
study and detected analgesics and other pharmaceuticals including diclofenac, 
ibuprofen, ketoprofen, naproxen and tramadol in the plasma of the fish. In this study 
the NSAIDs had the highest concentrations in the fish tissues compared to those of 
any of the other pharmaceuticals measured. This was a direct result of the high 
concentrations in the effluent (e.g. ibuprofen, ketoprofen and naproxen were 
detected at a concentration 103 times higher than the hormone levonorgestrel or the 
anti-hypertensive verapamil). It was found that ibuprofen bioconcentrated the most 
followed by ketoprofen, diclofenac, naproxen and tramadol (e.g. BCFs were 58, 48, 
29, 28 and 3.3 respectively). Ibuprofen has also been shown to bioconcentrate in 
adipose and muscle tissue of O. mykiss in a study by Zhang et al. (2010). In this 
study a mixture of pharmaceuticals, including several NSAIDs (e.g. naproxen, 
diclofenac and ibuprofen), was tested. Ibuprofen was detected at the highest 
concentrations of all the NSAIDs, ca 68 ng g-1 in the adipose tissue and ca 5 ng g-1 
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in the muscle, with BCFs of 1.50 and 23.69 in the muscle and adipose tissue 
respectively. By contrast naproxen and diclofenac did not accumulate in tissue.  
In the laboratory, research has been dominated by studies on diclofenac. Kallio et 
al. (2010) measured diclofenac in the bile of O. mykiss and identified several 
metabolites at environmentally relevant concentrations in waters (1.76 µg L-1). Large 
variations in the concentrations of diclofenac and its metabolites were observed in 
the bile between individual fish. No parent diclofenac was detected but was detected 
up to a maximum concentration of 110 µg L-1 in some individual fish, this was 103 
times greater than the exposure water containing 1.76 µg L-1. The BCFs calculated 
for total diclofenac (diclofenac plus its metabolites divided by water concentration) 
ranged between 320 and 950. Schwaiger et al. (2004) investigated uptake of 
diclofenac into the liver of O. mykiss and obtained BCFs of ca 700 and 2732 after a 
four week exposure to 5 and 1 µgL-1 of diclofenac respectively. The BCF for 
diclofenac determined in the field by Brown et al. (2007) are much lower in 
comparison (BCF of 5). These reported differences may be due to the type of the 
tissue sampled: Brown et al., (2007) sampled the blood plasma whereas Kallio et al. 
(2010) studied the bile and Schwaiger et al. (2004) studied liver. 
To summarise, some NSAIDs can bioaccumulate in fish tissues but there is inter- 
and intra-study variation in the literature reviewed. These variations are probably 
explained by differences in environmental conditions, exposure concentrations, the 
lipid content of the organism and the nature of the tissue sampled. Adverse effects 
such as gill and renal alterations in fish, and renal alterations in birds and mammals 
can occur at tissue concentrations found in fish (Hilton and Thomas, 2003, Ashton et 
al., 2004, Oaks et al., 2004, Schwaiger et al., 2004). The current literature shows 
that NSAIDs have the potential to cause toxic effects at the concentrations found in 
the environment. 
 
1.3.2 Antibacterial drugs 
Antibacterial drugs are widely used in modern medicine. They are pharmaceuticals 
which have a selective toxic action on single celled organisms and bacteria. 
Antibacterial drugs are used in human and veterinary medicine to treat bacterial 
infections and include compounds such as broad spectrum penicillins, beta – 
lactams and tetracyclines (Martin, 2010, Monteiro and Boxall, 2010).  
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Two studies (both laboratory and field) are available on the uptake of antibacterials 
from commercial fish farms into aquatic plants. In a field study the bryophyte, 
Fontinalis antipyretica was collected from sites in the vicinity of four fish farms and 
an STW to determine whether pharmaceuticals were present in plant tissues. 
Concentrations of oxolinic acid, florfenicol, flumequine and oxytetracycline at 
approximately 47, 120, 600 and 1000 ng g-1 respectively were detected in plant 
tissue (Pouliquen et al., 2009). Flumequine was found in 68 % of the plant samples 
tested and oxolinic acid was detected in 51 % of the samples. 
In the laboratory, Migliore et al. (2000) exposed the euryhaline aquatic weed, 
Lythrum salicaria to high aqueous concentrations (5000, 1000, 500, 100 and 50 µg 
L-1) of the flumequine. Measured concentrations in L. salicaria after 35 days 
exposure were 13,300, 8700, 700, 300 and 200 ng g-1 dry weight (pooled samples) 
respectively. These concentrations correlate in approximate BCFs in the range 2.6 
to 4. It is not clear whether a steady state was reached in the experiment and 
therefore BCFs are not unequivocal. Although most of these exposure 
concentrations were relatively high, the lowest exposure concentration was 
equivalent to concentrations measured downstream of an intensive bass farm 
(Migliore et al., 2000). 
 
1.3.3 Anti – depressants 
Antidepressants are primarily used to treat psychomotor and physiological changes 
(BNF, 2011). There are several subclasses of antidepressants including tricyclic 
antidepressants, monoamine oxidase inhibitors, serotonin reuptake inhibitors 
(SRRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs; Martin, 2010). 
Clinical depression is a common illness affecting 15 % of people in the UK and 
therefore antidepressants are widely prescribed. SSRIs are the subclass of 
antidepressants that is most frequently dispensed in the UK with 231, 459, 000 
prescriptions written in 2009 (NHS, 2011). SSRIs include citalopram, escitalopram, 
fluoxetine, fluvoxamine, paroxetine and sertraline. Due to their abundant application 
SSRIs are frequently detected in fresh waters and subsequently they are dominant 
type of antidepressant studied in the laboratory and in the field. 
Citalopram is the most prescribed SSRI in the UK but has only been studied in the 
field in the USA on two occasions. It has been detected in the tissues of wild fish at 
low levels of detection (Gelsleichter, 2009, Schultz et al., 2010) and was found in 
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half of the juvenile bull sharks, Carcharhinus leucas sampled in the Caloosahatchee 
river (Florida, USA). Bull shark plasma concentrations were in the range of 0.25 – 
0.57 ng mL-1 (Gelsleichter, 2009). In a study by Schultz et al (2010), mean 
concentrations of citalopram of between 0.01 and 0.07 ng g-1 were seen in the brain 
tissue of the white sucker fish, Catostomus commersonii (sampled from rivers in 
Colorado and Iowa). These levels were an order of magnitude lower than the 
plasma of the bull sharks.  
Fluoxetine was the first SSRI developed and is the active ingredient in Prozac 
(Wong et al., 1995). It is probably the most well-known SSRI and is the most studied 
in fish by environmental scientists. Fluoxetine has been shown to accumulate in 
different tissues including the brain, liver and muscle and concentrations can differ 
over two orders of magnitude. Field surveys have detected fluoxetine and its major 
metabolite norfluoxetine in a number of species of fish in the US and Canada since 
2005. Brooks et al (2005) was the first to report SSRIs in wild fish populations taken 
from an effluent dominated stream (Texas, USA). In this study fluoxetine was 
measured in the brain, liver and muscle of three species of fish; the Black crappie, 
Pomoxis nigromaculatus; the Blue gill, Lepomis macrochirus, and the Channel 
catfish, Ictalurus punctatus. Fluoxetine was found to accumulate in the brain of the 
three fish species with a maximum concentration of 1.58 ng g-1. Fluoxetine was 
detected in the muscle tissue but this was the lowest concentration recorded (0.11 
ng g-1). These results were consistent with whole body concentrations of fluoxetine 
in the gizzard shad, Dorosoma cepedianum and the brown bullhead, Ameiurus 
nebulosus (0.16 – 1.02 and 0.14 – 0.31 ng g-1 respectively) sampled from Hamilton 
Harbour (Canada) by Chu and Metcalfe (2007). In a recent study by Schultz et al 
(2010) fluoxetine was one of the primary antidepressants measured in fish tissues 
and was detected in fish brain tissue of the white sucker, Catostomus commersoni 
at seven out of eight sites in Boulder Creek (Colorado, USA). Mean concentrations 
(± standard deviation) ranged from 0.02 ± 0.03 – 0.6 ± 0.06 ng g-1. The highest 
recorded concentration of fluoxetine in a wild fish was reported by Ramirez et al 
(2009). This study was the most spatially diverse survey and fish were sampled in 
six states across the USA. Fluoxetine was measured in the livers of C. commersoni 
and the largemouth bass Micropterus salmoides in two states (Illinois and 
Pennsylvania), mean concentrations were 19 and 70 ng g-1 for C. commersoni and 
M. salmoides respectively. The highest concentration (80 ng g-1) recorded in C. 
commersoni was at least 49 times than the concentrations reported in other studies. 
By contrast fluoxetine was not detected in four of the six sites sampled in the same 
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study. Also, fluoxetine was under the limit of quantification (0.030 ng g-1) in the 
muscle of fish sampled at two sites downstream of STWs (Zhou et al., 2008). The 
authors suggested that recent upgrades at the STW may have enhanced the 
removal of fluoxetine from the water. Another possible contributory factor to the non-
detection of fluoxetine was the selection of muscle tissue. Brooks et al. (2005), 
reported that of all tissues tested, muscle contained the lowest concentrations of 
fluoxetine.  
Fluoxetine is one of the few antidepressants that have been studied in fish in the 
laboratory. BCFs for fluoxetine have been determined in two sub-species of 
Japanese Medaka, Oryzias latipes and O. mykiss. BCFs have been determined 
using different methods and using different tissues (muscle, adipose, whole body 
and liver tissues), at different exposure concentrations and at varying pH, which 
probably explains why the measured BCFs range over two orders of magnitude. 
Nakamura et al. (2008) determined BCFs for fluoxetine in O. latipes at different pH 
conditions. When exposed to 10 µg L-1 of fluoxetine at pH 7, 8 or 9, BCFs of 8.8, 30 
and 260 in the whole body and 330, 580 and 3100 for the liver were obtained. This 
shows that the bioconcentration of fluoxetine, which is a basic ionisable compound, 
is strongly influenced by pH. The BCF increases with increasing pH indicating that 
fluoxetine uptake is greater when the compound is in the undissociated form. Similar 
results were found for norfluoxetine, a metabolite of fluoxetine (Figure 1.4). 
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Figure 1.4 The bioconcentration of fluoxetine and its metabolite norfluoxetine 
into Oryzias latipes at differing pH values in freshwater. Data points are 
calculated log BCF values (adapted from Nakamura et al., 2008). 
 
BCFs calculated for fluoxetine in muscle and adipose tissue of O. mykiss, were 
58.98 ± 16.81 and 143.36 ± 21.50 respectively Zhang et al. (2010). O. mykiss were 
exposed to a mixture of pharmaceutical compounds for eight days (3 µg L-1 
fluoxetine but at a total pharmaceutical concentration of 1.03 g L-1). This study 
showed that fluoxetine uptake in both tissues increased continually throughout the 
exposure period but the rate of uptake differed between the tissue types. Uptake 
and clearance of fluoxetine has also been determined in O. latipes by Paterson and 
Metcalfe (2008). Fish were exposed to a mean concentration of 0.55 µg L-1 of 
fluoxetine for seven days and then transferred to clean water for twenty one days for 
clearance. The fish accumulated fluoxetine within five hours with a maximum 
concentration of 49.4 ± 6.4 ng g-1 observed in the whole body tissues at day 3 of the 
exposure. Two BCFs were estimated, a BCF of 74 was calculated from the mean 
exposure concentration and the concentration accumulated in the fish and a BCF of 
80 was calculated from a modelled uptake constant of 5.9 ± 0.5 d-1 and a clearance 
constant of 0.074 ± 0.009 d-1. The BCFs measured in this study were slightly higher 
Chapter 1 
41 
 
than those measured by Nakamura et al. (2008) for the same exposure pH range 
(7.2 – 7.5). 
Fluvoxamine has only been reported once in fish in the plasma of C. leucas sampled 
in the Caloosahatchee River (Florida, USA). Although fluvoxamine was not detected 
in any of the water samples taken it was measured at low concentrations (0.15 – 
0.90 ng mL-1) in the plasma of four out of ten sharks sampled. This study shows that 
fluvoxamine may have some potential to bioaccumulate in fish tissues (Gelsleichter, 
2009). 
Although Paroxetine has been observed on several occasions in wild fish tissues, 
there is no laboratory data on the uptake of this compound. The concentrations 
measured in wild fish are fairly consistent across the different studies, which have 
included different species and tissues and have been performed at different study 
sites. The concentrations detected ranged between 0.11 to 0.58 ng g-1 (Chu and 
Metcalfe, 2007, Gelsleichter, 2009, Schultz et al., 2010).  
The most recent detection was made by Schultz et al. (2010). Paroxetine was found 
in the brain tissue of C. commersoni at three out of eight sites. In this study mean 
concentrations of paroxetine ranged between 0.01 to 0.02 ng g-1, with a maximum 
recorded concentration of 0.113 ng g-1. Gelsleichter (2009) measured 
concentrations of 0.03-0.55 ng g-1 in the plasma of C. leucas and Chu and Metcalfe 
(2007) found paroxetine in half the fish collected from Hamilton Harbour in Canada 
at concentrations in the range of ND – 0.58 ng g-1. In the laboratory there are 
currently few studies of the toxicokinetics of paroxetine. More investigation is 
needed into the uptake of paroxetine because it has been previously documented 
that paroxetine has a high binding affinity to the serotonin transporter in the plasma 
membrane of fish, and maybe actively transported across fish cell membrane. 
Paroxetine is known to influence the serotonin levels by inhibiting serotonin uptake 
in O. mykiss (Ferriere et al., 1996). 
Sertraline, the most prescribed antidepressant in the US has been found in fresh 
waters at concentrations up to 37.5 ng L-1 and has subsequently been identified in 
wild fish. Sertraline uptake has been studied in the laboratory. Schultz et al. (2010) 
reported that sertraline concentrations (Cmax 4.24 ng g-1) in the brain of C. 
commersoni were higher compared to other antidepressants surveyed including 
citalopram and venlafaxine. This is similar to the highest sertraline concentration 
(4.27 ng g-1) found in the brain tissue of fish by Brooks et al. (2005). Brooks et al. 
(2005) also found that sertraline accumulates into the brain tissue more than in the 
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liver or in the muscle tissues. Ramirez et al. (2009) found that sertraline was 
regularly present in the liver tissue of seven different species of fish sampled in five 
different states in the U.S. The mean liver concentration ranged from 5 to 381 ng g-1. 
This can be compared to the muscle tissue of these fish, where sertraline was found 
at only two of the sampling sites at much lower concentrations of 5 – 11 ng g-1, 35 x 
lower than the liver tissue. Sertraline was also present at higher concentrations than 
any other antidepressant in the plasma of C. leucas (Gelsleichter, 2009). The 
concentrations (0.25 – 0.97 ng g-1) were lower compared to those from other 
studies.  
Fick et al. (2010) exposed O. mykiss in semi-field conditions to effluent from three 
STWs. Concentrations of sertraline were only quantifiable in the effluent from one 
STW at low concentrations (mean 8 ng L-1). Despite this sertraline was detectable in 
fish plasma at fish from two of the STWs (mean concentrations were 1.2 ng g-1 and 
1.1 ng g-1). These findings resulted in fairly large BCFs for the two STW exposures > 
240 and 138 determined using concentrations in the water and the plasma. However 
these BCFs were still lower than predicted by Fish Plasma Model (FPM; Huggett et 
al., 2003a).  
Venlafaxine is an SNRI and 2,630,500 prescriptions were dispensed in the UK in 
2011. Although it is more popular than sertraline in the UK it has rarely been studied 
in the environment (NHS, 2011). It has been detected by Gelsleichter (2009) in C. 
leucas at similar concentrations to other antidepressant detected in the sharks (ND 
– 0.32 ng g-1). It has been reported to occur at low concentrations in the brain tissue 
(ND – 0.13 ng g-1) of C. commersoni by Schultz et al. (2010). In this study, the 
authors suggested that the low levels of venlafaxine could be due to its low 
lipophilicity (logKow -0.37). 
In addition to looking for the parent pharmaceutical compound, a number of studies 
have explored the occurrence of metabolites of anti-depressants in aquatic 
organisms. The metabolites of fluoxetine and sertraline have been identified in fish; 
both norsertraline and norfluoxetine have accumulated in wild fish tissues and the 
biotransformation of fluoxetine to norfluoxetine in fish has been demonstrated in the 
laboratory. In general it has been shown that the metabolites of antidepressants 
such as norfluoxetine and norsertraline have longer half –lives than the parent 
compound which allows them to accumulate to a greater extent. This has been 
demonstrated in the field (Brooks et al., 2005, Chu and Metcalfe, 2007, Gelsleichter, 
2009, Ramirez et al., 2009, Schultz et al., 2010) and in laboratory studies 
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(Nakamura et al., 2008, Paterson and Metcalfe, 2008). For example Schultz et al. 
(2010) observed maximum concentrations as high as 3.58 and 28.9 ng g-1 for 
norfluoxetine and norsertraline which were 2.5 and 7 times higher than the 
concentrations of the parent compounds fluoxetine and sertraline (Cmax 1.68 and 
4.24 ng g-1 respectively). In the laboratory, Paterson and Metcalfe (2008) showed 
that norfluoxetine was formed in fish after 5 hours exposure to 0.55 µg L-1 of 
fluoxetine. At 5 hours exposure, the norfluoxetine concentration was approximately 
40 % of the parent fluoxetine concentration. The concentration of the metabolite was 
lower than that of the parent until after 7 days when norfluoxetine concentrations 
exceeded fluoxetine concentrations. The maximum concentration observed for 
norfluoxetine was 64.3 ng g-1 compared to 49.4 ng g-1 for the parent fluoxetine. A 
pseudo BCF of 74 was calculated using the measured concentration of norfluoxetine 
in the fish compared to the average fluoxetine concentration in the water. The 
detection of both parent and metabolite SSRIs in fish may indicate equivalent 
metabolic pathways between fish and mammals. 
In general the literature suggests that tissue concentrations and BCFs for SSRIs 
and antidepressants can range over several orders of magnitude. Factors such as 
the analytical methods used, exposure concentration, pH, organisms differences 
and metabolic processes can influence the concentrations found. It is also important 
to recognise the anti-depressants do not necessarily occur in organisms as 
individual residues but can occur with a cocktail of other anti-depressants, other 
pharmaceuticals and other chemical classes (Schultz et al., 2010). It is possible that 
uptake, metabolism and clearance of mixtures will differ compared to single 
substances and this is an area where further research is required. 
 
1.3.4 Anti-epileptics 
Anti-epileptic medicines such as carbamazepine prevent or reduce the severity of 
seizures in various types of epilepsy. Some anti-epileptics prevent neurons firing 
rapidly (e.g. carbamazepine, lamotrigine). Others (e.g. barbiturates, benzodiazepine, 
vigabatrin) enhance the function of inhibitory synapses and some have multiple 
actions (BNF, 2009). Anti-epileptics are widely used and 14,011,600 prescriptions 
were dispensed in the UK in 2009 (NHS, 2011). Carbamazepine is one of the most 
highly dispensed anti-epileptic and is one of the more commonly found in final 
sewage effluent and surfaces waters (Monteiro and Boxall, 2010). Subsequently 
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carbamazepine has been studied in fish, invertebrates and algae in field and the 
laboratory.  
Ramirez et al. (2007) detected carbamazepine at concentrations of 0.83 – 1.44 ng g-
1 in muscles tissue of O. mykiss collected from Pecan Creek in Texas. Ramirez et 
al. (2009) also detected carbamazepine at 2.3 and 6 ng g-1 in the muscle and liver of 
M. salmoides. The maximum concentration of carbamazepine detected was 8 ng g-1 
in the liver tissues. By contrast Zhou et al. (2009) did not detect carbamazepine in 
fish collected from three STW impacted rivers in Canada. Similarly Kwon et al 2009 
did not detect carbamazepine in the liver tissue of turbot, Pleuronichthys verticalis 
collected from Californian coastal waters, a coastal not riverine study.  
In a semi-field study (Fick et al., 2010) exposed O. mykiss, to STW effluent from 
three treatment plants in Sweden and showed accumulation of carbamazepine in 
their plasma. The mean concentration measured ranged between 0.3 and 1.0 ng g-1 
and the calculated BCFs ranged from 0.8 – 4.2. These concentrations are in the 
range of those found by Ramirez et al. (2007) in the field. However, the BCF are 
slightly higher than the BAFs determined by Zhou et al. (2008). Zhou et al. (2008) 
carried out bioaccumulation experiments in fish muscle in the laboratory. BAFs of 
0.44 and 0.22 were determined after 7 and 14 days exposure respectively. The 
lower BAF (following a longer exposure to carbamazepine) may reflect metabolic 
capacity of O. mykiss for carbamazepine. 
Tissue specific accumulation has been identified for carbamazepine. 
Carbamazepine was shown to accumulate more in the adipose tissue than the 
muscle tissue (Zhang et al., 2010). Zhang et al. (2010) calculated a BCF of 0.52 for 
muscle tissue of O. mykiss which was similar to the BAF in the study by Zhou et al. 
(2008). Zhang et al. (2010) also calculated a BCF of 4.16 in the adipose tissue of O. 
mykiss. The adipose tissue in this study has a larger BCF than the muscle tissue 
which may be due to tissue specific accumulation, possibly a function of lipophilicity. 
Carbamazepine has been studied over a wider diversity of taxonomic groups 
compared to other pharmaceuticals; in addition to fish, both invertebrates and algae 
have also been investigated. For example Lajeunesse et al. (2009) validated a 
method which allowed detection of carbamazepine in invertebrates and measured a 
concentration of 129 ± 57 ng g-1 in the crustacean, Thamnocephalus platyurus. This 
method was employed for the detection of the accumulation of carbamazepine in 
organisms at different trophic levels. Vernouillet et al. (2010) showed that the algae, 
Pseudokirchneriella subcapitata can accumulate carbamazepine to a concentration 
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of 10.2 ng g-1 when exposed to 0.15 ng mL-1. A crustacean, T. platyurus fed the 
exposed algae accumulated carbamazepine from the food to a maximum 
concentration of 128.6 ng g-1. However, when a cnidarian, Hydra attenuata was fed 
the crustacean, negligible accumulation was observed. BAFs for P. subcapitata and 
T. platyurus were 2.2 and 12.6 respectively. In another study concerning algae, 
Andreozzi et al. (2002) found that carbamazepine was not accumulated by the 
algae, Selenastrum capricornutum and Ankistrodesmus braunii which contradict the 
findings of Vernouillet et al. (2010). 
To date carbamazepine is the only antiepileptic compound to be studied in non-
target organisms. So far research has shown that carbamazepine can accumulate in 
fish, invertebrates and algae and there is also the potential for it to be metabolised 
by non-target organisms. More work should be carried out into the potential 
accumulation of carbamazepine in algae as they are a primary food resource for 
many other organisms. Preliminary work shows that there may be the potential for 
transfer through the food-chain but again more research is needed. 
 
1.3.5 Anti-histamine 
Although detections of anti-histamine medicines are not well documented in fresh 
waters and sewage effluents, there have been a number of detections in the tissues 
of wild fish. Ramirez et al. (2007) found diphenhydramine present in the muscle 
tissue of fish sampled from Pecan Creek Texas with concentrations ranging 
between 0.66 and 1.32 ng g-1. In a more recent study, Ramirez et al. (2009) 
conducted a survey of fish from Chicago, Dallas, Phoenix and West Chester. Mean 
concentrations of diphenhydramine were detected in all rivers at concentrations that 
ranged from 0.13 to 0.15 ng g-1 in the muscle and at 0.5 to 10 ng g-1 in the liver 
tissue. Zhou et al. (2008) detected diphenhydramine at concentrations of 0.032 ± 
0.005 and 0.081.63 ± 0.008 ng g-1 in C. commersoni and the Johnny darter 
(Etheostoma nigrum) respectively. These concentrations were approximately one 
order of magnitude lower than those found by Ramirez et al. (2007), (2009). Zhou et 
al. (2008) did not detect more commonly found pharmaceuticals such as 
carbamazepine and fluoxetine, therefore the lower concentrations detected of 
diphenhydramine compared to other studies might be explained by recent upgrades 
at the STWs in the study area. 
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Other anti-histamine compounds have also been detected in fish tissues. In a semi-
field study, Fick et al. (2010) exposed O. mykiss to STW effluent and reported 
detectable levels of meclizine in the plasma of the fish. Three exposures were 
maintained and each had effluent from three different STWs in Sweden. Meclizine 
was not detected in any of the exposure effluents in the study by Fick et al. (2010) 
but was found in fish tissues at concentrations of 0.1 to 0.7 ng g-1 in two out of three 
exposures. This may indicate bioaccumulation potential for meclizine in fish tissues. 
Minimum BCFs of > 200 and > 1400 were calculated using the LOQ for meclizine in 
the absence of measured water concentrations. These were both lower than the 
BCF of 2521 predicted by the FPM. 
 
1.3.6 Cardiovascular drugs 
Cardiovascular medicines are generally prescribed to treat high blood pressure 
angina, glaucoma and other related conditions, they include thiazide diuretics, the 
pyridazine angiotensin-converting enzyme (ACE) inhibitors, the calcium channel 
blockers, the beta blockers, and the angiotensin II receptor antagonists or ARBs 
(BNF, 2009). 
The ACE inhibitor, cilazapril and the calcium channel blocker, diltiazem were 
detected by Fick et al. (2010) when O. mykiss were exposed to effluent from three 
different STWs in Sweden. Cilazapril was below the level of quantification in the 
three exposure effluents, however detectable concentrations were found in the fish 
plasma of 0.1 and 0.7 ng g-1. This may indicate bioaccumulation and BCFs of > 100 
and > 700 were calculated, which were 17 – 117 times greater than the predicted 
BCF of 6. The literature suggests that factors in addition to the log Kow are important 
for bioaccumulation (Fick et al., 2010). 
Diltiazem is the most commonly detected cardiovascular drug and has been 
reported in wild fish tissue by a number of researchers including Fick et al. (2010). 
Concentrations ranged from 0.002 to 0.7 ng g-1, with a mean concentration of 0.9 ng 
g-1 in the plasma of fish and a calculated BCF of 24. There were three semi-field 
sites in the study and only one out of the three exposures showed bioaccumulation 
in the fish plasma, despite all having similar exposure concentrations. These results 
show high variation between the fish. 
Diltiazem has been found at concentrations similar to those recorded by Fick et al. 
(2010) in wild fish in other studies. Ramirez et al. (2009) recorded diltiazem 
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concentrations ranging from 0.13 to 0.15 ng g-1 in the muscle and 0.3 to 0.7 ng g-1 in 
the liver tissue of M. salmoides. Ramirez et al. (2007) detected concentrations of 
between 0.11 and 0.27 ng g-1 in the muscle of Lepomis species. Zhou et al. (2008) 
measured diltiazem in fish at concentrations that were two orders of magnitude 
lower at 0.002 and 0.0056 ng g-1 in C. commersoni and E. nigrum respectively. 
Although these concentrations were lower than those found by other researchers, 
diltiazem was one of few pharmaceuticals detected by Zhou et al. (2008) most likely 
due to enhanced STW technology at this site. Therefore, it could be expected that 
the concentrations found by Zhou et al. (2008) are not typical for diltiazem in the 
field. 
Beta blockers such as propranolol and atenolol have not been detected in wild fish 
tissues but have been studied in the laboratory (Winter et al., 2008, Owen et al., 
2009, Ramirez et al., 2009). Owen et al. (2009) measured the uptake of propranolol 
into the plasma of the fish O. mykiss after exposure to 0.1, 1, 10, 100, 1000 and 
10,000 µg L-1 for forty days. At the lowest exposure concentration, propranolol was 
measured at 0.94 ng g-1 (pooled sample) in the plasma of exposed fish. At the 
highest exposure concentration, plasma propranolol reached a mean concentration 
of 5,200 ± 1,333 ng g-1. This study showed that propranolol plasma concentrations 
could reach similar concentrations to the exposure concentration; however this 
relationship was variable ranging between approximately 16 - 94 % of the exposure 
concentration. In this study the authors were able to predict plasma concentrations 
from the water concentrations using the mammalian fish leverage model (Huggett et 
al., 2004). A relationship between predicted and measured plasma concentration 
was obtained and 59 % of the measured concentration could be explained by the 
predicted values. 
Winter et al. (2008) studied the plasma concentration of atenolol in fathead minnow, 
Pimephales promelas. Aqueous concentrations were 100, 320, 1000, 3200 and 
10,000 µg L-1. In the male fish atenolol concentrations ranged from 4.2 ng g-1 when 
exposed to 100 µg L-1, to 164.3 ng g-1 when exposed at the highest concentration. 
For female fish concentrations ranged from < 0.5 ng g-1 when exposed to 100 µg L-1, 
to 291 ng g-1 when exposed at the highest concentration. Plasma atenolol 
concentrations were between 1.8 and 6.2 % (males) and between 0 and 12.2 % 
(females) of the exposure concentrations. These plasma concentrations relative to 
the corresponding water concentrations were less than those found by Owen et al. 
(2009) which shows the variability of plasma concentrations between beta-blockers.  
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The literature for cardiovascular drugs shows that compounds such as cilazapril 
could potentially be bioaccumulative in fish and that accumulation may involve 
processes other than passive diffusion. However, at the concentrations found in the 
surfaces waters, cardiovascular drugs such as propranolol would be expected to 
give rise to only pg g-1 concentrations in fish plasma, which is several orders of 
magnitude lower than the therapeutic dose (Owen et al., 2009). Cardiovascular 
compounds are expected to occur in the environment in mixtures and additive 
effects for compounds with similar modes of action have to be considered. 
 
1.3.7 Lipid regulators 
Lipid regulating agents are medicines that lower the concentrations of lipoproteins, 
the agents that transport cholesterol and triglycerides, in blood (BNF, 2009). There 
are several types of lipid regulators including fibric acid derivatives (e.g. gemfibrozil), 
statins (e.g. simvastatin) and niacin (e.g. vitamin B). Bioaccumulation of lipid 
regulators in fish has been studied in the field and the laboratory. Ramirez et al 
(2009) found gemfibrozil in the liver tissue of C. commersoni and the Koi carp, 
Cyprinus carpio from the field. Liver concentrations were 27.1 and 70 ng g-1 for C. 
commersoni and C. carpio respectively. This was an order of magnitude less than 
the concentration found in O. mykiss in a semi-field study by Brown et al (2007) 
caged O. mykiss in the effluent outflow channel of Gryaab STW in Sweden for 16 
days. Gemfibrozil accumulated to a concentration of 210 ng g-1 in the plasma of the 
fish. Fish were also caged at Gråbo and Spenshult STWs, but gemfibrozil was not 
detected in the fish at these sites. This may be a result of the exposure 
concentration as the gemfibrozil concentration was two times lower at Gråbo and 
Spenshult compared to Gryaab STW (e.g. 0.5 ng mL-1 compared to 1.0 ng mL-1 at 
Gryaab). Another lipid regulator, simvastatin was investigated in the field at a marine 
site by Kwon et al (2008). In this study simvastatin was below the limit of detection 
(< 12.3 ng g-1) in all ten fish livers sampled. 
Gemfibrozil is the only lipid regulating compound to have been studied in fish in the 
laboratory. In a study by Zhang et al (2010) the uptake of gemfibrozil was observed 
in O. mykiss. The fish were exposed to a mixture of pharmaceuticals. The total 
pharmaceutical concentration was 1.0 g L-1 and the individual compound 
concentration was 3 µg L-1. The uptake of individual compounds was monitored in 
the adipose tissue and the muscle tissue of the fish. The concentration of 
gemfibrozil reached a maximum of ca 54 ng g-1 in the adipose and 0.8 ng g-1 in the 
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muscle tissue after 8 and 6 days respectively. BCFs of 20.75 in the adipose and 0.4 
in the muscle tissue were calculated. 
Another study that explored the bioconcentration of gemfibrozil in fish was 
conducted by Mimeault et al. (2005). Goldfish, Carassius auratus were exposed for 
fourteen days to both 1.5 and 1500 µg L-1 gemfibrozil. Plasma concentrations of the 
goldfish reached 170 ± 20 and 78,000 ± 5000 ng g-1 with corresponding BCFs of 89 
and 16 at the low and high concentration exposures respectively. After the 
observation that gemfibrozil could bioconcentrate in goldfish, the authors 
investigated whether gemfibrozil could be taken up from tap water. Although 
gemfibrozil was not detected in the water used to hold the goldfish (dechlorinated 
tap water), it was detected at low concentrations in the control fish after 14 days. 
This highlights that the exposure concentration in the water is not indicative of the 
concentrations in the fish and that there is potential for lipid regulators to accumulate 
in fish tissues even at very low exposure concentrations (Mimeault et al., 2005). 
 
1.3.8 Synthetic hormones  
The bioconcentration of synthetic hormones and their metabolites has been 
documented in several different species of fish (in both field and laboratory studies) 
and invertebrates. In a study by Al-Ansari et al. (2010), 50 % of the Shorthead 
Redhorse Suckers (Moxostoma macrolepidotum) sampled downstream of a STW 
discharge were found to contain 17 α-ethinylestradiol in their bile. Houtman et al. 
(2004) reported 17 α-ethinylestradiol at concentrations of 17 ng mL-1 in the bile of 
wild bream (Abramis brama). It has also been documented that when O. mykiss are 
exposure to 100 % effluent from STWs the concentration of the synthetic hormone 
levonorgestrel in the plasma of the fish exceeded the human therapeutic 
concentration by a factor of 4 (Fick et al., 2010). 
Oestrogens, androgens and progestins are known to act as reproductive 
pheromones in fish at nanogram per litre concentrations and have been linked to a 
multitude of reproductive abnormalities in fish such as the promotion of vitellogenin 
synthesis and development of secondary sexual characteristics. The synthetic 
hormone 17 α-ethinylestradiol and naturally occurring hormones such as 17 β-
estradiol are thought to contribute to these effects (Sumpter and Jobling, 1995, 
Jobling et al., 1998, Houtman et al., 2004). As all oestrogenic chemicals act on the 
same receptors it is likely that their effects are additive manner and therefore will 
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cause pharmacological effects in fish downstream of STWs (Fick et al., 2010). It has 
been concluded in a number of papers that it is possible for synthetic hormones to 
accumulate (Larrson 1999; Houtmann et al 2004; Gelsleichter, 2009; Fick et al 
2010), this is also supported and by the analyses in this paper. Also, it is likely that 
some will bioconcentrate to concentrations close to the human therapeutic levels 
(Fick et al., 2010). 
 
1.3.9 Other pharmaceuticals 
Anxiolytic compounds and their metabolites have been identified in final effluents 
and fresh waters (Monteiro and Boxall, 2010) and recently in fish (Kwon et al., 
2008). Kwon et al. (2008) analysed the livers of marine fish, P. verticalis for a 
number of pharmaceuticals. The fish were collected from the sites near to ocean 
discharges of wastewater effluent. Diazepam was detected in the liver tissue of all 
ten fish samples. Concentrations of diazepam were in the range 23 to 45 ng g-1 in 
females and 58 to 110 ng g-1 for males. Oxazepam (an active metabolite of 
diazepam but also an pharmaceutical in its own right) was detected in all fish in the 
study by Fick et al. (2010). Despite the high exposure concentrations (701 to 881 ng 
L-1) the concentration of oxazepam (0.2 to 0.7 ng g-1) in fish plasma was low, with 
calculated BCFs of 0.7, 3.5 and 3.6. 
Psycho-active pharmaceuticals are a large group of pharmaceuticals including 
antidepressants discussed earlier in section 1.3.3 on page 37. Anti – psychotic 
medicines used as tranquilizers in the treatment of schizophrenia and delirium (BNF, 
2009). Fick et al. (2010) detected psycho-active pharmaceuticals in the plasma of O. 
mykiss when the fish were exposed to STW effluent. In the semi-field exposure, O. 
mykiss accumulated 1.2 ng g-1 of haloperidol and 0.3 – 2.4 ng g-1 of risperidone in 
the plasma. Haloperidol was present at detectable concentrations in the effluent at a 
maximum concentration of 374 ng L-1, but risperidone was below the detection limit 
in the effluent and therefore may be accumulating in fish.  
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Memantine is drug used for the treatment of dementia specifically for Alzheimer’s 
disease and was also detected in the fish by Fick et al. (2010). Plasma 
concentrations of 2.3 ng g-1 in O. mykiss were recorded after exposure to 14 ng L-1 
of memantine. The concentration of memantine in fresh waters in the U.K. will be 
lower than the USA and as the National Institute for Clinical Excellence does not 
recommend its use and it contributes only 4 % of the total medicines prescribed for 
dementia (NICE, 2009). Other psycho active pharmaceuticals such as caffeine and 
paraxanthine as well as those from other classes have not been detected in fish 
tissues (Ramirez et al., 2009). 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Analgesic & Anti-inflammatory 
Fish 
ibuprofen Oncorhynchus mykiss laboratory Muscle ca 5 1.50 ± 0.25 Zhang et al., 2010 
ibuprofen Oncorhynchus mykiss laboratory adipose  ca 68 23.69 ± 2.23 Zhang et al., 2010 
ketoprofen Oncorhynchus mykiss laboratory plasma 15 – 107 3.5 – 48 Fick et al., 2010 
naproxen Oncorhynchus mykiss field plasma < LOQ – 14 < 2 – 56 Brown et al., 2007 
naproxen Oncorhynchus mykiss laboratory plasma 33 – 46 22 – 28 Fick et al., 2010 
tramadol Oncorhynchus mykiss laboratory plasma 1.1 – 1.9 2.3 – 3.3 Fick et al., 2010 
Analgesic & Anti-inflammatory Metabolites 
4’- hydroxydiclofenac Oncorhynchus mykiss laboratory bile 20 – 70  Kallio et al., 2010 
5 - hydroxydiclofenac Oncorhynchus mykiss laboratory bile nd – 40  Kallio et al., 2010 
acyl glucuronide of diclofenac Oncorhynchus mykiss laboratory bile nd – 220  Kallio et al., 2010 
acyl glucuronide  Oncorhynchus mykiss laboratory Bile ca 290 – ca 620  Kallio et al., 2010 
 
  
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Analgesic & Anti-inflammatory 
Fish 
acyl glucuronide of 5- hydroxydiclofenac Oncorhynchus mykiss laboratory bile ca 90 – ca 400  Kallio et al., 2010 
acyl glucuronide of 3’- hydroxydiclofenac Oncorhynchus mykiss laboratory bile nd – ca 120  Kallio et al., 2010 
ether glucuronide of 4’- hydroxydiclofenac Oncorhynchus mykiss laboratory bile nd – ca 40  Kallio et al., 2010 
sulphate conjugate of 5 - hydroxydiclofenac Oncorhynchus mykiss laboratory bile ca 20 – ca 50  Kallio et al., 2010 
Anti-biotic 
Plants 
florfenicol Fontinalis antipyretica field whole body ca 120  Pouliquen et al., 2009 
flumequine Fontinalis antipyretica field whole body ca 600  Pouliquen et al., 2009 
flumequine Lythrum salicaria laboratory whole body 200 – 13300  Migloire et al., 2000 
 
  
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Anti-biotic 
Plants 
oxolinic acid Fontinalis antipyretica field whole body 47  Pouliquen et al., 2009 
oxytetracyline Fontinalis antipyretica field whole body ca 1000  Pouliquen et al., 2009 
Anti-depressant 
Fish 
citalopram Carcharhinus leucas  field plasma ND – 0.57  Gelsleichter 2009 
citalopram Catostomus commersonii field brain ND – 0.21  Schultz et al., 2010 
fluoxetine Three fish species field brain 1.58 ± 0.74  Brook et al., 2005 
fluoxetine Three fish species field liver 1.34 ± 0.65  Brook et al., 2005 
fluoxetine Three fish species field muscle 0.11 ± 0.03  Brook et al., 2005 
fluoxetine Dorosoma cepedianum field whole body 0.16 – 1.02  Chu and Metcalfe 2007 
fluoxetine Ameiurus nebulosus field whole body 0.14 – 0.31  Chu and Metcalfe 2007 
fluoxetine Micropterus salmoides field liver 19  Ramirez et al., 2009 
fluoxetine Catostomus commersonii field liver 70  Ramirez et al., 2009 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Anti-depressant 
Fish 
fluoxetine Catostomus commersonii field brain ND – 1.65  Schultz et al., 2010 
fluoxetine Oryzias latipes laboratory whole body  8.8 Nakamura et al., 2008 
fluoxetine Oryzias latipes laboratory whole body  30 Nakamura et al., 2008 
fluoxetine Oryzias latipes laboratory whole body  260 Nakamura et al., 2008 
fluoxetine Oryzias latipes laboratory liver  330 Nakamura et al., 2008 
fluoxetine Oryzias latipes laboratory liver  580 Nakamura et al., 2008 
fluoxetine Oryzias latipes laboratory liver  3100 Nakamura et al., 2008 
fluoxetine Oryzias latipes laboratory whole body 49.4 ± 6.4 74 – 80 Paterson and Metcalfe 2008 
fluoxetine Oncorhynchus mykiss laboratory muscle  58.98 ± 16.81 Zhang et al., 2010 
fluoxetine Oncorhynchus mykiss laboratory adipose   143.36 ± 21.50 Zhang et al., 2010 
fluvoxamine Carcharhinus leucas  field plasma ND – 0.9  Gelsleichter 2009 
paroxetine Dorosoma cepedianum field whole body ND – 0.58  Chu and Metcalfe 2007 
paroxetine Ameiurus nebulosus field whole body ND – 0.48  Chu and Metcalfe 2007 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Anti-depressant 
Fish 
paroxetine Carcharhinus leucas  field plasma ND – 0.55  Gelsleichter 2009 
paroxetine Catostomus commersonii field brain ND – 0.11  Schultz et al., 2010 
sertraline Three fish species field brain 4.27 ± 1.4  Brooks et al., 2005 
sertraline Three fish species field liver 3.59 ± 1.67  Brooks et al., 2005 
sertraline Three fish species field muscle 0.34 ± 0.09  Brooks et al., 2005 
sertraline Carcharhinus leucas  field plasma ND – 0.97  Gelsleichter 2009 
sertraline Cyprinus carpio field muscle 5.0  Ramirez et al., 2009 
sertraline Catostomus commersonii field muscle 11  Ramirez et al., 2009 
sertraline Micropterus salmoides field liver 84  Ramirez et al., 2009 
sertraline Ictiobus bubalus field liver 27  Ramirez et al., 2009 
sertraline Amia calva field liver 21  Ramirez et al., 2009 
sertraline Cyprinus carpio field liver 71  Ramirez et al., 2009 
sertraline Catostomus commersonii field liver 381  Ramirez et al., 2009 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Anti-depressant 
Fish 
sertraline Catostomus commersonii field brain ND – 4.24  Schultz et al., 2010 
sertraline Oncorhynchus mykiss laboratory plasma < LOQ – 1.2 138 – > 240 Fick et al., 2010 
venlafaxine Carcharhinus leucas  field plasma ND – 0.56  Gelsleichter 2009 
venlafaxine Catostomus commersonii field brain ND – 1.12  Schultz et al., 2010 
Anti-depressant metabolite 
norfluoxetine Dorosoma cepedianum field whole body ND – 1.08  Chu and Metcalfe 2007 
norfluoxetine Ameiurus nebulosus field whole body ND – 0.19  Chu and Metcalfe 2007 
norfluoxetine Carcharhinus leucas  field plasma ND – 4.08  Gelsleichter 2009 
norfluoxetine Three fish species field brain 8.86 ± 5.9  Brooks et al., 2005 
norfluoxetine Three fish species field liver 10.27 ± 5.73  Brooks et al., 2005 
norfluoxetine Three fish species field muscle 1.07 ± 0.41  Brooks et al., 2005 
norfluoxetine Lepomis sp. field muscle 3.49 – 5.14  Ramirez et al., 2007 
norfluoxetine Micropterus salmoides field muscle 3.2  Ramirez et al., 2009 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Anti-depressant metabolite 
Fish 
norfluoxetine Ictiobus bubalus field liver 37  Ramirez et al., 2009 
norfluoxetine Cyprinus carpio field muscle 4.0  Ramirez et al., 2009 
norfluoxetine Catostomus commersonii field muscle 3.9  Ramirez et al., 2009 
norfluoxetine Micropterus salmoides field liver 73  Ramirez et al., 2009 
norfluoxetine Amia calva field liver 57  Ramirez et al., 2009 
norfluoxetine Cyprinus carpio field liver 33  Ramirez et al., 2009 
norfluoxetine Catostomus commersonii field liver 38  Ramirez et al., 2009 
norfluoxetine Catostomus commersonii field brain ND – 3.57  Schultz et al., 2010 
norsertraline Three fish species field liver 12.94 ± 10.45  Brooks et al., 2005 
norsertraline Three fish species field brain 15.6 ± 14.3  Brooks et al., 2005 
norsertraline Three fish species field muscle 0.69 ± 0.59  Brooks et al., 2005 
norsertraline Catostomus commersonii field brain ND – 28.9  Schultz et al., 2010 
 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Anti-epileptic 
Fish 
carbamazepine Lepomis sp. field muscle 0.83 – 1.44  Ramirez et al., 2007 
carbamazepine Micropterus salmoides field muscle 2.3  Ramirez et al., 2009 
carbamazepine Micropterus salmoides field liver 6  Ramirez et al., 2009 
carbamazepine Oncorhynchus mykiss laboratory plasma 0.3 – 1.0 0.8 – 4.2 Fick et al., 2010 
carbamazepine Oncorhynchus mykiss laboratory muscle  0.52 ± 0.11 Zhang et al., 2010 
carbamazepine Oncorhynchus mykiss laboratory adipose   4.16 ± 0.87 Zhang et al., 2010 
carbamazepine Oncorhynchus mykiss laboratory muscle  0.22 – 0.44 Zhou et al., 2008 
Algae 
carbamazepine Psuedokirchneriella subcapita laboratory whole body 10.2 mgg 2.2 Vernouillet et al., 2010 
Invertebrate 
carbamazepine Thamnocephalus platyurus laboratory whole body 128.6 mgg 12.6 Vernouillet et al., 2010 
 
  
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Fish 
Anti-histamine 
diphenhydramine Lepomis sp. field muscle 0.66 – 1.32  Ramirez et al., 2007 
diphenhydramine Micropterus salmoides field muscle 1.4  Ramirez et al., 2009 
diphenhydramine Cyprinus carpio field muscle 1.2  Ramirez et al., 2009 
diphenhydramine Catostomus commersoni field muscle 1.7  Ramirez et al., 2009 
diphenhydramine Micropterus salmoides field liver 7  Ramirez et al., 2009 
diphenhydramine Ictiobus bubalus field liver 0.5  Ramirez et al., 2009 
diphenhydramine Cyprinus carpio field liver 7  Ramirez et al., 2009 
diphenhydramine Catostomus commersoni field liver 10  Ramirez et al., 2009 
diphenhydramine Catostomus commersoni field muscle 0.032 ± 0.005  Zhou et al., 2008 
diphenhydramine Etheostoma nigrum field muscle 0.081.63 ± 0.008  Zhou et al., 2008 
meclozine Oncorhynchus mykiss laboratory plasma < LOQ – 0.7 > 200 – > 1400 Fick et al., 2010 
orphenadrine Oncorhynchus mykiss laboratory plasma < LOQ – 0.9 < 100 Fick et al., 2010 
  
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Fish 
Anti-hypertensive 
atenolol  Pimephales promelas laboratory plasma 4.2 – 291  Winter et al., 2008 
cilazapril Oncorhynchus mykiss laboratory plasma < LOQ – 0.7 > 100 – > 700 Fick et al., 2010 
diltiazem Lepomis sp. field muscle 0.11 – 0.27  Ramirez et al., 2007 
diltiazem Micropterus salmoides field muscle 0.13  Ramirez et al., 2009 
diltiazem Catostomus commersoni field muscle 0.15  Ramirez et al., 2009 
diltiazem Micropterus salmoides field liver 0.7  Ramirez et al., 2009 
diltiazem Cyprinus carpio field liver 0.3  Ramirez et al., 2009 
diltiazem Catostomus commersoni field liver 0.7  Ramirez et al., 2009 
diltiazem Catostomus commersoni field muscle 0.002 ± 0.0006  Zhou et al., 2008 
diltiazem Etheostoma nigrum field muscle 0.0056 ± 0.0004  Zhou et al., 2008 
diltiazem Oncorhynchus mykiss laboratory plasma < LOQ – 0.9 24 Fick et al., 2010 
propanalol Oncorhynchus mykiss laboratory plasma 0.94-5200 ± 1333  Owen et al., 2009 
verapamil Oncorhynchus mykiss laboratory plasma < LOQ – 0.7 175 Fick et al., 2010 
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Fish 
Lipid regulators 
gemfibrozil Oncorhynchus mykiss field plasma < LOQ – 210 2 – 199 Brown et al., 2007 
gemfibrozil Cyprinus carpio field liver 70  Ramirez et al., 2009 
gemfibrozil Catostomus commersoni field liver 27.1  Ramirez et al., 2009 
gemfibrozil Carassius aratus laboratory plasma 170 ± 20 – 78000 ± 5000 16 – 89 Mimeault et al., 2005 
gemfibrozil Oncorhynchus mykiss laboratory muscle  0.4 ± 0.21 Zhang et al., 2010 
gemfibrozil Oncorhynchus mykiss laboratory adipose   20.75 ± 3.74 Zhang et al., 2010 
Synthetic Hormones 
17 ɑ-ethynylestradiol Moxostoma macrolepidotum field whole body 0.48 – 2.30  Al-Ansari et al., 2010 
17 ɑ-ethynylestradiol Carcharhinus leucas  field plasma ND – 3.79  Gelsleichter 2009 
17 ɑ-ethynylestradiol Abramis brama field bile 17  Houtman et al., 2004 
17 ɑ-ethynylestradiol Oncorhynchus mykiss field bile 300 – 1200  Larsson et al., 1999 
  
  
Table 1.2 Tissue concentration, bioconcentration and bioaccumulation literature data (1999-2010) for pharmaceuticals in aquatic 
species  
Compound Species Study type Tissue type Tissue concentration (ng g
-1
) BAF/BCF Reference 
Fish 
Synthetic Hormones 
17 ɑ-ethynylestradiol Oncorhynchus mykiss laboratory bile 360000  Larsson et al., 1999 
17 ɑ-ethynylestradiol Rutilis rutilis laboratory bile 59000 – 2388000  Flores-Valverde et al., 2010 
17 ɑ-ethynylestradiol Pimephales promelas laboratory whole body < 0.38 – 31 610 – < 2400 Lange et al., 2001 
levonorgestrel Oncorhynchus mykiss laboratory plasma < LOQ – 12 > 8500 – 12000 Fick et al., 2010 
Other Pharmaceuticals 
diazepam Pleuronichthys verticalus field liver 23 - 110  Kwon et al., 2009 
haloperidol Oncorhynchus mykiss laboratory plasma < LOQ – 1.2 3.2 Fick et al., 2010 
memantine Oncorhynchus mykiss laboratory plasma < LOQ – 2.3 164 Fick et al., 2010 
oxazepam Oncorhynchus mykiss laboratory plasma 0.2 – 0.7 0.7 – 3.6 Fick et al., 2010 
risperidone Oncorhynchus mykiss laboratory plasma 0.3 – 2.4 > 60 – > 480 Fick et al., 2010 
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1.4 Factors influencing the uptake and bioconcentration of 
pharmaceuticals in aquatic organisms 
There are many factors and processes that influence uptake and bioconcentration of 
pharmaceuticals in aquatic organisms, these can be environmental, chemical and 
biological (table 1.3). There are some data available for pharmaceuticals (see 
previous section) however information on factors and processes will be drawn from 
a variety of chemical classes and included in the following sections. 
 
Table 1.3 Summary of the factors that can influence uptake and 
bioconcentration in aquatic organisms 
Factors influencing uptake 
Environmental Chemical Biological 
Climate – temperature, rainfall, 
season 
Water quality – pH, dissolved 
oxygen, hardness, organic matter 
content 
Chemical form 
Ionization potential 
Steric properties –size & shape 
Hydrophobicity 
Bioavailability 
Size 
Growth 
Life stage 
Lipid content 
Metabolic processes 
Behaviour 
Disease status 
 
 
1.4.1 Environmental factors 
Uptake and elimination are strongly influenced by local environmental conditions; 
factors such as climate (e.g. season, rainfall and temperature) and water quality 
(hardness, dissolved oxygen and pH) can heavily impact upon bioconcentration. 
Season can influence bioconcentration by both changing the exposure conditions 
(e.g. concentration) and by altering the organisms biological processes involved in 
uptake (e.g. growth).  
Passive diffusion, which is thought to be the main process for uptake is dictated by 
the exposure concentration, the amount of pharmaceutical loaded into the fresh 
water along with hydrological processes such as flow rates and dilution can change 
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the exposure concentration throughout the year (Ashton et al., 2004, Gelsleichter, 
2009). Greater flow conditions in rivers and streams will increase the dilution of a 
chemical contaminant, reducing its concentration in the water and thus decreasing 
the uptake of pharmaceuticals compounds into organisms (Vieno et al., 2005, 
Powell et al., 2009). By contrast low flows will increase the proportion of compounds 
in effluent dominated streams (Loraine and Pettigrove, 2005, Peng et al., 2008). In 
one study by Kolpin et al. (2004) antibacterial drugs and other prescription 
pharmaceuticals were frequently detected during low flow conditions but not during 
high flow conditions. In winter time, rivers affected by the presence of snow and ice 
can have high concentrations of pharmaceuticals due to low flow conditions in 
addition to decreased removal efficiency of STWs (Vieno et al., 2005, Daneshvar et 
al., 2010). Daneshvar et al. (2010) found that concentrations of ibuprofen, naproxen, 
diclofenac, and ketoprofen in effluent were at their highest (31 to 1,852 ng L−1) 
during winter, whilst bezafibrate, a lipid regulator was observed at higher 
concentrations in spring. Peng et al. (2008) found the detection frequencies of 
twenty pharmaceuticals and personal care products increased in periods of low flow 
where rainfall was less. Some hormonally active compounds such as 17α-
ethinylestradiol and estriol were only detected in low flow conditions.  
The temperature of fresh water is dependent on the season and has several impacts 
on the exposure of organisms to compounds. Temperature can influence partitioning 
of compounds between the aqueous and the particulate phases in water (Borgå et 
al., 2010, Haftka et al., 2010, Hallanger et al., 2011). Partitioning of compounds to 
particulate and dissolved matter is intimately linked to the bioavailability of a 
compound for uptake by aquatic organisms (Böhm and Düring, 2010, Borgå et al., 
2010). Reduced bioavailability due to increased partitioning to the particulate phase 
of the water has been demonstrated for a number of compounds including PCBs 
(Jota and Hassett, 1991, Akkanen and Kukkonen, 2003, Böhm and Düring, 2010, 
Haftka et al., 2010, Ruotsalainen et al., 2010). Belden et al. (2007) demonstrated 
that partitioning of ciprofloxacin an antibiotic occurs with both coarse particulate 
organic matter and fine particulate organic matter. The partitioning process is also 
influenced by the age, geochemical origin, and history of the organic material (Tang 
and Weber, 2006). Many organisms rely on the organic fraction in water as a food 
resource therefore the partitioning of a pharmaceutical to organic material may 
influence the route of uptake into an organism. 
Climatic conditions not only influence the exposure concentration but the biological 
processes within the organism. When seasonality influences flow rates in rivers it 
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also influences an organism’s physiology, biochemistry and behaviour. In wetter 
conditions there will be larger volumes of water in rivers and greater flow conditions. 
This may influence uptake by changing the respiration rates of fish, through directly 
affecting the compound exchange between the water and the respiratory surface 
(Powell et al., 2009). Variation of temperature significantly affects the rates of 
feeding, growth, and lipid deposition in fish and this consequently affects the uptake 
and deposition of compounds such as pharmaceuticals (Brecken-Folse et al., 1994). 
In general, an increase in the temperature will increase the rates of uptake and 
elimination (Barron, 1990, Nawaz and Kirk, 1996). Typically a 10 °C increase in 
constant temperature results in a 2-fold increase in uptake of pollutants such as 
PCBs, DDT, and methylmercury from food or water (Spigarelli et al., 1983). 
Honkanen and Kukkonen (2006) found that the uptake rate of bisphenol-A into the 
common frog, Rana temporaria increased at higher temperatures compared to lower 
temperatures. A similar pattern was recorded in a study by Brown et al. (2007), 
where lower temperatures were thought to decrease the uptake of pharmaceuticals 
in the field. Difference in the uptake at different sites with similar exposure 
concentrations was attributed to lower ventilation and metabolic rates of the fish at 
lower temperatures (Brown et al., 2007). The effects of temperature on uptake and 
bioconcentration are dependent on the organisms and the compound studied. Other 
temperature dependent processes involved in uptake include diffusion through 
cytosol, solvation, protein-binding, and changes in the permeability of tissue 
membranes because of changes to the lipid composition necessary to maintain 
membrane fluidity (Barron, 1990). 
Water quality parameters such as water hardness, salinity, dissolved oxygen 
content and pH are thought to affect the uptake of compounds in organisms. It is 
currently thought that as water hardness increases the bioconcentration of 
compounds increases (Tolls et al., 1994). An increase from low to intermediate 
water hardness increases the uptake rate of linear alkylbenzenesulfonate (a 
surfactant) in O. mykiss (Tolls et al., 1999). This may be due to water hardness 
decreasing the partitioning efficiency of a variety of compounds to organic matter. 
As discussed previously the partitioning of compounds reduces their bioavailability 
and therefore bioconcentration and uptake from the water (Penttinen et al., 1995, 
Tolls et al., 1999, Akkanen and Kukkonen, 2001).  
Water bodies that are in coastal and especially estuarine areas experience a variety 
of salinities (Jeon et al., 2010). Salinity is an important factor that may influence the 
bioconcentration of a variety of compounds in organisms. Brecken-Folse et al. 
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(1994) found that bioconcentration of trichlorfon in Grass shrimps and Sheephead 
minnows tended to decrease with increasing salinity, but in the same study no effect 
was shown for nitrophenols. Jeon et al. (2010) found that uptake and elimination of 
polyfluorinated compounds increased with increasing salinity. As freshwater fish are 
hyperosmotic to the environment the diffusion of water may facilitate uptake of 
chemicals into to the organism (Barron, 1990). 
Temporal depletion of oxygen content in fresh waters occurs frequently (Hattink et 
al., 2005). Fish have developed mechanisms to manage hypoxia that involve 
changing physiological and behavioural responses to increase oxygen transport to 
the gills. The two main strategies are to increase ventilation rates and decrease 
metabolic activity to conserve energy when hypoxia is prolonged (Lloyd, 1961, 
McKim and Goeden, 1982). When compounds such as pharmaceuticals are present 
in the water, increasing ventilation rates and reducing metabolic activity may result 
in increased compound stress due to increased uptake (Lloyd, 1961). However the 
evidence surrounding this remains unclear (Brian et al., 2008). 
Pharmaceuticals are ionic compounds and uptake in organisms can be very 
sensitive to changes in environmental pH. The atmospheric transport of acidifying 
substances (e.g., CO2, SO 2 and NO2) and the effects of low pH on biota are well-
known (Larsson et al., 1991, Arnold et al., 2009). Many organic compounds that are 
globally distributed are un-ionised. However many pharmaceuticals ionisable which 
means that their behaviour will be influenced by the pH of the environment. Studies 
with traditional ionisable pollutants such as pentachlorophenol show that 
bioconcentration is very different in acidified waters compared to non-acidified 
waters (Larsson et al., 1991). The ionisation state of the compound is co-dependent 
on the chemistry of the pharmaceutical so this topic will be discussed in more detail 
in the next section. 
There is currently limited information available on the influence of environmental 
fluctuations on uptake and bioconcentration of pharmaceuticals in the environment, 
this subject will become increasingly important in view of our changing climate 
(Arnold et al. 2009). 
 
1.4.2 Chemical factors  
Bioconcentration and uptake of compounds is generally assumed to be a 
thermodynamically driven process of exchange between the water and lipids of 
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organisms (Walker, 1990, Meylan et al., 1999, Gatermann et al., 2002, Barber, 
2003). It has been reported that the uptake and elimination of both endogenous 
compounds (such as bile acids) and exogenous compounds (such as 
pharmaceuticals) can occur through carrier mediated transport (Yamazaki et al., 
1996); however, the exact uptake mechanism for pharmaceuticals is unknown. It is 
well known that physicochemical properties of the compound will profoundly affect 
the toxicokinetics of a substance (Arnot et al., 2010). The factors that are important 
in determining the bioconcentration of the compound are the electronic, hydrophobic 
and steric factors (Barron, 1990). 
In fish there are several anionic, cationic and neutral transporters that permit active 
and facilitated diffusion (Kallio et al., 2010). As diffusion across cellular membranes 
is concentration dependent, it will be influenced by the compounds solubility and 
molecular form. Pharmaceuticals as a group of compounds vary in both of these 
properties; for example carvedilol has a solubility of 0.5 mg L-1, diazepam has a 
solubility of 50 mg L-1 and the solubility of rifampicin can vary depending on its 
crystalline state by a factor of 8 (195 – 1576 mg L-1). Various different salts are 
commonly used as anionic surfactants in pharmaceutical formulations which may 
have different physicochemical properties compared to the API itself. For example 
docusate sodium is used in pharmaceuticals formulations and is not readily 
biodegradable and with a log Kow of 6 it is indicative of a bioaccumulative substance 
(Carlsson et al., 2006). It has been theorized that surfactants may enhance the 
bioconcentration of ibuprofen in O. mykiss (Jones-Lepp and Stevens, 2007). 
Therefore, measuring and estimating the APIs potential to bioconcentrate or 
bioaccumulate in organisms, using single compound studies, may not reflect 
realistic exposure to pharmaceutical formulations. 
Cellular membranes are comprised of phospholipids and therefore uptake of a 
substance is influenced by its lipophilicity: moderately lipophilic compounds readily 
diffuse across membranes and will be accumulate via aqueous uptake, but highly 
lipophilic compounds will accumulate via dietary uptake (Barber, 2008). Lipophilicity 
is generally expressed in terms of the octanol/water partition coefficient (Kow) and 
has proved to be an invaluable parameter in bioaccumulation modelling (Nuutinen et 
al., 2003b, Giulio and Hinton, 2008, Powell et al., 2009, Borgå et al., 2010). Linear 
relationships between lipophilicity and both uptake rate and bioconcentration have 
been developed (Álvarez-Muñoz et al., 2010). Substances with high Kow coefficients 
have high absorption and low elimination rates in a variety of organisms. A fair 
approximation of the bioaccumulative nature of a substance can be made using the 
Chapter 1 
 
69 
 
Kow coefficients for compounds with log Kow coefficients between 1 and 6 for non-
ionic and non-metabolised substances (Meylan et al., 1999). However for very 
lipophilic compounds the relationship breaks down as they often have lower BCFs 
and BAFs (Meylan et al., 1999, Borgå et al., 2010). The breakdown in the 
relationship is thought to be due to lack of compound in the aqueous elements of the 
lipid membrane and aqueous resistance limiting the diffusion (Arnot et al., 2010). 
Evidence suggests that non-ionised substances diffuse more easily across 
membranes than ionised substances, and there is some discussion in the literature 
as to whether Kow is likely to be a good descriptor for the uptake of many 
pharmaceuticals which are ionisable (Daughton and Brooks, 2011). Zhang et al. 
(2010) found accumulation of gemfibrozil, ibuprofen, carbamazepine and fluoxetine 
in O. mykiss was a function of the Kow but also suggested that for some compounds, 
such as fluoxetine, protein binding played an important role. The collation of data 
from the literature suggests that lipophilicity of a pharmaceuticals has a weak 
relationship with bioconcentration (R2 = 0.39, figure 1.5). Therefore other factors and 
processes may influence bioconcentration. Wu et al. (2010b) suggested that uptake 
of ionisable compounds into plants is influenced by a combination of 
physicochemical properties including lipophilicity and the compounds dissociation 
constant (pKa). The BCF is influenced by the pH of the exposure water if the 
compound has ionization potential. A good example of this pH dependence is 
presented by Nakamura et al (2008) where the extent of uptake of fluoxetine (pKa 
10) changes with the water alkalinity (figure 1.4, page 40). 
The epithelium of organisms is more permeable to the non-ionised, neutral form of 
compounds. However, the internal pH of an organism is different from the external 
environment so that neutral compounds which diffuse easily into a cell can become 
ionised inside the cell and become trapped. This mechanism, known as ion-
trapping, can lead to differences in bioconcentration depending on the pH (Lo and 
Hayton, 1981, Hayton and Schultz, 1991, Trapp et al., 2010, Neuwoehner and 
Escher, 2011).  
A better parameter for estimating uptake of ionisable compounds may be the Dow. 
The Dow accounts for difference in partitioning of the neutral and ionic species of a 
molecule at a particular pH value. Dow is calculated using a combination of the pKa 
and the Kow by using the Henderson Hasselbach equation (page 89; Po and 
Senozan, 2001). 
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Several other molecular parameters such as size and shape have been used to 
describe the process of passive diffusion across cellular membranes (Arnot et al., 
2010). Bioconcentration of polychlorinated naphthalene and biphenyls directly 
depend on their molecular size rather lipophilicity (Barron, 1990). Although lipophilic 
these compounds do not readily diffuse through lipid membranes due to their large 
size. It is thought that the tightly packed lipid membrane of organisms will act as a 
filter for molecules above a certain size (Arnot et al., 2010). Structure-activity 
relationships have therefore been proposed that use molecular size to identify 
bioaccumulative compounds (Qin et al., 2009, Nendza and Müller, 2010). 
 
 
Figure 1.5. The linear relationship between pharmaceutical bioconcentration 
/bioaccumulation factors and octanol – water partition coefficient. Data for 
fish measured in the laboratory (n =16) ; regression relationship: BCF= 208.04 
log Kow - 598.03, R
2 = 0.39). 
 
The structure of the lipid membrane may also limit the uptake of some molecules of 
long chain length and or large cross sectional area (Barron, 1990, Martin et al., 
2003). And steric properties such as maximum molecular length and maximum 
cross-sectional diameter will limit the diffusion of a compound (Dimitrov et al., 2002, 
Sakuratani et al., 2008, Dimitrova et al., 2010, Louwen and Stedeford, 2011). 
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The physicochemical properties of pharmaceuticals will play an important role in the 
uptake, distribution and elimination of these compounds in biological tissues. 
Relationships already established for non-ionisable contaminants may not be 
appropriate to describe those for pharmaceuticals. Therefore, more research is 
needed to refine the prediction of bioaccumulation in these ionisable compounds. 
 
1.4.3 Biological factors 
The significance of biological factors should be taken into account when considering 
the bioconcentration of compounds (Leppänen, 1995). Diversity in biology and 
ecology play a fundamental role in uptake and elimination of contaminants (Larsson 
et al., 1991, Li et al., 2009, Rubach et al., 2010, Rubach et al., 2011). The 
bioconcentration of many aquatic contaminants is organism dependent (Davies and 
Dobbs, 1984, Barron, 1990). Different factors such as size, lipid content, respiration 
strategy, feeding strategy and habit as well as metabolic processes will all be 
controlling factors in uptake and bioconcentration (Barron, 1990).  
Size has been recognized as important in determining physiology and anatomy and 
has been shown to influence processes such as uptake and bioconcentration 
(Barron, 1990). Organisms size has been negatively correlated with absorption and 
elimination rates of substances in both aquatic and terrestrial organisms (Hendriks 
and Heikens, 2001, Ashauer et al., 2010). Hendriks and Heikens (2001) found 
significant relationships between the weight of an organism and internal 
concentrations of 14 compounds. However both positive and negative correlations 
were observed, and the small slopes of the relationships between wet weight and 
internal concentration indicated that the relationships were not ecotoxicologically 
relevant (Ashauer et al., 2010). 
The lipid content of the exposed organism plays a role in the bioconcentration of 
many contaminants because uptake is considered to be a partitioning process 
between lipids of the organism and the ambient water. Clear relationships between 
bioconcentration of neutral contaminants and lipid content have previously been 
established (Geyer et al., 2000). This has been shown to be the case for 
pharmaceuticals as well. Recently Al-Ansari et al. (2010) found a significant positive 
correlation between the tissue concentration of the synthetic hormone 17 ɑ-
ethinylestradiol and lipid content of Moxostoma macrolepidotum the Red horse 
sucker fish. Also, Zhang et al. (2010) found that the higher lipid percentages in the 
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adipose tissue compared to the dorsal muscle of O. mykiss contributed to the 
differential concentrations of several pharmaceuticals.  
The gill respiratory surface provides a relatively large exchange epithelium for the 
uptake of contaminants. Respiration strategies play an important role in providing 
vast differences among organisms in terms of physiological contact with the 
surrounding water (Buchwalter et al., 2003). Buchwalter et al. (2002) found that 
respiratory strategy was a major determinant of chlorpyrifos in aquatic insects. 
Several studies have shown that organisms that have large gas exchange 
epitheliums are more susceptible to contaminant accumulation (Buchwalter et al., 
2003, Buchwalter et al., 2004, Buchwalter et al., 2008). Currently there is no data 
available for the impact of these traits on the uptake and bioconcentration of 
pharmaceuticals in non-target organisms.  
Feeding strategy should be considered when studying bioaccumulation. Feeding 
habits such as feeding rate and food source are important regulating factors in 
bioaccumulation (Leppänen, 1995). Feeding habits have been shown to influence 
the accumulation pattern of chemicals such as PCBs (Zhou et al., 1999, Lee et al., 
2000). Carnivorous and omnivorous fish were more susceptible to PCB 
bioaccumulation than filter feeders (Zhou et al., 1999). This is also true for 
invertebrate organisms where different bioaccumulation patterns have been 
determined depending on the feeding type of the organisms. The feeding strategies 
studied have included engulfers, piercers, filter feeders and deposit feeders (Lee et 
al., 2000, Brooks et al., 2009). 
 
1.4.3.1 Metabolism 
Pharmaceuticals are absorbed and distributed from the site of adsorption to the site 
of metabolism. Metabolism is the conversion of one chemical entity to another in the 
body by enzymes (Rang et al., 2007). Metabolic processes such as the nature and 
activity of detoxification enzymes and hence biotransformation routes can influence 
the toxicokinetics of contaminants. Drug metabolism in humans occurs mainly in the 
liver by the cytochrome P450 enzyme system (CYP – 450). The animal kingdom has 
evolved complex metabolic systems that can detoxify xenobiotics including 
pharmaceuticals (Rand and Dales, 2008). Metabolism involves two types of reaction 
known as phase I and phase 2 which will be discussed further in Chapter 3 (see 
page 114). After performing its therapeutic effect, the pharmaceutical is usually 
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metabolised to a more hydrophilic substance and excreted. Metabolism can 
substantially increase the elimination of substances by increasing solubility and 
creating conjugates that are substrates for active transport systems (Giulio and 
Hinton, 2008). 
Our current knowledge of metabolism and detoxification pathways for 
pharmaceuticals in mammals is extensive due to preclinical and clinical data sets 
required for marketing a pharmaceutical product (Winter et al., 2010) whilst less is 
known about metabolism in non-target organisms. Biotransformation of 
pharmaceuticals has been observed in the laboratory for aquatic organisms, mainly 
in fish (Paterson and Metcalfe, 2008, Kallio et al., 2010). Schwaiger et al. (2004) first 
suggested that diclofenac could be metabolised in the liver of fish when O. mykiss 
were exposed to 1 µgL-1, diclofenac showed ultra-structural cellular reactions in the 
liver. This was also suggested in a study by Hoeger et al. (2008) where the 
distribution kinetics of C-14 labeled diclofenac in fish was shown. This study 
demonstrated that diclofenac undergoes enterohepatic circulation and accumulates 
in the bile. The author concluded that diclofenac may have incomplete first pass 
metabolism which results in a higher accumulation. More recently Kallio et al. (2010) 
observed that diclofenac was metabolized in O. mykiss to acyl glucuronides of 
hydroxydiclofenac and one ether glucuronides of hydroxydiclofenac. 
Metabolic studies in fish of the anti-depressant fluoxetine has shown that it can be 
metabolised to its N-demethylated derivative norfluoxetine (Nakamura et al., 2008, 
Paterson and Metcalfe, 2008, Smith et al., 2010). Smith et al. (2010) showed that 
fluoxetine could be metabolised by several species of fish including rainbow trout, 
goldfish, zebrafish, and killifish. Generally killifish showed higher rates of metabolism 
and rainbow trout showed a lower capacity for metabolism of fluoxetine. However 
there was a lot of variability between individual samples and significance of the 
results could not be established. This study showed that fluoxetine was lost at a 
greater rate than norfluoxetine was formed, indicating that norfluoxetine may not be 
the main biotransformation product of fluoxetine in fish. Smith et al. (2010) also 
showed that CYP – 450 can be induced by pre-exposure to carbamazepine but 
unlike mammals may not be involved in metabolism of fluoxetine in fish. 
Pharmaceuticals such as fluoxetine have metabolites with greater elimination half-
lives than the parent compound. In mammals fluoxetine has an elimination half-live 
of 50 hours whereas its metabolite norfluoxetine requires several weeks to be 
eliminated in mammals (Giulio and Hinton, 2008). The length of elimination half-life 
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of the metabolite will influence the bioconcentration in the tissue. This is reflected in 
fish studies where the norfluoxetine bioconcentrates to a greater extent than the 
parent compound and elimination from the tissue is slower in fish (Nakamura et al., 
2008, Paterson and Metcalfe, 2008). Patterson and Metcalfe (2009) showed that 
fluoxetine has an elimination half-life of 9.5 days in the Japanese Medaka, 
approximately 4.5 times longer than that of humans (Baldessarini, 2001). This 
probably indicates that fish have less capacity to metabolise and eliminate fluoxetine 
and this may be the major reason why this compound bioaccumulates in fish tissue 
(Paterson and Metcalfe, 2008, Smith et al., 2010). Also pharmaceuticals such as 
fluoxetine and diclofenac may be metabolised to active metabolites (Baldessarini, 
2001, Hoeger et al., 2008). Liver and kidney pathology observed by some authors 
would certainly suggest that diclofenac could be excreted as a reactive metabolite 
(Schwaiger et al., 2004, Hoeger et al., 2008). Decreased liver function may also 
contribute to accumulation in tissues.  
Field surveys have detected pharmaceutical biotransformation products such as 
norfluoxetine and norsertraline, the derivative of sertraline, in wild fish tissue. It is not 
clear whether these field observations are due to metabolism of the parent 
compound in fish or to the uptake of human biotransformation products from water. 
However, laboratory data for fluoxetine and norfluoxetine certainly suggest that 
detections of metabolites in fish tissue can be at least partly attributed to fish 
metabolism. 
Currently there is limited information regarding biotransformation of pharmaceutical 
compounds in invertebrates or algae, however many organisms maybe capable of 
metabolising pharmaceutical contaminants. Invertebrates possess a suite of 
biotransformation enzymes in the digestive tissue (Livingstone, 1998) and have 
been shown to metabolise other contaminants (Nuutinen et al., 2003a). More 
research is needed to elucidate which organisms are capable of metabolising 
pharmaceutical compounds. 
Also, biotransformation rates for any organisms can be useful for predictive 
modelling of BCFs and BAFs for neutral compounds (Arnot, 2009), as there are 
biotransformation data available for pharmaceuticals from clinical data these should 
be used to enhance predictive models for bioconcentration. 
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1.5 Summary 
In the past five years there has been increasing scientific interest in the occurrence 
of pharmaceuticals in the tissues of aquatic organisms and a number of studies 
have been published reporting uptake of pharmaceuticals into aquatic and terrestrial 
organisms. In this chapter the data currently available has been reviewed. Based on 
the previous Sections, it can be concluded that: 
 There are several analytical techniques available for measuring ng g-1 
concentrations of pharmaceuticals in a variety of biological tissues and there 
are many factors that affect uptake and bioaccumulation of compounds. 
These include environmental, chemical and biological factors which lead to 
inter and intra study variability in values such as tissue concentrations, BCFs 
and uptake rates.  
 BCFs are reported and calculated in a number of ways, some are reported 
for whole body, some a specific tissue or on a lipid basis. BCFs are 
calculated using nominal concentrations or measured concentrations and if 
there is no detectable concentration BCFs will be calculated using the LOQ 
generating a minimum or maximum value, thus creating variation between 
studies 
 There is data for several pharmaceutical classes however the most studied 
are hormones and antidepressants. The highest concentration of a 
pharmaceutical recorded in wild fish was the hormone 17 ɑ - ethinylestradiol 
and the largest BCF recorded was for ibuprofen. Several pharmaceutical 
compounds at concentrations below the limits of detection in fresh waters 
and effluent were found in exposed fish, indicating their potential to 
bioaccumulate. 
 Some data suggests that uptake of pharmaceuticals such as lipid regulators 
into fish is through passive diffusion over the gills. However, preliminary work 
shows that some pharmaceuticals such as the SSRIs may have the potential 
to be selectively accumulated into fish. Therefore facilitated diffusion or 
active transport may play a role in the uptake of some pharmaceuticals but 
more research must be completed to elucidate this. 
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 There are few data on the metabolism of pharmaceutical compounds in 
aquatic organisms. To date studies have shown that pharmaceuticals, 
including diclofenac, fluoxetine, sertraline and 17 ɑ - ethinylestradiol, can be 
metabolized in fish to metabolites that have been characterized using human 
metabolic pathways. There is a great deal of unpublished information about 
the metabolism of pharmaceuticals in mammals generated by the 
pharmaceutical industry that could assist targeted screening approaches for 
pharmaceutical metabolites. 
 There is contradiction in many studies as to whether traditional ways of 
predicting the uptake in aquatic organisms using the log Kow, would be 
appropriate for pharmaceuticals compounds considering their ionsization 
potential, thus more work is needed to develop predictive power of traditional 
models 
 Information for aquatic invertebrates and plants is very limited but 
preliminarily data indicate that they may accumulate pharmaceuticals. Also, 
information on trophic transfer is limited but it demonstrates that dietary 
uptake of pharmaceuticals may play a role in their accumulation in 
invertebrate organisms. Data indicates that humans may be potentially 
exposed to a number of pharmaceutical classes through consumption of 
contaminated fish, albeit at concentrations below therapeutic levels. Further 
data is required to assess the potential impact of pharmaceuticals on the 
food chain.  
 
1.6 Recommendations for further research 
There are currently large knowledge gaps and more research is needed into the 
uptake, metabolism and bioaccumulation of pharmaceutical compounds in aquatic 
organisms. Recommendations for further work therefore include: 
 Assessment of a wider range of pharmaceuticals in order to develop 
improved models for estimating uptake - Much of the information gathered to 
date has been focused on particular compounds such as fluoxetine. By 
testing a wider range of compounds in a more systematic way, it should be 
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possible to develop relationships for predicting uptake based on the 
properties of a pharmaceutical. 
 Most studies to assess the uptake of pharmaceuticals through food chains 
have focused on uptake in single organisms. In order to protect the wider 
environment, it would be beneficial to begin to understand those factors and 
processes affecting the uptake pharmaceuticals into, and through food 
chains.  
 Integrating clinical data, available for pharmaceuticals, to better predict 
bioaccumulation and effects could therefore reduce the need for animal 
testing 
 Assessment of environmental properties on uptake – Available data indicate 
that the uptake of pharmaceuticals is very dependent on the characteristics 
of the environment (e.g. pH, temperature). Further research is required to 
identify and assess the influence of environmental parameters on 
pharmaceutical uptake. 
 Establishment of the effects of species traits on uptake – Most work to date 
has focused on fish with a few studies exploring uptake into invertebrates 
and algae. We should look at a wider range of organisms from different 
trophic levels and ultimately aim to develop trait-based models for assessing 
uptake into aquatic and terrestrial organisms. 
 
1.7 Aims and objectives  
This PhD project addresses many of the knowledge gaps described above. The 
understanding of those factors and processes affecting the uptake and 
pharmaceuticals in aquatic invertebrates will allow more accurate prediction of their 
bioconcentration in organisms in the aquatic environment. This will be invaluable for 
understanding the risks pharmaceuticals pose to the aquatic environment. 
  
Chapter 1 
 
78 
 
The core hypotheses behind this thesis were: 
1. The uptake and clearance of pharmaceuticals in aquatic invertebrates 
are determined by the properties of the pharmaceutical, the traits of an 
aquatic invertebrate and the degree of metabolism within an organism; 
2. Pharmaceuticals have the potential to biomagnify through aquatic food 
chains; and 
3. The bioconcentration of pharmaceuticals into aquatic invertebrates is 
predictable based on the physicochemical properties of the 
pharmaceutical, knowledge of pharmacological behavior in humans and 
from the individual traits of the organism 
In order to test these hypotheses, the following objectives were set: 
1. To explore the influence of physicochemical properties of a variety of 
pharmaceuticals on uptake and clearance in the aquatic invertebrates  
2. To compare uptake of these pharmaceuticals in aquatic invertebrates with 
contrasting biological traits 
3. To develop models to predict the uptake of pharmaceuticals in aquatic 
invertebrates using data on physicochemical properties of the 
pharmaceutical, pharmacological behavior in humans and individual traits of 
the test organism 
4. To develop methods to characterise the metabolism of pharmaceuticals in 
aquatic invertebrates and apply these methods to explore the metabolism of 
selected pharmaceuticals in aquatic invertebrates 
5. To explore the uptake of selected pharmaceuticals from food and investigate 
biomagnification through a simple aquatic food chain 
The thesis is based on laboratory studies using a set of model human 
pharmaceuticals namely: 5-fluorouracil, carbamazepine, carvedilol, diazepam, 
fluoxetine and moclobemide. The selection of pharmaceuticals was based on their 
physicochemical properties including their octanol water partition coefficient, 
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disassociation constant and molecular weight. The aquatic invertebrates chosen 
were selected based on their size; lipid content, respiration strategy, feeding 
behaviour and environmental occurrence and availability. The organisms included in 
the studies were Gammarus pulex, Notonecta glauca, Lymnea stagnalis and 
Planorbarius corneus. 
This thesis comprises five chapters. A brief description of each chapter is presented 
below. 
Chapter 2 describes experiments exploring uptake and clearance of 
pharmaceuticals from water into the three study aquatic invertebrates. The resulting 
data are used to explore the relationships between pharmaceutical physic-chemical 
and pharmacological properties and uptake into invertebrates. 
Chapter 3 describes experiments to characterize the metabolism of pharmaceuticals 
in Gammarus pulex. A Time of Flight Mass Spectrometry-based methodology was 
developed to detect and identify pharmaceutical and their metabolites in the 
organism. Where pharmaceutical metabolites were detected, uptake and clearance 
experiments were undertaken to determine the formation of metabolites over time 
and the influence on bioconcentration. 
Chapter 4 describes experiments into the uptake of pharmaceuticals from the 
organisms’ food using Gammarus pulex and Notonecta glauca. Uptake from the 
food and the water were compared to identify the predominant route of uptake for 
the organisms. Experiments were performed to evaluate the potential for trophic 
transfer and biomagnification of pharmaceuticals through a simple experimental 
food chain. 
Chapter 5 synthesises the results of Chapters 2-4 and describes the broader 
implications of the reported findings in terms of the risks of pharmaceuticals to 
aquatic systems. Recommendations for further research in the area are also 
proposed. 
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Chapter 2 Uptake of pharmaceuticals in aquatic 
invertebrates 
 
2.1 Introduction 
Due to the large number of pharmaceuticals in use, there is increasing interest in the 
use of mammalian pharmakinetic data to identify whether effects on non-target 
organisms occur and which organisms are likely to be sensitive to a particular 
pharmaceutical (e.g. Huggett et al., 2003a, Berninger and Brooks). In order for these 
approaches to work, it is essential that knowledge is available on the uptake of 
pharmaceuticals into non-target organisms. While the toxicity of many 
pharmaceuticals has been studied (e.g. Fent et al., 2006), our understanding of the 
factors and processes influencing uptake and bioconcentration of pharmaceuticals is 
less well developed (See Chapter 1; Brooks et al., 2009). Uptake of pharmaceuticals 
into non-target organisms has been previously reported in agricultural crops (e.g. 
Kumar et al., 2005, Boxall et al., 2006, Dolliver et al., 2007) and in aquatic 
organisms (Mimeault et al., 2005, Nakamura et al., 2008, Paterson and Metcalfe, 
2008, Dussault et al., 2009). For example, Dussault et al., (2009) showed 
bioaccumulation of 17 α-ethinylestradiol in two benthic invertebrates (Chironomus 
tentans and Hyalella azteca). The uptake of the selective serotonin re-uptake 
inhibitor, fluoxetine, has also been shown in the Japanese fish Medaka (Oryzias 
latipes) (Nakamura et al., 2008, Paterson and Metcalfe, 2008).  
Traditionally the octanol/water partition coefficient (Kow) is used to estimate uptake of 
neutral organic compounds. However, Kow is unlikely to be a good descriptor for the 
uptake of pharmaceuticals, many of which are ionisable. Uptake of pharmaceuticals 
can also be very sensitive to changes in pH of the environment due to their 
ionization potential. For example, Nakamura et al., (2008) demonstrated that the 
extent of uptake of fluoxetine changes between pH 7 and pH 9. The pH-corrected 
octanol-water partition coefficient (Dow) is likely to be a better parameter for 
estimating uptake of pharmaceuticals as it accounts for difference in partitioning of 
the neutral and ionic species of a molecule at a particular pH value (Kah and Brown, 
2008, Nakamura et al., 2008, Paterson and Metcalfe, 2008). Estimations of uptake 
may be further improved using pH-corrected liposome–water partition coefficients 
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(Dlipw) as liposomes are more characteristic of biomembranes, which are 
predominantly composed of phospholipids, compared to octanol (Escher et al., 
2000, Nakamura et al., 2008, Paterson and Metcalfe, 2008). It has also been 
suggested that it may be possible to use pharmacological data to estimate the fate 
and effects of pharmaceuticals in the environment. For example, recent studies 
have shown that the Volume of Distribution (VD) of a pharmaceutical, which is the 
distribution of the pharmaceutical in the human body, is potentially a good predictor 
of the sorption behaviour of a pharmaceutical in the natural environment (Williams et 
al., 2009). VD could also be used as a basis to predict uptake into aquatic 
organisms. 
As discussed in Chapter 1, uptake of chemicals is not only influenced by 
physicochemical properties, but also by biological factors. Diversity in biology and 
ecology, such as taxon, size, life cycle, reproductive strategy and habitat preference, 
can affect uptake and can determine the sensitivity of organisms to contaminants 
(Usseglio-Polatera et al., 2000, Baird and Van den Brink, 2007, Rubach et al., 2010, 
Rubach et al., 2010b). In a recent study, Rubach et al. (2010b) suggested that 
reproduction, respiration type/source of oxygen, feeding type and habitat are key 
biological traits in determining the sensitivity of aquatic organisms to pesticides. 
However, there is limited research on the influence of species traits in uptake and 
depuration studies with pharmaceuticals. 
This chapter explores the relationship between pharmaceutical physicochemical 
properties and pharmacological properties and uptake, using pharmaceuticals from 
a range of therapeutic classes and with a range of physicochemical properties. The 
study focuses on two aquatic invertebrates: Gammarus pulex is a benthic 
crustacean and Notonecta glauca is a water column predator. For one 
pharmaceutical (carvedilol), uptake studies were also performed on the freshwater 
snail Planorbarius corneus, a grazing, pulmonate gastropod to explore organisms 
differences in uptake.  
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2.2 Materials and methods 
2.2.1 Pharmaceutical compounds 
Radiolabelled and unlabeled pharmaceuticals, 5-fluorouracil, carvedilol, diazepam 
and moclobemide were provided by F. Hoffman-la Roche Ltd (Basel, Switzerland), 
whilst carbamazepine and fluoxetine were obtained from Agriculture and Agri-Food 
Canada, London, Ontario. All radiolabelled pharmaceuticals used in uptake and 
depuration for Gammarus pulex were labelled with C-14 with the exception of the 
fluoxetine, which was labelled with 3H. Information on the chemical properties of the 
pharmaceuticals are provided in table 2.1 and table 2.2. These compounds are used 
extensively in medicine and may reach significant concentrations the aquatic 
environment. The annual number of prescriptions written in 2011 are as follows; 5-
fluorouracil, 93,300; carbamazepine, 2,435,000; carvedilol, 496,000; diazepam, 
54,148,400; fluoxetine, 5,384,300 and moclobemide, 23,600. They a diverse group 
with different physico – chemical properties so that any relationships between 
properties and uptake could be established (Table 2.1)  
 
Table 2.1 Chemical properties of the radioactive study compounds 
Pharmaceutical CAS Number Position of radiolabel 
Chemical 
Purity [%] 
Specific Activity
 
[GBq mmol
-1
] 
5-fluorouracil 51-21-8 5-fluoro-1H,6[C-14]-pyrimidine 98.0 1.87 
Carbamazepine 298-46-4 Carbonyl – [C-14] 99.9 0.83 
Carvedilol 72956-09-3 2-[C14]-propanol 96.6 2.23 
Diazepam 439-14-5 5-[C14]-phenyl 98.2 2.04 
Fluoxetine 54910-89-3 N-methyl – [3H] >99 2960 
Moclobemide 71320-77-9 2-morpholin-4[C14]-ylethyl 98.6 1.02 
  
  
 
 
Table 2.2 Physicochemical properties of the study pharmaceuticals  
Pharmaceutical  Therapeutic 
class 
Molecular weight 
[g mol
-1
]
a 
Water 
Solubility 
[mg l
-1
] 
a
 
Log Kow 
b
 Acid/Base 
c 
pKa 
VD 
[l kg
-1
]
d 
Polar Surface 
Area
a 
Biological half-
life [hours]
d 
Plasma Binding 
[%]
d 
5-fluorouracil anti – cancer 130 > 1 - 0.81 weak acid 8.02
a
 1.4 ± 0.4 58.20 0.18 ± 0.07
 
8-12 
Carbamazepine anti – epileptic 236 18 2.25 neutral 7 1.5 ± 0.3 46.33 53 ± 41 94 
Carvedilol beta – blocker 406 0.6 3.05 weak base 8.00
d
 1.1 ± 0.3 75.74 15 ± 5 74 ± 3 
Diazepam anxyolitic agent 285 50 2.70 weak base 3.40 
a
 0.3 ± 0.12 32.67 2.2 ± 0.3 95 
Fluoxetine anti – depressant 309 50 4.65 weak base 10.01
e
 35 ± 21 21.26 43 ± 13 98.7 ± 0.2 
Moclobemide anti – depressant 269 - 1.16 weak base 6.20
 f
 1.4 ± 0.4 41.57 2-4
f 
50
f 
a DrugBank (http://www.drugbank.ca/) accessed 08/2011, b EPI suite V4.0,c Pubchem Compound NCBI (http ://pubchem.ncbi.nlm.nih.gov/) 
accessed 08/2011, d Bulter et al., 2006, e Nakamura et al. (2007), f IPCS InCHEM database (http://www.inchem.org/) accessed 08/2011, g 
Specific Activity of compound 
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2.2.2 Test organisms 
Gammarus pulex were collected from Bishop Wilton Beck, York, UK. (National Grid 
Reference (NGR) SE 797 553). Notonecta glauca were obtained from Blades 
Biological Ltd (Kent, UK). G. pulex were maintained in a 5 L aquarium in water 
collected from Bishop Wilton Beck (BWW) which was filtered to 1 µm using a 
Millipore vacuum filter. N. glauca were maintained in a 1.5 L aquarium in artificial 
pond water (APW; Naylor et al., 1989). Planorbarius corneus were obtained from 
New Forest Koi (Hampshire, UK) and were maintained in a 15 L high density plastic 
tanks filled with APW. All organisms were kept at c. 20 °C under a natural light 
regime. G. pulex were fed rehydrated horse chestnut (Aesculus hippocastanum) 
leaves inoculated with the fungus Cladosporium herbarum. N. glauca were fed with 
adult G. pulex and P. corneus were fed with a mixture of duck weed, Lemna minor 
and algal tablets (King British, Pets at Home, London UK). 
 
2.2.4 Toxicity assessment 
Experiments were carried out between March 2007 and November 2008 to 
determine if any of the pharmaceuticals had toxic effects on G. pulex and N. glauca 
at the concentrations used in the uptake studies. The endpoint chosen for the 
toxicity tests was mortality. Exposure concentrations for G. pulex were based on 
limited data for another aquatic invertebrate, D. magna (table 2.3). At the time of the 
experimental design toxicity data was only available for diazepam and fluoxetine, 
however more data has now become available for the other pharmaceuticals (table 
2.3). 
G. pulex were exposed in 500 mL of BWW with 2, 4, 8, 16 and 32 µmol L-1 (or 0.25, 
0.5, 1, 2 and 4 mg L-1) of 5-fluorouracil; 1, 2, 4, 8 and 16 µmol L-1 (or 0.25, 0.5, 1, 2 
and 4 mg L-1) of carbamazepine; 0.5, 1, 2, 5 and 10 µmol L-1 (or 0.25, 0.5, 1, 2 and 4 
mg L-1) of carvedilol; 2, 4, 8, 14 and 28 µmol L-1 (or 0.5, 1, 2, 4 and 8 mg L-1) of 
diazepam; 0.4, 0.8, 2, 4 and 6 µmol L-1 (or 0.1, 0.25, 0.5, 1 and 2 mg L-1) of 
fluoxetine; and 8, 16, 32, 64 and 128 µmol L-1 (or 2.1, 4.3, 8.5, 17 and 34 mg L-1) of 
moclobemide. 
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Table 2.3 Acute effective concentration µmol L-1 [mg L-1] for Daphnia magna 
taken from published literature (1995 – 2012) 
Pharmaceutical  EC50 Daphnia magna µmol L
-1 [mgL-1] Endpoint Reference 
5-fluorouracil 276 [36] Immobilisation Zounkova´ et al. 2007
 a 
Carbamazepine 58 [>13.8] Immobilisation Ferrari et al. 2007
 a 
Carvedilol [7.3] Immobilisation FASS.se 2012 
a 
Diazepam [4.25] Immobilisation Liljus et al. 1995 
Fluoxetine [0.82] Immobilisation  Brooks et al. 2003 
Moclobemide - - - 
a Data available after the experiment was performed 
 
Studies with N. glauca were carried out at a single concentration for each compound 
which was ten times that used in the uptake studies (8, 4, 2, 4, 3 and 4 µmol L-1 or 1 
mg L-1) 5-fluorouracil, carbamazepine, carvedilol, diazepam, fluoxetine and 
moclobemide respectively). If toxicity was observed in the assessment for N. glauca, 
more concentrations would be tested. G. pulex, studies were carried out using three 
replicates of ten animals whereas five single animal replicates were used for the N. 
glauca studies. All organisms were exposed to test solution for 48 hours and the 
percentage survival was observed. The percentage survival was arcsine – square 
root transformed and the treatments were statistically compared to the controls 
using a one – way ANOVA with post – hoc Dunnett’s test. 
 
2.2.5 Uptake and depuration study 
Uptake and depuration studies were carried out using the method of Ashauer et al. 
(2006) between July 2007 and February 2009. Test organisms were acclimatized to 
the test conditions for 24 hours without food under a specific photoperiod (12 hours 
light: 12 hours dark). With the exception of fluoxetine, a static exposure was used. 
Preliminary studies showed that fluoxetine adsorbed to the beakers and therefore a 
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static renewal approach was used for this compound (Appendix A). The static 
renewal approach for fluoxetine consisted of transferring the organisms in each 
beaker into fresh test solution every 24 hours. A sample of water (1 mL) was taken 
to determine the exposure concentration once the water had been renewed. Water 
quality parameters (pH, dissolved oxygen) were monitored throughout the 
experimental periods with a Symphony SB80BD bench top meter (VWR 
International LtD, UK).  
All organisms were exposed to 0.8, 0.4, 0.2, 0.4, 0.3 and 0.4 µmol L-1 (or 0.1 mg L-1) 
of 5-fluorouracil, carbamazepine, carvedilol, diazepam, fluoxetine and moclobemide 
respectively. Uptake studies were run for 48 hours with the exception of G. pulex 
studies with fluoxetine and the P. corneus study with carvedilol. For fluoxetine and 
carvedilol in the crustacean and gastropod exposure period was extended to 72 
hours. For the uptake studies, animals were exposed in 500 mL (G. pulex) or 150 
mL (N. glauca and P. corneus) of test solution for 0, 3, 6, 12, 24 and 48 hours. For 
the 72 hour exposure period, animals were exposed for 0, 3, 6, 12, 24, 48 and 72 
hours. For G. pulex, there were a minimum of three replicates of 12 animals where 
individual animals in each replicate separated by stainless steel cages to avoid 
cannibalism. One animal was taken from each replicate at each sampling point 
which left three sets of six animals at the end of the uptake study for use in the 
depuration study. For N. glauca and P. corneus, there were six sets of three 
replicates of single animals for each time point and a further six sets of three 
replicates to be used for the depuration studies. At each sampling point, 1 mL of the 
exposure water was taken to determine the pharmaceutical exposure concentration. 
After the exposure period the remaining organisms were transferred into water with 
no pharmaceutical present for the depuration test. The depuration test was run for 
the same period as the uptake test and samples were taken at the same time points.  
The water sample was directly transferred to a scintillation vial and 10 mL of 
Ecoscint A (National Diagnostics, UK) were added. The sample was shaken to mix 
and left to settle and the radioactivity measured in the dark by liquid scintillation 
counting (LSC; Beckham LS6000 TA Liquid Scintillation Counter, Beckham 
Instruments Inc. USA).  
Once removed from the beakers, each organism was rinsed in deionised water to 
remove any pharmaceutical residue from its surface. The tissue samples were then 
frozen at – 20 °C prior to analysis. Pharmaceuticals were extracted from G. pulex 
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and N. glauca using 2 mL of Soluene 350 (Perkin Elmer, UK) and 100 µL of 
hydrogen peroxide (30%; Sigma Aldrich, UK). The hydrogen peroxide bleached the 
tissue so that no colour quenching occurred during the analysis phase. The samples 
were then heated in a water bath for 24 hours until the tissue had dissolved. The N. 
glauca tissue sometimes took longer to bleach due to their dark colour.  
Carvedilol was extracted from P. corneus using a Dionex 200 Accelerated Solvent 
Extractor (ASE) fitted with 33 ml stainless steel extraction cells. The gastropod 
whole body was removed from the shell, the tissue was placed in a mortar and 
pestle along with 6 g salt (Na2SO4) and c. 5.78 g of general purpose grade sand 
(Fisher Scientific, UK) and then homogenised into a fine powder. ASE cells were 
prepared with a filter paper, 1.35 g of hydromatrix (Varian Inc. California, USA) 
being placed at the bottom of the cell upon which the sample mixture was then 
added. To ensure the pharmaceutical was completely removed from the mortar and 
pestle, a further 34.68 g of sand was homogenised in the mortar and then 
transferred to the cell. Three ASE extractions with 100 % methanol as the carrier 
solvent were run for each sample. Once in the ASE, the samples were preheated for 
5 minutes and extracted at 100 °C at a pressure of 1500 psi. The samples were 
transferred from the extraction vials into beakers and the solvent was allowed to 
evaporate off. Once evaporated, 2 mL of methanol were added to the beakers which 
were placed on an orbital shaker for ten minutes and then sonicated for five minutes 
to ensure no radioactivity remained sorbed to the beaker. The samples were 
transferred to scintillation vials. Using this method an extraction efficiency of 81 % 
was achieved. 
All extracts were mixed with 10 mL Hionic Fluor scintillation cocktail (Perkin Elmer, 
UK) and the concentration of pharmaceuticals determined using LSC. Samples were 
counted three times for 5 minutes. Sample counts were corrected for background 
activity by using blank controls. Counting efficiency and colour quenching were 
corrected using the external standard ratio method. 
 
2.2.6 Effect of pharmaceutical concentration on uptake 
Carvedilol and fluoxetine have been shown to cause chronic effects on some 
aquatic invertebrates at low concentrations (De Lange et al., 2006, Sánchez-
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Argüello et al., 2009, Guler and Ford, 2010) which might affect uptake and 
depuration rates. To assess whether the uptake and depuration rates of 
pharmaceuticals might be affected by the concentration of the test substances, an 
additional study was carried out on fluoxetine and carvedilol at a much lower 
concentration than used in the studies described above. Sets of six individual G. 
pulex were exposed to either 0.2 or 246 nmol L-1 of carvedilol and 0.3 or 323 nmol L-
1 of fluoxetine. The lower concentrations of pharmaceuticals (0.2 and 0.3 nmol L-1 
carvedilol and fluoxetine) were prepared with only radioactive pharmaceutical (5 Bq 
L-1). However the higher concentrations (246 and 323 nmol L-1 carvedilol and 
fluoxetine) were prepared with radiolabeled (5 Bq L-1) and non-radiolabelled 
pharmaceuticals. To evaluate whether any toxicity at the higher concentration would 
influence uptake into the organism; the uptake of radioactivity was statistically 
compared at both concentrations after 72 hours exposure. The experimental 
conditions and extraction methods were the same as described above.  
 
2.2.7 Derivation of uptake and depuration rate constants and bioconcentration 
factors 
A first-order one-compartment toxicokinetic model was fitted to the internal 
concentration data using individual replicates to estimate the parameters uptake and 
elimination rate constants (Ashauer et al., 2006, Ashauer et al., 2010, Rubach et al., 
2010). The toxicokinetic model is: 
 
Equation 2.1  
          
  
                                   
 
Where t is time, Cinternal is the internal concentration [pmol g
-1], Cwater is the 
concentration in the water [pmol mL-1], and kint and kout are the uptake rate constant 
[mL g-1 d-1] and the depuration rate constant [d-1] respectively. The model was 
parameterized using least-squares minimization with the Levenberg-Marquardt 
algorithm followed by Monte-Carlo Markov-Chain (MCMC) to obtain a sample of 
parameter combinations that approximates the posterior distributions of the 
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parameters including their co-variances (Ashauer et al., 2010). Subsequently we ran 
the model for all these parameter combinations and chose the 2.5th and 97.5th 
percentile as prediction intervals. Bioconcentration factors (BCFs) and their 
confidence intervals were calculated by setting Cwater equal 1 and running the model 
beyond steady-state for all combinations of the parameter sample (Ashauer et al., 
2010). All simulations and parameter estimations were carried out using OpenModel 
(version 9th Dec 2009, http://www.nottingham.ac.uk/environmental-
modelling/OpenModel.htm).  
 
2.2.8 Development of relationships between pharmaceutical physico-
chemical/pharmacological properties and uptake 
Linear regression analysis was used to derive the relationships between VD and 
BCFs; Log Dlipw and BCFs; solubility; molecular weight (MW) or polar surface area 
(PSA) and BCFs for G. pulex and N. glauca. VD data were obtained from the 
literature. Log Dlipw values were estimated from predicted values of log Kow obtained 
from the Kowin package (EPISuite40). Log Dow for the pH of the experiment was 
initially derived from the log Kow using the Henderson Hasselbach equation (Po and 
Senozan, 2001). Initially the fraction of ionised and unionised compounds at the test 
pH was determined using equation 2.2. The Log Dow was then estimated using 
equation 2.3. 
 
Equation 2.2                             
 
Equation 2.3                                            
 
Where ion is the activity of the ion at a particular pH; neutral is the activity of the 
neutral species; fion is the fraction of the ion at the study pH; fneutral is the fraction of 
the neutral species at the pH. Kow(ion) and Kow(neutral) are the octanol water partition 
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coefficients for the neutral and ionic species respectively. It was assumed that the 
partition coefficient between octanol and water of the ionic species was 3.5 log units 
lower than the neutral species (Trapp and Horobin, 2005). Log Dlipw was then 
estimated equation 2.4 for non-polar compounds (i.e. carbamazepine) or equation 
2.5 for polar compounds (i.e. all other compounds) (Escher et al., 2009). 
 
Equation 2.4                             
 
Equation 2.5                             
 
Solubility, MW and PSA were obtained from the online database DrugBank (Wishart 
et al., 2008). The relationships between VD; Log Kow; Log Dlipw; solubility; MW and 
PSA of the pharmaceutical and bioconcentration were analysed by linear regression 
analysis, all statistical analysis was completed using Microsoft Excel and SPSS 
v17.0.0. 
 
2.3 Results and discussion 
2.3.1 Toxicity studies  
There was no significant effect of any of the study pharmaceuticals on G. pulex 
mortality at any of the concentrations tested (Appendix B). At the highest test 
concentration (6 µmol L-1) of fluoxetine, G. pulex survival was reduced to 70 %, 
however this was not significant compared to the controls (ANOVA p = 0.1). 
Similarly, all the studied pharmaceuticals had no effect on N. glauca mortality 
(Appendix B). While the toxicity of carvedilol to P. corneus was not determined, data 
for another snail, Lymnea stagnalis indicate that the compound has no effect on the 
mortality of the snail at 2 µmol L-1 (Appendix B). 
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The results for carbamazepine and diazepam are in accordance with the published 
literature where EC50 values between 18 and > 351 µmol L
-1 have been reported 
(Calleja et al., 1994, Lilius et al., 1995, Ferrari et al., 2003, Nunes et al., 2005, Quinn 
et al., 2008). There are limited data from the literature to compare to 5-fluorouracil, 
moclobemide and carvedilol. The results for fluoxetine indicate that G. pulex is less 
sensitive than other crustaceans to fluoxetine. Studies with Daphnia magna have 
reported LC50 values as low as 2 µmol L
-1 and chronic toxicity values of 0.1 µmol L-1 
(Brooks et al., 2003, Flaherty and Dodson, 2005). The sensitivity pattern follows the 
findings of Rubach et al. (2010) where Daphnids were the most sensitive organisms 
to organophosphates, followed by Gammarids and Notonectids. 
 
2.3.2 Uptake, depuration and bioconcentration 
The results from the toxicity tests indicated that there were no significant effects of 
any of the test pharmaceuticals on the survival of the organism, therefore 0.8, 0.4, 
0.2, 0.4, 0.3 and 0.4 µmol L-1 (or 0.1 mg L-1) of 5-fluorouracil, carbamazepine, 
carvedilol, diazepam, fluoxetine and moclobemide were chosen as the exposure 
concentrations. These concentration were at least one tenth of the lowest 
concentrations tested in the toxicity test section 2.2.4, therefore it was assumed that 
toxicity would not influence the uptake of the compound into the organism at these 
exposure concentrations.  
Analysis of exposure solutions confirmed that for diazepam, carvedilol, 5-
fluorouracil, carbamazepine and moclobemide exposure concentrations remained 
constant throughout the uptake phase of the studies (figure 2.1 to figure 2.3). For 
fluoxetine, concentrations declined over time so a static renewal approach was 
required to maintain the exposure concentrations. The observed dissipation of 
fluoxetine contrasts with published data which indicate that the compound is both 
photolytically and hydrolytically stable in a range of aqueous media (Kwon and 
Armbrust, 2006), and the disappearance over time may be due to sorption of the 
compound onto the test vessels. A photolysis and sorption experiment was carried 
out and details can be found in Appendix A. Water quality parameters were 
measured throughout the experiments and are shown in table 2.4. 
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Figure 2.1 Mean measured water concentrations (± standard deviation) in 
Gammarus pulex uptake experiments. Nominal water concentration 0.8, 0.4, 
0.2, 0.4, 0.3 and 0.4 µmol L-1 (or 0.1 mg L-1) of 5-fluorouracil (n=8), 
carbamazepine (n=8), carvedilol (n=8), diazepam (n=8), fluoxetine (n=3) and 
moclobemide (n=8) 
  
Figure 2.2 Mean measured water concentrations (± standard deviation) in 
Notonecta glauca uptake experiments (n=3). Nominal water concentration 0.8, 
0.4, 0.2, 0.4, 0.3 and 0.4 µmol L-1 (or 0.1 mg L-1) of 5-fluorouracil, 
carbamazepine, carvedilol, diazepam, fluoxetine and moclobemide 
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Figure 2.3 Mean measured water concentrations (± standard deviation) in 
Planorbarius corneus uptake experiments (n=3), nominal water concentration 
0.2 µmol L-1 (or 0.1 mg L-1) 
 
Table 2.4 Mean water quality parameters for uptake and depuration 
experiments with Gammarus pulex, Notonecta, glauca and Planorbarius 
corneus.  
Species Pharmaceutical Dissolved O2 [mgL
-1
] pH Temperature (°C) 
G. pulex  5-fluorouracil 8.49 8.61 12.10 
 
Carbamazepine 7.59 8.51 12.50 
 
Carvedilol 8.21 8.69 12.13 
 
Diazepam 8.17 8.93 11.59 
 
Fluoxetine 8.99 8.51 12.45 
 
Moclobemide 7.56 8.61 11.98 
N. glauca  5-fluorouracil 8.31 7.94 20.19 
 
Carbamazepine 8.36 7.85 20.11 
 
Carvedilol 9.76 7.92 20.50 
 
Diazepam 7.54 7.94 19.96 
 
Fluoxetine 8.36 7.87 20.12 
 
Moclobemide 8.99 7.95 20.02 
P. corneus  Carvedilol 7.66 7.93 20.15 
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Figure 2.4 The mean measured internal concentration (± standard deviation) of 
Carvedilol in Gammarus pulex (n=6) at high (246 nmol L-1 or 0.1 mg L-1) and 
low (0.2 nmol L-1 or 0.1µg L-1) test concentrations  
 
Figure 2.5 The mean measured internal concentration (± standard deviation) of 
Fluoxetine in Gammarus pulex (n=6) at high (324 nmol L-1 or 0.1 mg L-1) and 
low (0.3 nmol L-1 or 0.1 µg L-1) test concentrations  
 
As carvedilol and fluoxetine have previously been shown to cause effects on 
invertebrates at low concentrations, a study was performed to assess the effect of 
concentration of these two pharmaceuticals on uptake (Brooks et al ,2003; Flaherty 
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and Dobson, 2005). There was no significant difference in the uptake of radioactivity 
at concentrations of 0.2 or 246 nmol L-1 of carvedilol and 0.3 or 323 nmol L-1 of 
fluoxetine. (t – test p = 0.62 and p = 0.34 for carvedilol and fluoxetine respectively; 
figures 2.4 and 2.5). The uptake and depuration rates and BCFs should therefore 
not be influenced by any toxicity occurring at the test concentration. 
The first order-one compartment kinetic model was fitted to the uptake and 
depuration measurements for G. pulex, P. corneus and N. glauca. The experimental 
measurements and modelled uptake and depuration curves are shown in figure 2.6 
to figure 2.12 and the rate constants and bioconcentration factors are provided in 
table 2.5. In G. pulex, BCFs ranged from 4.6 – 185900 and increased in the order 
moclobemide < 5-fluoruracil < carbamazepine < diazepam < carvedilol < fluoxetine. 
In N. glauca BCFs ranged from 0.1 – 1.6 and increased in the order 5-fluorouracil < 
carbamazepine < moclobemide < diazepam < fluoxetine < carvedilol. For P. corneus 
the BCF for carvedilol was 57.3. The largest BCF of 185900 was calculated for 
fluoxetine in G. pulex. The large BCF in G. pulex is due to the limited depuration in 
the animal (e.g. kout of 0.0008 d
-1, table 2.5) and is over 700 times higher than those 
reported in the literature. Published data on the uptake of pharmaceuticals are 
limited, but data are available on uptake of fluoxetine into fish (O. latipes) which 
provides some data for comparison. Nakamura et al., (2008) reported BCFs of 8.8 – 
260 and Patterson and Metcalfe (2008) reported BCFs of 74 - 80. Environmental 
monitoring studies have also shown concentrations of fluoxetine in fish to be 
significantly higher than concentrations in the surrounding water column 
(Lajeunesse et al., 2009, Schultz et al., 2010). 
The differences in the order of uptake between compounds in G. pulex and N. 
glauca may be partially explained by the ionisation state of the compounds in the 
test systems. The pH in the N. glauca uptake studies was 7.9, whereas in the G. 
pulex studies pH ranged from 8.5 – 8.9. Uptake of 5-fluorouracil, carvedilol and 
fluoxetine, which have pKa values in the range 8 – 10, would be sensitive to 
changes in pH in the range observed. However, in the experiments with 
carbamazepine, diazepam and moclobemide the same effects were observed where 
the effects of pH may not have been as important. Effects of pH on uptake of 
fluoxetine have been seen in fish in previous work, where uptake has increased 
from pH 7 to pH 9 (Nakamura et al., 2008). 
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Figure 2.6 Measured internal wet weight concentrations in a) Gammarus pulex 
(n=7; September 2007) and b) Notonecta glauca (n=3; July 2009) exposed to 
0.1 mg L-1 of 5-fluorouracil, providing an uptake and depuration curve over 
time. Black diamonds are the measured concentration of individual replicates, 
the blue line is the model fit and the red lines represent 95 % confidence 
intervals. The dashed line represents change from exposure solution to 
freshwater  
0
1000
2000
3000
4000
5000
6000
0 1 2 3 4 5
C
o
n
c
e
n
tr
a
ti
o
n
 [
p
m
o
l 
g
-1
]
Time [days]
depuration uptake 
0
50
100
150
200
250
0 1 2 3 4 5
C
o
n
c
e
n
tr
a
ti
o
n
 [
p
m
o
l 
g
-1
]
Time [days]
b 
Chapter 2 
97 
 
 
 
Figure 2.7 Measured internal wet weight concentrations in a) Gammarus pulex 
(n=7; September 2008) and b) Notonecta glauca (n=3; July 2009) exposed to 
0.1 mg L-1 of carbamazepine, providing an uptake and depuration curve over 
time. Black diamonds are the measured concentration of individual replicates, 
the blue line is the model fit and the red lines represent 95 % confidence 
intervals. The dashed line represents change from exposure solution to 
freshwater  
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Figure 2.8 Measured internal wet weight concentrations in a) Gammarus pulex 
(n=7; July 2007), b) Notonecta glauca (n=3; July 2008) and c) Planabarius 
corneus (n=3; February 2009) exposed to 0.1 mg L-1 of carvedilol. Black 
diamonds are the measured concentration of individual replicates, the blue 
line is the model fit and the red lines represent 95 % confidence intervals. The 
dashed line represents change from exposure solution to freshwater  
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Figure 2.9 Measured internal wet weight concentrations in a) Gammarus pulex 
(n=7; August 2007) and b) Notonecta glauca (n=3; July 2009) exposed to 0.1 
mg L-1 of diazepam, providing an uptake and depuration curve over time. 
Black diamonds are the measured concentration of individual replicates, the 
blue line is the model fit and the red lines represent 95 % confidence intervals. 
The dashed line represents change from exposure solution to freshwater 
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Figure 2.10 Measured internal wet weight concentrations in a) Gammarus 
pulex (n=3; June 2008) and b) Notonecta glauca (n=3; July 2009) exposed to 
0.1 mg L-1 of fluoxetine, providing uptake and depuration curve over time. 
Black diamonds are the measured concentration of individual replicates, the 
blue line is the model fit and the red lines represent 95 % confidence intervals. 
The dashed line represents change from exposure solution to freshwater  
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Figure 2.11 Measured internal wet weight concentrations in a) Gammarus 
pulex (n=7; September 2007) and b) Notonecta glauca (n=3; July 2009) 
exposed to 0.1 mg L-1 of moclobemide, providing an uptake and depuration 
curve over time. Black diamonds are the measured concentration of individual 
replicates, the blue line is the model fit and the red lines represent 95 % 
confidence intervals. The dashed line represents change from exposure 
solution to freshwater  
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5 – fluorouracil carbamazepine 
  
carvedilol diazepam 
  
fluoxetine moclobemide 
  
Figure 2.12 Measured internal wet weight concentrations on a log scale in 
Gammarus pulex, Notonecta glauca and Planabarius corneus exposed to 0.1 
mg L-1 of test pharmaceuticals between July 2007 and February 2009. 
Diamonds are the measured concentration of individual replicates, the red line 
is the model fit and the black lines represent 95 % confidence intervals 
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Table 2.5 Modelled mean uptake and depuration rate constants (± standard deviation), Bioconcentration Factors and goodness of fit 
data (95th percentiles) for the uptake into Gammarus pulex, Notonecta glauca and Planabarius corneus exposed to 0.1 mg L-1 of test 
pharmaceuticals 
Chemical Species Cw (µg l
-1
)
b
 
kint (L kg
-1 
d
-1
) 
mean ± SD (ML) 
a
 
kout (d
-1
) 
mean ± SD (ML) 
a
 
BCF (L kg
-1
) 
[95
th
 percentiles] 
5 – fluorouracil G. pulex 92.22 ± 1.66 2.70 ± 0.53 (2.86) 0.37 ± 0.16 (0.42) 6.48 [4.37 - 9.17] 
 N. glauca 100 ± 2.41 0.34 ± 0.09 (0.34) 2.52 ± 0.7 (2.6) 0.13 [0.07 - 0.21] 
carbamazepine G. pulex 142.68 ± 2.38 5.20 ± 0.66 (5.23) 0.72 ± 0.13 (0.73) 7.09 [5.47 - 8.94] 
 N. glauca 100 ± 0.56 0.29 ± 0.048 (0.30) 1.18 ± 0.23 (1.20) 0.24 [0.17 - 0.33] 
carvedilol G. pulex 94.78 ± 3.10 38.9 ± 2.26 (39.3) 0.13 ± 0.039 (0.15) 270.8 [240.6 - 303.4] 
 N. glauca 100 ± 1.03 4.72 ± 0.81 (4.62) 3.03 ± 0.52 (2.30) 1.6 [1.14 - 2.19] 
 P. corneus 91.38 ± 0.91 12.39 ± 1.37 (12.68) 0.20 ± 0.056 (0.22) 57.3 [50.46 - 71.29] 
diazepam G. pulex 92.93 ± 1.16 91.3 ± 14.5 (90.2) 2.48 ± 0.40 (2.44) 37.47 [26.49 - 50.22] 
 N. glauca 95.98 ± 1.82 0.97 ± 0.17 (0.96) 1.01 ± 0.22 (0.99) 0.98 [0.70 - 1.36] 
fluoxetine G. pulex 98.55 ± 16.54 51.6 ± 3.33 (51.8) 0.0008 ± 0.0008 (0.00028) 185900 [161800 - 209500] 
 N. glauca 95.65 ± 7.27 1.95 ± 0.24 (1.94) 1.42 ± 0.18 (1.41) 1.39 [1.08 - 1.75] 
moclobemide G. pulex 95.01 ± 0.93 0.46 ± 0.81 (4.65) 0.98 ± 0.21 (1.00) 4.55 [3.19 - 6.32] 
 N. glauca 100 ± 1.46 0.25 ± 0.062 (0.26) 0.70 ± 0.25 (0.75) 0.33 [0.19 - 0.52] 
a Mean ± SD (Standard Deviation) of sample of posterior, ML (Maximum Likelihood parameter value) 
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2.3.3 Comparison of uptake in G. pulex, N. glauca and P. corneus  
Uptake rates for all pharmaceuticals were greater in G. pulex than in N. glauca 
which can be clearly seen when transforming the uptake and depuration data onto a 
log scale (figure 2.12). The uptake rate constants were 8 (carvedilol) to 27 
(fluoxetine) times greater in G. pulex than N. glauca. Similarly, for 5 – fluoruracil, 
carbamazepine, diazepam and moclobemide, depuration rates were higher in G. 
pulex than N. glauca. However, for fluoxetine and carvedilol, following the uptake 
phase, only limited depuration was seen in G. pulex, so that depuration rates were 
slower than in N. glauca. BCFs in G. pulex ranged from 15 (moclobemide) to 
143000 (fluoxetine) times higher than in N. glauca. These findings are in agreement 
with those of Rubach et al., (2010) who investigated the uptake of the pesticide 
chlorpyrifos into 15 aquatic arthropods covering a range of species traits, including 
G. pulex and another Notonectid, Notonecta maculata. Uptake of chlorpyrifos into G. 
pulex was found to be much faster than for the other organisms tested. The uptake 
and depuration rate constants and the BCFs were, 5, 17.9 and 2.5 times greater in 
G. pulex than N. maculata, respectively. Possible explanations for the difference 
observed in the uptake between the test species for carvedilol may include 
differences in: respiration strategy, locomotion and behaviour and differences in the 
temperature and pH of the test system (Rubach et al., 2010a). Each of these is 
discussed in more detail below. 
Respiration in G. pulex occurs through the gills directly from the water whereas N. 
glauca respires via a plastron which stores a thin layer of air for the insect to breathe 
(Felten et al., 2008, Matthews and Seymour, 2010). Pulmonate molluscs use both 
cutaneous respiration through the skin and pulmonary respiration via a siphon from 
the surface to the mantle cavity (Jones, 1964). Uptake through the gills of aquatic 
organisms is a primary route of exposure to pharmaceuticals and other chemicals 
(Mimeault et al., 2005, Felten et al., 2008). The results of this study suggest that 
aquatic organisms that utilize plastron or pulmonary respiration may be less 
exposed to dissolved contaminants than those that breathe dissolved oxygen 
through gills. Both Baird and Van den Brink (2007) and Rubach et al (2010b) 
suggest that respiration type explained much of organisms sensitivity to 
contaminants. 
Locomotion mode may also have influenced the uptake of pharmaceuticals into 
tissues. G. pulex is an epibenthic crustacean and was therefore fully submerged 
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throughout the exposure. P. corneus, also a benthic dwelling organism, only 
remains near the water surface when filling the lung (Jones, 1964). However, N. 
glauca is a surface swimmer and active flier (Usseglio-Polatera et al., 2000). On one 
occasion in the present study a Notonectid was seen to have climbed up the side of 
the beaker before re-submerging itself. This type of avoidance behaviour has been 
previously recorded in response to a predator (Cook and Streams, 1984) and may 
well reduce the internal exposure concentration in the organism. The escape 
response of N. glauca was not quantified but may add to any variation in the data.  
Other biological traits play a key role in influencing uptake and bioconcentration 
such as size, lipid content and the metabolic capacity of the organism (e.g. Hendriks 
and Heikens, 2001, Rubach et al., 2010). In this study we found no correlations 
when comparing the wet weight or lipid content of any of the organisms and the 
internal concentration. Rubach et al., (2010b) also found no relationship between 
lipid content and chlorpyrifos uptake in all of the 15 organisms they tested.  
There is limited information available on the biotransformation of the study 
pharmaceuticals in aquatic organisms. However, information available for fish 
indicates that hepatic metabolism of pharmaceuticals such as fluoxetine is much 
less that for mammals (Smith et al., 2010). It is possible that pharmaceuticals are 
also metabolised to different extents in aquatic invertebrates, however further work 
is required to confirm or discount this. Chapter 3 will describe a series of studies that 
explore the metabolism of the study pharmaceuticals in G. pulex.  
 
2.3.4 Estimation methods for uptake of pharmaceuticals 
There are over 3,000 pharmaceuticals in use today (Richman and Castensson, 
2008). It is probably impractical to experimentally assess the environmental impact 
of all of these. One approach to estimating impacts is to measure internal 
concentrations of a pharmaceutical within an aquatic organism and to use data on 
plasma concentrations in humans alongside genomic information to estimate 
whether an effect is likely (e.g.Huggett et al., 2003a). One of the key parameters 
needed in this approach is the bioconcentration factor; therefore the relationships 
between BCF and the VD, Kow, Dlipw, solubility, MW and the PSA of the 
pharmaceutical were explored using linear regression (figure 2.13 to figure 2.17 and 
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table 2.6. The best relationship for G. pulex was found between VD and the 
bioconcentration factor. This supports previous work by Williams et al. (2009), where 
VD provided a good estimation of the distribution of the pharmaceutical between 
water and solids. A strong relationship was also obtained between BCF and Kow. 
Although pharmaceuticals are ionisable the data shows that Dlipw did not describe 
bioconcentration better than Kow for G. pulex when using a linear relationship. For N. 
glauca however, the linear relationships obtained proved stronger and more 
significant than those found for G. pulex. PSA showed the best relationship with 
bioconcentration followed by Dlipw; MW; Kow and VD.  
PSA describes the surface of the molecule in terms of its polar atoms and the 
molecules ability to permeate cells via active transport (Ertl et al., 2000). The 
relationships found between BCF and PSA were strong however to obtain the best 
fit carvedilol was excluded from the analysis. This may imply that some 
pharmaceuticals are transported actively while some are not, however much more 
research will be needed to elucidate this hypothesis. For both animals no 
relationships were found between BCF and solubility.  
The linear regression fitted to the data between BCF and PSA, VD, Kow, and Dlipw 
show that some of the relationships were not significant (table 2.6). Other nonlinear 
analyses such as exponential regression may be more appropriate and provide a 
better fit to the observed data (Appendix C), however more compounds should be 
tested to provide a more complete picture. These relationships could be invaluable 
in the future in prioritising testing requirements for pharmaceuticals in environmental 
systems. 
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Figure 2.13 Relationships between bioconcentration factors (± 95th percentile) 
for the study pharmaceuticals and Volume of Distribution (VD) for a) 
Gammarus pulex and b) Notonecta glauca. Diamonds are data points and the 
lines are linear regression 
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Figure 2.14 Relationships between bioconcentration factors (± 95th percentile) 
for the study pharmaceuticals and Log Kow for a) Gammarus pulex and b) 
Notonecta glauca. Diamonds are data points and the lines are linear 
regression 
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Figure 2.15 Relationships between bioconcentration factors (± 95th percentile) 
for the study pharmaceuticals and Log Dlipw for a) Gammarus pulex and b) 
Notonecta glauca. Diamonds are data points and the lines are linear 
regression 
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Figure 2.16 Relationships between bioconcentration factors (± 95th percentile) 
for the study pharmaceuticals and molecular weight for a) Gammarus pulex 
and b) Notonecta glauca. Diamonds are data points and the lines are linear 
regression 
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Figure 2.17 Relationships between bioconcentration factors for the study 
pharmaceuticals and Predicted Polar Surface Area for a) Gammarus pulex and 
b) Nontonecta glauca. Diamonds are data points and the lines are linear 
regression 
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Table 2.6 Regression analysis of the relationships between bioconcentration factors calculated for the study pharmaceuticals and 
physicochemical properties 
Organism 
Parameter for Predicting 
BCF 
Regression R
2
 Equation P value Figure 
G. pulex 
Log VD 
linear 0.80 BCF= 2.25 x Log VD + 1.39 0.06 2.13 a 
N. glauca linear 0.42 BCF= 0.42 x Log VD – 0.38 0.67 2.13 b 
G. pulex 
Log Kow 
linear 0.64 BCF= 0.76 x Log Kow + 0.28 0.06 2.14 a 
N. glauca linear 0.75 BCF = 0.21 x Log Kow - 0.73 0.03 2.14 b 
G. pulex 
Log Dlipw 
linear 0.50 BCF= 0.76 x Log Dlipw + 0.29 0.12 2.15 a 
N. glauca linear 0.84 BCF = 0.25 x Log Dlipw - 0.82 0.01 2.15 b 
G. pulex 
MW
a 
linear 0.24 BCF = 0.009 x MW – 0.65 0.33 2.16 a 
N. glauca linear 0.81 BCF = 0.004 x MW – 1.49 0.02 2.16 b 
G. pulex 
PSA 
b 
linear 
c
 0.67 BCF= -0.11 x PSA + 6.41 0.09 2.17 a 
N. glauca linear 
c 
0.96 BCF= -0.03 x PSA + 0.83 0.004 2.17 b 
aMW Molecular weight; b PSA Polar Surface Area; c linear relationship excludes carvedilol 
Chapter 2 
113 
 
2.4 Conclusions 
The present study has shown that pharmaceuticals can be taken up from the 
ambient water into the tissues of aquatic invertebrates. The extent of uptake is 
dependent on the physico-chemical properties of the pharmaceutical and may be 
influenced by the test species itself. Uptake into an individual invertebrate species 
can be estimated based on the pH-corrected liposome water partition coefficient of a 
pharmaceutical. When combined with information on predicted exposure 
concentrations, receptor conservation within an organism and pharmacological 
information, these relationships are likely to be invaluable in identifying 
pharmaceuticals which are likely to pose the greatest concern in aquatic systems. 
Further work is now needed on a broader range of organisms covering a wide range 
of traits and with different levels of metabolic activity. Ultimately, we should aim to 
be developing relationships that combine physico-chemical properties and the 
biological traits in order to understand the internal exposure within an organism. By 
combining these relationships with information on drug potency and conservation of 
drug receptors within aquatic organisms we should be much better placed to 
establish the broad risks of pharmaceuticals to aquatic ecosystems 
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Chapter 3 The metabolism of pharmaceuticals in Gammarus 
pulex 
 
3.1 Introduction 
As discussed in Chapter 1 the fate of pharmaceuticals in crustaceans such as G. 
pulex is determined by the processes of uptake, metabolism and elimination. 
Radiolabelled studies such as those described in Chapter 2 enable the 
measurement of internal concentrations, uptake and elimination of pharmaceuticals 
in small tissue samples; but they do not provide information on the metabolism of 
the compound. The BCF determination should be based on the parent compound 
and should not include metabolites. Uncertainty in BCFs calculated for radiolabelled 
compounds arises because there is no differentiation between radiolabelled parent 
and radiolabelled metabolites (Arnot and Gobas, 2006). An over estimation of a BCF 
determined with radiolabelled compounds can occur when the parent is metabolized 
to a radiolabelled metabolite. By contrast an underestimate of the BCF can occur if 
the radiolabelled metabolite is eliminated to the water resulting in an over estimation 
of the radiolabelled parent compound in the water (Arnot and Gobas, 2006). Also 
degradation of the parent compound in the water during the exposure can contribute 
to error in calculation of the BCF. This demonstrates the need for an approach that 
is able to measure parent and any transformation products individually when 
investigating metabolism. 
The metabolic fate of a compound can have an important influence on its 
accumulation potential in the organism. In mammals metabolism of compounds can 
be grouped into two phases; phase 1 reactions that introduce a functional group on 
the parent compound including oxidation, reduction and hydrolysis; and phase 2 
reactions which lead to the covalent linkage between sulphate groups, sugars or 
peptides with polar elements such as –COOH, -OH, or –NH2 groups increasing the 
polarity of the compound. This allows the compound to be eliminated rapidly 
(Timbrell, 2002, Brouwer and Lee, 2007). For examples of the metabolic pathways 
of human pharmaceuticals in man the reader is referred to Figure 3.1. 
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Figure 3.1 Metabolic pathways of human pharmaceuticals in man; A, 5-
fluorouracil; B, carbamazepine and C, fluoxetine (Drug Bank 
http://www.drugbank.ca/)  
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Figure 3.1 continued Metabolic pathways of human pharmaceuticals in man; 
D, carvedilol and E, diazepam (Drug Bank http://www.drugbank.ca/)  
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The majority of phase 1 oxidation reactions are catalysed by the cytochrome P450 
enzymes (CYP-450) which are widely distributed across the animal kingdom 
(Wilkinson, 2001). They may play an important role in the metabolism of compounds 
in many organisms including fish and crustaceans (James and Boyle, 1998).  
Pharmaceuticals are engineered to act on a particular target such as enzymes, ion 
channels and receptors (Winter et al. 2009). Many of these particular targets could 
be well-conserved through evolutionary lines. There are complete genomes mapped 
for several aquatic species including the Gasterosteus aculeatus (Three-spined 
stickleback), Danio rerio (zebrafish) and Daphnia pulex (water flea). Work by 
Gunnasson et al. 2008 evaluated the conservation of different functional drug 
targets and found that in D. pulex 61 % were derived from a common ancestral 
protein to those found in man. Also manual curation of the D. pulex genome has 
identified 75 functional CYP-450 genes. The genes for processing CYP-450 2, 3, 4, 
enzymes identified in the Daphnia pulex genome are similar to those CYP-450 
genes identified insects and vertebrates (Baldwin et al., 2009). Many of these CYP-
450 enzymes are used for metabolising pharmaceuticals, suggesting that it may be 
possible to predict the metabolism and effects of pharmaceuticals in non-target 
species. These predictions could be based on mammalian metabolic pathways and 
known interactions between pharmaceuticals and drug targets in man (Gunnasson 
et al. 2008). For example the identification of norfluoxetine in fish after exposure to 
fluoxetine by Paterson and Metcalfe (2008) could have been predicted from known 
metabolic pathways of fluoxetine in man (figure 3.1C). Other known metabolites of 
human pharmaceuticals have also been identified by a number of authors in fish 
including metabolites of diclofenac, sertraline and 17 α-ethinylestradiol (Brooks et 
al., 2005, Flores and Hill, 2008, Kallio et al., 2010). 
For invertebrates, research into metabolism of pharmaceuticals is limited, however 
they have been shown to metabolise other environmental contaminants (Nuutinen et 
al., 2003b). For example, it is known that in crustaceans the hepatopancreas 
accumulates many of the compounds transported by the haemolymph from the site 
of uptake and performs many of functions that are associated with the liver in 
mammals such as the metabolism of xenobiotic compounds (Brouwer and Lee, 
2007). Invertebrates possess a suite of metabolic enzymes and have been shown to 
metabolise environmental contaminants (Livingstone, 1998, Nuutinen et al., 2003b), 
such as polyaromatic hydrocarbons, pesticides and steroids. For example, steroid 
hydroxylated metabolites and conjugates have been shown to be formed after 
exposure to progesterone and testosterone (Summavielle et al., 2003). There is 
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evidence to suggests that pharmaceuticals can also be metabolized by CYP-450 
enzymes in crustaceans for example oxidized metabolites of erythromycin and 
sulfadimethoxine, pharmaceuticals commonly used in aquaculture, were found in 
the American lobster, Homarus americanus (James, 1990a, James, 1990b, James 
and Boyle, 1998). 
Research into the metabolism of pharmaceuticals in non-target organisms is 
important as it has implications for the environmental risk assessment of these 
compounds. Knowledge of the metabolic capacity of non-target organisms is 
necessary for accurate calculation of BCFs and the toxicity of the compound to the 
organism. In Phase 1 metabolism the reactions are catabolic and the metabolites 
formed are often chemically more reactive (Rand and Dales, 2008). Active 
metabolites such as norfluoxetine contribute to the overall potency of the parent 
compound and can have longer elimination half-lives (Paterson and Metcalfe, 2008, 
Straub, 2008). This will lead to an increased potential for bioaccumulation of active 
metabolites compared to the parent compound only, leading to increased potential 
of toxic effects on non-target organisms (Paterson and Metcalfe, 2008). 
New methods have to be developed in order to study the metabolism of 
pharmaceuticals in aquatic invertebrates as when studying radiolabelled compounds 
there is no differentiation between radiolabelled parent and radiolabelled 
metabolites. The use of mass spectrometry methods has increased enormously in 
recent years due to improved mass resolution for small molecules (m/z <800), 
selectivity, throughput of analysis and greater affordability. Mass spectrometry 
techniques gaining in popularity include tandem quadrupole (QqQ-MS), ion trap (IT-
MS) and accurate mass measurement methods such as. time-of-flight (Tof-MS) and 
LTQ-Orbitrap-MS (Gilbert et al., 2009). These techniques have been shown to be 
useful tools in the structural identification of small molecules in the pharmaceutical 
industry (Pérez-Carrera et al., 2010) and are beginning to be applied to the 
identification of 'unknowns', such as pharmaceutical-transformation products, in the 
environment (Radjenović et al., 2009). 
The research described in this Chapter is among the first to investigate the 
metabolism of human-pharmaceuticals in Crustacea. The objective of the research 
was to detect and identify any metabolites formed after exposure of Gammarus 
pulex to pharmaceuticals. The research involved: 
 The development and evaluation of a simple solvent extraction 
procedure suitable to isolate analytes from Gammarus pulex and 
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compatible with ultra-performance liquid chromatography – 
quadrupole – time of flight mass spectrometry (UPLC-QTof-MS) 
 The optimization of UPLC-QTof-MS parameters (including software 
protocols) for the detection, quantification and identification of parent 
compounds and metabolites present in the tissues of Gammarus 
pulex exposed to human pharmaceuticals 
 To repeat pharmacokinetic experiments using non-labelled 
pharmaceuticals to allow measurements by the optimized UPLC-
QTof-MS methods 
 To compare the results for uptake and depuration of parent and 
metabolite compounds obtained from radio-labelled experiments and 
measurements using LSC, with those obtained using non labeled 
pharmaceuticals measured by UPLC-QTof-MS 
 
3.2 Materials and methods 
3.2.1 Experimental organisms, exposure water and handling 
Gammarus pulex (both males and females) were collected from Bishop Wilton Beck, 
a small stream northeast of York U.K. (E479600, N455000) in February 2008 for 
metabolite identification studies and September 2009 for uptake and depuration 
studies. In the laboratory the animals were maintained in a 5 L aquarium in APW 
and kept at ca. 20 °C under a natural light regime (Naylor et al. 1989). Animals were 
fed a diet of rehydrated horse-chestnut leaves (Aesculus hippocastanum) inoculated 
with the fungus Cladosporium herbarum prior to use. 
 
3.2.2 Pharmaceuticals compounds 
Radiolabelled and unlabelled pharmaceuticals 5-fluorouracil, carvedilol, diazepam, 
nordiazepam and moclobemide (Figure 3.2) were provided by F. Hoffman-la Roche 
Ltd (Basel, Switzerland), whilst carbamazepine and fluoxetine were obtained from 
Agriculture and Agri-Food Canada, London, Ontario and Sigma-Aldrich Company 
Ltd.UK. Information on the chemical properties of the pharmaceuticals is provided in 
table 2.1 and table 2.2. 
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Figure 3.2 Molecular structures of the test pharmaceuticals 
 
3.2.3 Experimental procedure 
3.2.3.1 Preparation of stock standard solutions 
Standard stock solutions of pharmaceuticals (10 µg mL-1) were prepared by 
dissolving the compound in methanol at room temperature. All stocks were stored in 
the dark at - 20 °C before use in the metabolism studies.  
 
3.2.3.2 Development and evaluation of the solvent extraction procedure using 
radiolabelled compounds 
An alternative simple and rapid extraction procedure was required that avoided the 
use of Soluene in order to be compatible with UPLC-QTof-MS. The extraction 
procedure needed to provide effective extraction of parent and metabolite 
5-fluorouracil 
5-fluorouracil 
carbamazepine 
carvedilol 
fluoxetine moclobemide diazepam 
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compounds, but with minimal clean-up in order to avoid any losses of analytes of 
interest. It was therefore decided to employ a simple solvent extraction. 
It was not permitted to analyse radio-labelled compounds using the UPLC-QTof-MS 
instrumentation available to the project. Therefore, the initial evaluation of the 
methanol extraction was undertaken by spiking radio-labelled pharmaceuticals onto 
homogenized Gammarus pulex tissues and then determination of the ‘recovery’ of 
spiked analytes by LSC. The spiking approach does not determine the ‘extraction 
efficiency’ of incurred or bound residues but simply indicates any losses of analytes 
occurring during extraction and clean-up. 
Five non-treated (‘blank’) G. pulex samples (0.24 ± 0.04 g mean ± standard 
deviation, n=5) were ground with methanol (1 mL) using a pestle and mortar until 
the mixture was visibly homogeneous. The homogenized tissue was spiked with 10 
µL of each radioactive stock solution. The spiking solutions added were then 
allowed to permeate the sample for approximately two minutes. 
The spiked homogenate was transferred to a Teflon centrifuge tube using methanol 
(2 x 2 mL) to rinse the pestle and mortar. The final volume of the extract was 
approximately 5 mL. The extract was shaken on a rotary shaker, 200 MOT for 10 
minutes then centrifuged at 3500 rpm at 5 °C for 15 minutes. The supernatant of 
each sample was filtered through a 0.2 µm PTFE 13 mm minisart filter (Sigma-
Aldrich Company Ltd. Dorset, UK) and the filtrate evaporated to dryness in the fume 
hood overnight. The resulting residue was made up with methanol (1 mL), with 
vortex mixing (Clifton cyclone, 1min) and sonication (15 minutes) to aid dissolution 
of the matrix. A sub-sample (300 µL) was taken for LSC analysis and the remaining 
extract was stored at -20 °C.  
To evaluate the recovery of analyte, the concentration in the extract were analysed 
against radioactive pharmaceutical standards prepared in methanol. The final 
extracts and solvent standards were mixed with Hionic fluor scintillant (Perkin Elmer, 
USA; 10 mL) and left to stand (approx. 15 min). The radioactivity in the samples was 
measured by LSC using the methods described in section 2.2.5. The radioactivity of 
the residues obtained from extracts of G. pulex was compared to the radioactivity in 
the corresponding solvent standard to determine the recovery of the pharmaceutical 
analytes from the sample. 
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3.2.3.3 Preliminary screening experiments for the detection and identification 
of metabolites using UPLC-Tof-MS 
Firstly, small-scale experiments were undertaken for all of the test compounds to 
evaluate the method and also to provide G. pulex tissue that could be screened for 
the presence of metabolites. Three replicate vessels containing ten animals in 500 
mL of APW (pH 8.78 ± 0.14, dissolved oxygen 7.59 ± 0.4 mg L-1 at 12 °C mean ± 
standard deviation, n=3) were prepared for each pharmaceutical treatment, and one 
set of replicates used as the solvent control (0.1% Methanol). The vessels were 
equilibrated to the experimental conditions for 48 hours prior to the start of the 
experiments. The vessels were then spiked with the individual non-labelled 
pharmaceutical (0.5 mg L-1) and G. pulex were exposed for 48 hours. After the 
exposure period, the G. pulex were removed, rinsed in deionised water and frozen 
at - 20 °C before extraction with methanol (see Chapter 2) and analysis by UPLC-
QTof. 
 
3.2.3.4 Preparation of standard solutions in solvent, pond water and G. pulex 
tissue for calibration of UPLC-QTof-MS  
Three sets of calibration standards at concentrations of 5, 1, 0.5, 0.1, 0.05 and 0.01 
µg mL-1 were prepared by serial dilution of standard stock solution into methanol, 
APW or extracted G. pulex (matrix). The UPLC-Tof-MS responses for these 
standards were compared to evaluate MS suppression effects. Also, the stability of 
the compounds in the calibration standards prepared 6 months previously was 
tested by reanalysing samples against freshly prepared stock solutions by UPLC-
QTof-MS. 
 
3.2.3.5 Large-scale-pharmacokinetic experiment using non-labelled diazepam 
Uptake and depuration studies were carried out using the method as described in 
section 2.2.5 adapted from Ashauer et al. (2006). Test species were acclimatized to 
the test conditions for 24 hours without food under a specific photoperiod (12 hours 
light: 12 hours dark). A static exposure was used and water quality parameters (pH, 
dissolved oxygen) were monitored throughout the experimental periods using a 
Symphony SB80BD bench top meter (VWR International LtD, UK). G. pulex were 
exposed to 2 µmol L-1 (0.5 mg L-1) of diazepam. 
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Animals were exposed to 500 mL of test solution for 0, 3, 6, 12, 24 and 48 hours. 
Each individual pharmaceutical experiment comprised five replicates of twenty 
animals with the individual animals separated by stainless steel cages to avoid 
cannibalism. After 48 hours exposure to diazepam the remaining organisms were 
transferred to clean non-treated water in order to study depuration. The depuration 
study was run for the same time period as the uptake study with samples collected 
at the equivalent time points. At each sampling point, two animals were taken from 
each replicate and pooled (n = 10). The animals were rinsed in deionised water to 
remove any pharmaceutical residue from their surface and weighed. The samples 
were then frozen at – 20 °C prior to analysis. Sample of exposure water (1 mL) were 
collected at each time point to enable determination of the diazepam exposure 
concentration by UPLC-Tof MS analysis. 
 
3.2.3.6 Instrumentation: Liquid chromatography 
Chromatographic separation was performed using an ACQUITY® UPLC® system 
operating with a ACQUITY® UPLC® HSS C18, 2.1 x 50 mm, 1.8 mm column 
(Waters, Manchester, U.K.). Mobile phase A comprised of 0.1 % formic acid in water 
and mobile phase B comprised of 0.1 % formic acid in methanol. A linear gradient 
was applied: 0 min: 100 % A; 6 min: 0 % A; 8 min: 0 % A; 8.1 min: 100 % A; 10 min: 
100 % A. The flow rate was set to 0.6 mL min-1, the column temperature to 40 °C 
and sample extract temperature to 5 °C. The injection volume was 5 µL using a 5 
mL partial loop with no overfill. 
 
3.2.3.7 Instrumentation: Mass spectrometry 
The mass spectrometry was performed using a Waters-Xevo™ QTof-MS (Waters, 
Manchester, U.K.) operated in MSE mode to allow acquisition of low energy 
precursor ion data and high energy fragment ion data in a single run. The MSE low 
energy was set at 6.0 and higher energy 25 – 30 V. The electrospray ionisation 
interface was operated in either positive mode or negative mode. The capillary 
voltage was maintained at 0.8 kV and sample cone voltage at 10 V. The source 
temperature was 120 °C and desolvation temperature was 450 °C. Nitrogen was 
used both for the desolvation gas, 800 L hour-1 and the cone gas, 5 L hour-1. 
Cumulated spectra (m/z: 50 – 1000) were taken every 0.1 seconds. A LockSpray™ 
interface was used to correct the mass axis and the Lock spray compound was 
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Leucine enkephalin which has a two point lock mass (m/z 278.1141 and m/z 
556.2771). 
 
3.2.3.8 UPLC –QTof-MS analysis 
Four replicate injections were made of each of the extracts collected from the 
treated and non-treated experiments. To prevent carry-over of analyte into the 
following analysis methanol was injected after treated extracts. Mass spectra were 
acquired using the UPLC-Tof-MS conditions described in Sections 3.2.3.6 and 
3.2.3.7. Data acquisition and processing were performed using MassLynx V4.1 
Software (Waters, Manchester). 
 
3.2.3.9 UPLC-QTof-MS post acquisition data analysis 
The data was evaluated automatically using MetaboLynx XS proprietary software 
(Waters, Manchester UK) and using MassLynx V4.1 software to manually reverse 
search the total ion chromatogram for the exact monoisotopic mass of the formulae 
proposed by chemical modelling. An overview of data processing scheme is given in 
Figure 3.3. 
Post-acquisition data processing software MetaboLynx XS V4.0 (Waters, 
Manchester) was applied to both the full scan and product ion data. This software 
uses peak detection algorithms and complex statistical analysis to profile differences 
between the control samples (non-treated) and treated samples. Extracts are 
normally injected multiple times (n = at least 3) to improve the reliability. In theory, 
any differences are due to the treatments, but in practice the detection of significant 
differences (metabolites at trace concentrations) in complex matrices is extremely 
challenging. There is a risk that this automated non-targeted approach may fail to 
detect all of the metabolites. 
To minimize the risk of non detection a targeted approach (manual reverse 
searching) was also undertaken. The individual Tof MS (full range acquisition) mass 
chromatograms were reversed searched using the exact monisotopic data for all of 
the possible psedomolecular ions, adduct ions, and metabolite structures (predicted 
from chemical modelling; Table 3.1). 
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Figure 3.3 Sequence of the analysis of extracts using UPLC-QTof-MS 
 
The accurate mass of any suspect peaks (potential metabolites) from acquisition of 
Tof data over the full mass range provides the possible empirical formulae, but not 
the chemical structure and hence identity of the compound. Unequivocal 
identification requires the availability of the standard reference material and MS/MS 
fragmentation information. The identification of parents and metabolites is usually 
verified by confirming that the retention time, Tof spectra (including isotope pattern) 
and MS/MS product ion spectra of peaks in the sample extracts match with those 
from the analysis of the standard reference materials.  
The MetaboLynx software incorporates a ‘dealkylation tool’ to facilitate 
characterisation of fragments of the parent molecule by systematically identifying 
likely bond metabolic cleavages to predict the fragments produced during MS/MS. 
Once the identification is verified quantification was undertaken using QuanLynx 
software (Waters, Manchester) to compare the response of the measured mass of a 
MetaboLynx – Mass profiling (blank 
vs spiked extract) 
MassLynx – Reverse search using 
exact mass  
Raw Data 
QTof 
Comparison of standards with 
compounds in extract (RT and exact 
mass) 
Fragmentation 
identification of analyte 
quantification of analyte 
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component at a specified retention time with the corresponding response in matrix-
matched calibration standards. 
 
3.2.4 Derivation of uptake and depuration rate constants and bioconcentration 
factors 
A first-order one-compartment toxicokinetic model was fitted to the internal 
concentration data using individual replicates to estimate the parameters uptake and 
elimination rate constants and the BCFs, the reader is referred to Chapter 2. 
A pseudo BCF (Nakamura et al., 2008) was also calculated for metabolite residues, 
with the concentration of metabolite measured in G. pulex after 48 hours exposure 
and the average water concentration of the parent pharmaceutical using Equation 
3.1: 
 
Equation 3.1         
         
      
 
 
3.3. Results  
3.3.1 Extraction method performance 
An extraction methodology was required that would be compatible with Tof-MS. The 
extraction procedure used in radiolabelled studies in Chapter 2 was not suitable, as 
Soluene 350 (Perkin Elmer, USA) is highly corrosive. However, the use of radio-
labelled pharmaceuticals with LSC was employed to evaluate a simple extraction 
method. This approach was convenient because access to the Tof-MS 
Instrumentation was limited. Using methanol as extraction solvent the recovery of 
parent pharmaceutical compounds spiked into homogenized G. pulex tissue ranged 
from 82 – 97% and increased in the order fluoxetine < carvedilol < diazepam < 
carbamazepine < moclobemide < 5-fluorouracil (Figure 3.4). 
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Figure 3.4 Radiolabelled recoveries of incurred residues of test 
pharmaceuticals from Gammarus pulex tissues (n=5). Mean percentage 
recovery (± standard deviation) of 5-fluorouracil, carbamazepine, carvedilol, 
diazepam, fluoxetine and moclobemide  
50 60 70 80 90 100 110
5-fluorouracil
moclobemide
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Table 3.1 Target metabolites of test pharmaceuticals identified for post target screening, the exact monisotopic data predicted from 
chemical modelling 
Exact Mass [M+H]
+
 
Metabolite 5-fluorouracil carbamazepine carvedilol diazepam fluoxetine norfluoxetine moclobemide 
Hydroxylation/Sulphur oxidation (1) 147.02005 253.09715 423.19145 301.07383 326.13624 312.12059 285.1006 
Dihydroxylation/Sulphur oxidation (2) 163.01496 269.09207 439.18636 317.06875 342.13115 328.1155 301.19551 
Dehydroxylation 115.03022 221.10732 391.20162 269.084 294.14641 280.13076 253.11077 
Demethylation 117.00948 223.08659 393.18088 271.06327 296.12568 282.11003 255.09003 
Glucuronidation 307.05722 413.13433 583.22862 461.11101 486.17341 472.15776 445.13777 
Acetylation 173.0357 279.1128 449.2071 327.08948 352.15189 338.13624 311.11625 
Sulfation 210.98195 317.05905 487.15335 365.03573 390.09814 376.08249 349.0625 
Dehydrogenation 129.00948 235.08659 405.18088 283.06327 308.12568 294.11003 267.09003 
Oxidation (1) 145.0044 251.0815 421.1758 299.05818 324.12059 310.10494 283.08495 
Oxidation (2) 160.99931 267.07642 437.17071 315.0531 340.1155 326.09985 299.07986 
Hydration 149.0357 255.1128 425.2071 303.08948 328.15189 314.13624 287.11625 
Reduction 133.04078 239.11789 409.21218 287.09457 312.15698 298.14133 271.12133 
Glycosylation 293.07796 399.15505 569.24936 447.13174 472.19415 458.1785 431.1585 
Methylation 145.04078 251.11789 421.21218 299.09457 324.15698 310.14133 283.12133 
  
 
Table 3.1 continued: Target metabolites of test pharmaceuticals identified for post target screening, the exact monisotopic data 
predicted from chemical modelling 
Exact Mass [M+H]
+
 
Metabolite 5-fluorouracil carbamazepine carvedilol diazepam fluoxetine norfluoxetine moclobemide 
Carbamoyl glucuronidation 351.07086 457.14797 627.24226 505.12464 530.18705 516.1714 489.15141 
Glycine conjugation 188.0466 294.1237 464.218 342.10038 367.16279 353.14714 326.12714 
Taurine conjugation 236.01358 342.09069 512.18498 390.06737 415.12977 401.11412 374.09413 
Glutamine conjugation 259.08371 365.16082 535.25511 413.13749 438.1999 424.18425 397.16426 
Proline conjugation 228.0779 334.155 504.2493 382.13168 407.19409 393.17844 366.15844 
Serine conjugation 218.05716 324.13427 494.22856 372.11095 397.17335 383.1577 356.13771 
Arginine conjugation 287.12624 393.20335 563.29764 441.18003 466.24244 452.22679 425.20679 
Histidine conjugation 268.08404 374.16115 544.25545 422.13783 447.20024 433.18459 406.16459 
Aspartic acid conjugation 246.05208 352.12918 522.22348 400.10586 425.16827 411.15262 384.13262 
N-acetylcysteine conjugation 276.04488 382.12199 552.21628 430.09867 455.16107 441.14542 414.12543 
Gluthathione conjugation 438.10894 544.18605 714.28034 592.16272 617.22513 603.20948 576.18949 
Fluorine displacement 129.02947 NA NA NA 308.14566 294.13001 NA 
Chlorine displacement NA NA NA 267.1128 NA NA 251.13957 
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As methanol extraction provided satisfactory recovery for the purpose of detection 
and identification, no other organic solvents were tested. The presence of water in 
the tissues may have improved the recovery of the more polar compounds. The use 
of higher proportions of water or combinations of solvent (e.g. methanol/acetone) 
could be considered in future work and may be necessary if different pharmaceutical 
compounds are evaluated.  
The experiment undertaken only measures recovery of compounds spiked into the 
matrix and gives no information of the extraction efficiency of incurred residues. 
However, an indication of extraction efficiency of incurred residues was obtained by 
comparing results from radiolabelled studies with the results from methanol 
extraction and UPLC-QTof-MS analysis. These are outlined later in the text. 
 
3.3.2 Matrix suppression and standard stability of diazepam and nordiazepam 
Three sets of standards were prepared in solvent, APW and G. pulex extracts to 
assess any suppression (lowering of the detector response) of the Tof-MS signal. 
The results indicate that the APW and G. pulex matrices suppress the response of 
diazepam and nordiazepam compared to the solvent standards (Figure 3.5). This 
observation can be explained by the increased concentration of matrix co-
extractives providing competition for charge during the electrospray ionisation 
process. As a result less analyte ions enter the mass spectrometer so the response 
is decreased. 
Consequently calibration standards were prepared in appropriate blank matrix 
(instead of pure solvent) in order to provide accurate quantification of the 
concentrations of diazepam and nordiazepam. The concentrations of diazepam and 
nordiazepam were stable in samples that had been stored at -20 ºC for 6 months.  
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Figure 3.5 Suppression effects on the UPLC-QTof-MS response of 
nordiazepam in the matrix analysed tested at concentrations of 0.01, 0.05, 0.1, 
0.5, 1 and 5 µg mL-1 of nordiazepam (white diamonds are methanol solvent 
standards, blue diamonds are artificial pond water (APW) standards and red 
diamonds are Gammarus pulex extracts; n=3) 
 
3.3.3 Screening and identification of parent and metabolite pharmaceutical 
residues 
The chromatographic separation of the parent compounds is shown in Figure 3.6. 
Moclobemide, carvedilol, carbamazepine fluoxetine and diazepam gave best 
response in the positive ion mode, whilst 5-fluorouracil gave best response in the 
negative ion mode. The use of polarity switching enabled all of the compounds to be 
analysed in a single analysis.  
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Figure 3.6 Extracted mass chromatograms of test pharmaceuticals from 
extracts of Gammarus pulex after 48 hours exposure to 0.5 mg L-1; Compound 
identities and retention times (minutes) are: 5-fluorouracil (0.26), moclobemide 
(1.97) carvedilol (3.39) carbamazepine (3.63) fluoxetine (3.80) and diazepam 
(4.26) using UPLC-QTof-MS 
 
Since Tof-MS acquires ‘all of the data all of the time’ each peak is the combined 
response of a number of ions related to the analyte e.g. psudomolecular species, 
adducts, fragments etc. In practice the predominant species were the protonated 
[M+H]+ species in the positive mode and deprotonated [M-H]- species in the 
negative mode. Typical values for the measured accurate mass and the calculated 
exact mass for these species is given in Table 3.2. 
 
3.3.3.1 UPLC-QTof-MS post acquisition data analysis 
Processing the Tof-MS data either by MetaboLynx software or by reverse searching 
using exact mass (Table 3.1) did not detect any metabolites in the samples of G. 
pulex exposed to 5-fluorouracil, carbamazepine, carvedilol, fluoxetine or 
moclobemide. However, a compound with m/z 271.0638 possibly corresponding to 
the demethylated compound (nordiazepam) was detected in the G. pulex exposed 
to diazepam (Figure 3.7 and Figure 3.8). Nordiazepam the primary metabolite of 
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diazepam in mammals was not detected in the exposure water suggesting that 
diazepam was metabolized by G. pulex. Agreement of retention time (RT: 3.96), 
elemental composition, and isotope pattern (Figure 3.9) for this compound with 
standards prepared in matrix and solvent provides evidence of the identity as 
nordiazepam. 
 
Table 3.2 Measured masses of pharmaceutical residues found in Gammarus 
pulex tissues compared to exact masses of 5-fluorouracil, carbamazepine, 
carvedilol, diazepam, fluoxetine and moclobemide using UPLC-QTof-MS 
Compound Molecular mass [g 
mol
-1
] 
Exact mass Measured mass of incurred 
residues 
[M+H]
+
 [M-H]
-
 [M+H]
+
 [M-H]
-
 
5-fluorouracil 130.08 131.0257 129.0100 - 129.0103 
Carbamazepine 236.27 237.1028 235.0871 237.1043 - 
Carvedilol 406.47 407.1971 405.1814 407.1975 - 
Diazepam 284.75 285.0795 283.0638 285.0806 - 
Fluoxetine 309.33 310.1419 308.1262 310.1417 - 
Moclobemide 268.74 269.1057 267.0900 269.1069 - 
 
The measured accurate mass of nordiazepam in G. pulex tissues was m/z 271.0638 
which was 0 ppm different to the exact mass of nordiazepam m/z 271.0638 in the 
solvent standard. Since nordiazepam contains a chlorine atom the isotope pattern 
CL35/Cl37 is very characteristic and the software calculated i-fit (isotope fit) of 0. 
The agreement of the isotope pattern with the reference standard provides further 
evidence to support nordiazepam as the identity of the compound. 
For diazepam, the fragments generated by QTof (MSE experiments) were the same 
for the fragmentation of ions of the solvent standard and G. pulex extract. Extracted 
ion chromatograms for each of the fragment ions detected in the high energy MSE 
spectrum confirm that the fragment ions are related to the selected [M+H]+ 
precursor ion, m/z 285.0795, due to their identical retention times to the precursor 
ion (Figure 3.10). 
Unfortunately the MSE collision energy was too low to be able to differentiate the 
nordiazepam fragments from the matrix. Although retention time and the elemental 
composition data of nordiazepam provide convincing evidence, unequivocal 
confirmation requires UPLC-QTof-MS/MS fragmentation data. These studies are still 
in progress. 
  
 
 
 
Figure 3.7 Total ion chromatograms with high and low energies and extracted ion chromatograms for a) diazepam and b) 
nordiazepam in methanol solvent standards using UPLC-QTof-MS 
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Figure 3.8 Extracted ion chromatograms for a) diazepam and b) nordiazepam 
and c) MS
E
 total ion chromatogram with high and low energies in Gammarus 
pulex samples after 48 hours exposure to diazepam (0.5 mg L-1) using UPLC-
QTof-MS
B 
A 
C 
  
 
 
 
Figure 3.9 MassLynx software V4.1 screen shot of elemental composition of a) diazepam m/z 285.0806 and b) nordiazepam m/z 
271.0638 in Gammarus pulex tissues exposed to diazepam (0.5 mg L-1) for 48 hours. Masses ranked by closest isotope fit (post – 
acquisition data from UPLC QTof MS)  
B m/z 271.0638 
m/z 285.0806 
  
 
 
Figure 3.10 Extracted ion chromatograms precursor ion and fragment ions for diazepam in a) solvent standards and b) Gammarus 
pulex tissues in high energy MSE spectrum (post – acquisition data from UPLC QTof MS) 
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3.3.4 Pharmacokinetic studies with non-labelled diazepam 
The results from the metabolite detection and identification study indicated that 
diazepam was metabolized to nordiazepam by G. pulex. Therefore a 
pharmacokinetic study was performed to study the uptake and metabolism of 
diazepam over time. The water quality parameters remained constant during the 
study (Table 3.3). Water concentration of diazepam ranged between 90-85 % of the 
starting concentration and no nordiazepam was detected in the water throughout the 
study (Figure 3.11). 
Diazepam is accumulated immediately in G. pulex. After 3 hours of exposure 
nordiazepam is detectable in the animal (Figure 3.12). Once the animals are 
transferred into clean water, diazepam is removed from the animal quickly but 
nordiazepam is continually detected until the end of the study. As diazepam is 
eliminated or metabolised, the ratio between parent and metabolites changes, 
increasing the percentage of nordiazepam in the organism (Figure 3.13). This is 
demonstrated by the concentration of diazepam decreasing to 3 % of its highest 
concentration, whilst nordiazepam persists longer in the organism. This may 
account for nordiazepam contributing a larger portion of the total pharmaceutical 
concentration in G. pulex after the depuration period. These results also 
demonstrate the value of being able to measure these compounds individually. 
 
Table 3.3 Water quality parameters for pharmacokinetic study with Gammarus 
pulex exposed to 0.5 mg L-1 of Diazepam (mean values ± standard deviation; 
n=5) 
pH Dissolved Oxygen (mgL
-1
) Temperature (ºC) 
7.78 ± 0.20 9.45 ± 1.58 12.76 ± 0.45 
 
 
3.3.5 Bioconcentration factors for diazepam and nordiazepam 
BCFs were calculated using a one-compartment model for both total pharmaceutical 
(diazepam and nordiazepam) and diazepam in G pulex. The BCF for total 
pharmaceutical was 33.7 and the BCF for diazepam was 19.1. The pseudo BCF for 
nordiazepam calculated from the internal concentration and the diazepam water 
concentration at 48 hours was 1.36. 
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Figure 3.11 Measured concentration (n=2) of diazepam and nordiazepam in the 
exposure water during the uptake and depuration study using UPLC-QTof-MS 
 
3.4 Discussion 
The results obtained using UPLC-QTof-MS are consistent with the radiolabeled 
studies presented in Chapter 2 and confirm that G. pulex uptakes diazepam from 
the exposure water. Extraction with methanol recovered 82 – 97 % of the 
pharmaceuticals spiked into homogenized G. pulex matrix. These results are in 
agreement with the literature. Vernouillet et al. (2010) obtained 92 % mean recovery 
of carbamazepine from invertebrate tissues with a similar extraction methodology. 
All of the pharmaceuticals were detected by UPLC-Tof with good chromatographic 
separation, and excellent mass accuracy and stability. 
The peak shape for the most polar compound 5-fluorouracil is relatively broad. This 
is probably due to column disturbance effects caused by the difference in polarity of 
methanol (injection solvent) and the initial mobile phase conditions (100% aqueous). 
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Figure 3.12 Measured internal wet weight concentrations in Gammarus pulex 
with UPLC-Tof-MS when exposed to 0.5 mg L-1 of diazepam (n=2; September 
2008), providing an uptake and depuration curve over time of a) total 
diazepam and nordiazepam b) diazepam and c) nordiazepam. The diamonds 
are the measured concentration of individual replicates, the blue line is the 
model fit and the red lines represent 95 % confidence intervals 
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Figure 3.13 The percentage of nordiazepam metabolite detected compared to 
the parent diazepam detected in Gammarus pulex over 72 hours exposure 
(n=2) using UPLC-QTof-MS 
 
If the study was specifically focused on 5-fluorouracil alone, then the peak shape 
could be improved by closer matching of the injection solvent with the initial mobile 
conditions; either by increasing the organic solvent composition at the start of the 
elution programme (at the expense of chromatographic resolution), or dilution the 
extract at the expense of sensitivity (Kaufmann, 2009). Because of the need for a 
multi-component method a compromise was necessary. Metabolites are typically 
more polar than the parent compounds and therefore would be expected to elute 
with shorter retention times (Zuehlke et al., 2004). 
No metabolite residues were detected for 5-fluorouracil, carbamazepine, carvedilol, 
fluoxetine and moclobemide, however it is possible that concentrations of 
metabolites do occur but below the lowest calibrated concentration (equivalent to 
0.04 µg/g), either because losses during the extraction process or suppression by 
the matrix effects can occur when molecules coelute with the analyte of interest 
resulting in competition between the components and alteration of the ionization 
efficiency of the elecotrospray ion source (Paul, 2005). This has been observed for 
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pharmaceutical residues in complex environmental matrices previously (e.g. 
Zuehlke et al., 2004). 
However nordiazepam was detected and identified with evidence provided by 
UPLC-QTof–MS, The data which was acquired across the full mass range spectrum 
with high resolution and mass accuracy. The accurate mass of the major ion, the 
chlorine isotope pattern was in agreement with the same data obtained for reference 
standard materials. Product ion spectra produced from the MS/MS of m/z 285.0806 
[M+H]+ for diazepam provide unequivocal confirmation of the presence of diazepam 
in the Gammarus tissue. Unfortunately MSE collision energy employed was too low 
to be able to differentiate the nordiazepam product ion fragments from the matrix. 
For completeness, further work to provide QTof MS/MS fragmentation data and 
better sensitivity for nordiazepam is in progress. 
The concentration of diazepam and nordiazepam in the Gammarus after 48 hours 
exposure was quantified against matrix-matched. The detection of nordiazepam 
demonstrated that G. pulex will metabolise diazepam.  
In mammals nordiazepam is formed after demethylation of diazepam in phase 1 
metabolism (Straub, 2008). The pharmacokinetic study of diazepam showed that the 
uptake and metabolism of diazepam in G. pulex was similar to mammals. Preceding 
the application diazepam showed rapid uptake and the major phase one metabolite 
is nordiazepam was detected after only 3 hours and nordiazepam continued to be 
formed throughout the test. Diazepam was eliminated quickly from the organism 
however nordiazepam was eliminated more slowly. A contributing factor could be 
that nordiazepam has a longer elimination half-life and has a larger log Kow (log of 
Kow 3.89) compared to its parent diazepam (log of Kow 2.70) (Charney et al., 2001). 
In mammals the important CYP - 450 enzymes involved in the metabolism of 
diazepam to nordiazepam are CYP3A4, CYP2C19, CYP2B6, CYP2C9 and CYP3A5 
(Straub, 2008). This study is not conclusive that the CYP - 450 facilitates the 
metabolism of diazepam to nordiazepam in G. pulex, however nordiazepam was not 
detected in the water (Figure 3.11) and biotransformation of some compounds does 
not occur without initial oxygenation, which is usually dependent on the CYP - 450 
enzymes (James, 1990a). There are other kinetic studies of pharmaceuticals that 
are used frequently in the aquaculture of crustacean species. In these studies 
demethylated metabolites of erythromycin and sulfadimethoxine were also found. 
The authors suggested that these metabolites might have been formed by CYP - 
450 enzymes in the hepatopancreas (James and Boyle, 1998). Although no 
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definitive analysis was completed the demethylation of erythromycin in humans is 
facilitated by CYP - 450 3A enzyme (James and Boyle, 1998) which is similar to 
nordiazepam Figure 3.1. 
Therefore both the current study and the study by James (1990a) could suggest that 
crustaceans such as G. pulex possess the CYP - 450 3A enzyme and this enzyme 
maybe used in the metabolism of pharmaceutical compounds such as diazepam in 
crustacea. However fluoxetine, carbamazepine and carvedilol are also processed by 
the same enzyme in mammals but no metabolites were identified in G. pulex. 
Although metabolites of these compounds were not identified, they may have been 
at concentrations below the sensitivity of the instrument or may not have been 
recovered by the extraction method. Therefore there is uncertainty over the 
metabolic pathway in this crustacean and further research may be required to clarify 
this hypothesis. 
The pharmacokinetic study with diazepam is in agreement with the radiolabelled 
studies in Chapter 2. The BCF in this study for the total pharmaceutical (diazepam 
and nordiazepam) concentration was 33.7 compared to the BCF of 37.5 for the 
radiolabelled study. This study shows that the metabolism of diazepam to 
nordiazepam has an effect on the BCF. When calculating the parent compound 
alone the BCF for diazepam was 19.1. Therefore although radiolabelled studies can 
discern internal concentrations at low concentrations they provide information on 
total radioactive concentration and do not provide any information on the 
metabolism (Kaufmann, 2009). Radiolabelled studies may overestimate the BCF 
and internal concentration of the parent compound if a radiolabelled metabolite is 
equal to or more lipophilic than the parent (Arnot and Gobas, 2006). Also if a 
radiolabelled metabolite is more polar and excreted into the water there will be an 
overestimation in of the water concentration and underestimate the BCF (Arnot and 
Gobas, 2006).  
Some pharmaceuticals like diazepam are biotransformed to metabolites that are as 
potent as the parent compound. Nordiazepam is an active metabolite and may 
account for some of the therapeutic action of the parent pharmaceutical (Gutstein 
and Akil, 2001, Sinclair and Boxall, 2003). Therefore it can be justified to consider 
the total pharmaceutical concentration of both parent and metabolite. This may not 
be the case for all pharmaceuticals as potentially some compounds will be 
biotransformed to more polar metabolites that can be excreted easily with no 
therapeutic effect (Sinclair and Boxall, 2003). In some cases the metabolite maybe 
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the active part of the compound where the parent compound is designed for optimal 
absorption into the organism and is metabolized into an active compound that elicits 
the therapeutic effect (Sinclair and Boxall, 2003). 5-fluorouracil requires metabolic 
reaction to the nucleotide 5’-monophosphate which is incorporated into ribonucleic 
acid, this metabolic sequence is vital for its anti-cancer activity (Calabresi and 
Chanbner, 2001). 
Despite G. pulex being able to metabolise diazepam to nordiazepam, the BCFs and 
the internal concentrations were similar and no metabolites were detected for the 
five other pharmaceuticals. Therefore it is likely that the internal concentrations and 
the BCFs measured in Chapter 2 will reflect the measured internal concentrations 
and BCFs of G. pulex for the parent compounds tested. These data also confirm 
that extraction with methanol provides an extraction efficiency at least equivalent to 
extraction with Soluene 350 (Perkin Elmer, USA) when considering suppression 
effects of the matrix. 
The identification and measurements of pharmaceutical metabolites in 
environmental matrices is challenging; however this study shows that UPLC coupled 
to a QTof is an excellent tool for the detection and identification of metabolites in 
complex animal matrices. Future studies on different compounds with different 
organisms will be necessary to validate this method for robust environmental 
screening. 
 
3.5 Conclusions 
It can be concluded from this work that: 
 G. pulex is able to metabolise the pharmaceutical compound, diazepam. To 
the authors knowledge this is the first time that metabolism of a human 
pharmaceutical has been demonstrated in an aquatic invertebrate. 
 The extraction technique proposed in this study needs to be refined and 
validated before application to the assessment of other pharmaceuticals and 
invertebrate species. 
 The concentration of the test pharmaceuticals at which G. pulex were 
exposed in this study was high compared to those found in the environment. 
Additional research is required to test whether the extraction and detection 
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method for diazepam can measure metabolites at environmentally relevant 
concentrations. 
 Metabolites should be considered in the risk assessment process as some 
have longer elimination half-lives compared to the parent compound and 
may influence the BCF. Also this study shows that BCFs calculated from 
radiolabelled studies ignore the formation of metabolites  
 It could be implied from this work that CYP – 450 enzymes could be 
responsible for the metabolism of diazepam to nordiazepam, further work will 
be necessary to establish this conclusively. It may be possible to identify 
metabolites by looking at the metabolic pathways already identified in 
aquatic invertebrates. 
 Human pharmacological information on metabolic pathways should be 
investigated in aquatic organisms to allow the prediction of active 
metabolites in non-target species. 
Chapter 4 
146 
 
Chapter 4 Uptake of pharmaceuticals through aquatic food 
chains 
 
4.1 Introduction 
As described in Chapter 1, a growing body of evidence shows that pharmaceuticals 
can accumulate in aquatic species (Brooks et al., 2005, Brown et al., 2007, Chu and 
Metcalfe, 2007, Ramirez et al., 2007, Gelsleichter, 2009, Pouliquen et al., 2009, 
Ramirez et al., 2009, Fick et al., 2010, Schultz et al., 2010). A number of studies 
have also shown that even when pharmaceuticals are at concentrations below the 
limit of detection in the exposure water, they can be detected in fish; indicating that 
some pharmaceuticals may have the potential to bioaccumulate (Gelsleichter, 
2009). It is thought that bioaccumulation of a chemical occurs largely by uptake from 
the aqueous phase. It is often considered to be the predominant route because of 
the large volume of water transferred across the respiratory surfaces of aquatic 
organisms (Gross-Sorokin et al., 2003). Uptake of pharmaceuticals from the 
aqueous phase was explored in Chapter 2 of this thesis. The results tentatively 
indicated that all the aquatic invertebrates tested showed the potential to uptake 
pharmaceuticals from water and that the degree of uptake from the water can be 
influenced by species traits (e.g. organism size, mode of respiration and behaviour) 
and the chemicals properties (e.g. Log Kow or Log Dlipw). 
In its natural environment, an organism will not only uptake chemicals from the 
water but will also accumulate the chemicals associated with sediments or present 
in its food (Borgå et al., 2004, Borgå et al., 2010). Studying dietary uptake becomes 
increasingly important for more hydrophobic compounds (e.g. persistent organic 
pollutants and pesticides) and in REACH, the Log Kow is used to distinguish if a 
chemical has the potential for bioaccumulation, biomagnification and trophic transfer 
(Gross-Sorokin et al., 2003, Borgå et al., 2004, Wilding and Maltby, 2006).  
Trophic organization in aquatic systems can be very complex and invertebrates can 
be divided into groups based on their feeding mechanism and food type (Allan, 
1996). Coarse particulate organic matter (CPOM) is an essential energy input in 
aquatic food chains and much of the energy support for lotic food chains is derived 
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from non-living sources of organic matter such as CPOM (Cummins, 1974). Studies 
have shown that in aquatic systems neutral chemicals and hormones can sorb to 
dissolved organic matter (Yamamoto et al., 2003). Pharmaceuticals such as 
fluoxetine have a high affinity for organic matter, therefore it might be expected that 
these compounds may associate with sediments and detrital material (Ericson, 
2007, Kwon et al., 2008). 
As sediments and detrital material such as CPOM are key elements in aquatic food 
chains there may be potential for detritivores feeding on CPOM to be indirectly 
exposed to pharmaceuticals from their food. Microbial communities that colonize 
CPOM may alter the adsorption of chemicals to CPOM and also, uptake or degrade 
these chemicals themselves (Schocken and Speedie, 1984). Therefore, organisms 
such as crustaceans G. pulex and Asellus aquaticus that use detrital matter, such as 
leaf litter and sediment, as a food resource could be potentially to exposed 
chemicals from consuming CPOM and the microbial communities belonging to it 
(Herbst, 1982, Fazi and Rossi, 2000, Swan and Palmer, 2006)  
The relative importance of the route of uptake of chemicals from either food or water 
is unknown for many aquatic invertebrates and little is known about the factors that 
can influence accumulation. Feeding roles and feeding mechanisms may influence 
the dietary uptake of chemicals. The literature suggests that chemicals accumulation 
patterns can be related to feeding behaviour (Russell et al., 1999). For example 
when considering the feeding strategies of a piercer, scraper and an engulfer; the 
piercer will only be exposed to the imbibed body fluids, a scrapper will only be 
exposed to the chemical adsorbed to the external surfaces of the prey but the 
engulfer will be exposed to the chemical accumulated in the whole prey organism 
(Brooks et al., 2009).  
Studying the accumulation of contaminants from the food is especially critical for 
understanding trophic transfer in food chains (Wang and Fisher, 1999) and is 
important for establishing accurate models for the fate of chemicals such as 
pharmaceuticals in the environment (Munger and Hare, 1997). 
The chapter aims explore the accumulation of pharmaceuticals on CPOM and 
assessing the importance of feeding as an uptake route for pharmaceuticals 
compared to water exposure alone through a simple food chain. Using G. pulex and 
N. glauca this study will assess the influence of feeding strategy on the 
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accumulation pattern of pharmaceuticals; carvedilol and fluoxetine chosen as the 
study pharmaceuticals for their accumulative potential in the food source. 
The specific objectives are to: 
 Investigate the association of a range of pharmaceuticals with CPOM 
 Determine the influence of physico-chemical properties of the compounds 
and the effect that the presence of the common aquatic fungus 
Cladosporium herbarum will have on the sorption.  
 Investigate the impact of exposure route on accumulation, assessing the 
importance of feeding as an uptake route for pharmaceuticals compared to 
water exposure 
 Ascertain the influence of feeding strategy on the dietary uptake of 
pharmaceuticals in G. pulex and N. glauca 
 Establish whether pharmaceuticals can be transferred up a simple aquatic 
food chain using the CPOM as the primary trophic level, G. pulex as the 
consumer and N. glauca as a predator. Carvedilol and fluoxetine were 
chosen as the study pharmaceuticals for to their accumulative potential. 
 Use previously derived uptake and depuration rate constants from Chapter 2 
to estimate exposure at environmental relevant concentrations. 
 
4.2 Materials and methods 
4.2.1 Pharmaceutical compounds 
Radiolabelled and unlabeled, 5-fluorouracil, carvedilol, diazepam and moclobemide 
were obtained from F. Hoffman-la Roche Ltd (Basel, Switzerland). Radiolabelled 
carbamazepine and fluoxetine were obtained from American Radiolabeled 
Chemicals Incorporated (Missouri, USA). All pharmaceuticals were labeled with 14C, 
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chemical properties and specific activities of the pharmaceuticals are summarised 
(Table 2.1 and 2.2). 
 
4.2.2 Study organisms 
Horse-chestnut leaves (Aesculus hippocastanum) were collected in November 2008 
from St. Mary’s church yard Sand Hutton, North Yorkshire (NGR SE699583) after 
abscission. The leaves were inoculated with the fungus Cladosporium herbarum 
which was chosen as food source for the food uptake study with G. pulex. Mature C. 
herbarum cultures were obtained from the University of Sheffield (Sheffield, UK). 
Cultures were maintained at 22C plated on sterile malt extract broth (MEB) plates 
comprising 3 % malt extract and 0.25 % mycological peptone in distilled water. The 
cultures were sub-cultured monthly. The leaves were then dried and stored at 20 °C 
in the dry prior to use. 
Prior to each uptake study, the leaves were rehydrated and then cut into 2 cm 
diameter discs and placed into enriched water (Naylor et al., 1989). The leaf discs 
were then autoclaved at 121 °C, 15 PSI (1.034 kPa) for 20 minutes to kill any 
microorganisms present (Naylor et al., 1989). The prepared leaf discs were 
inoculated with mature C. herbarum at a standard ratio (fungi:leaves, 1:20). The 
inoculated flasks were agitated at 65 rpm on an orbital shaker for ten days before 
use. 
G. pulex were collected from a field population at Bishop Wilton Beck and N. glauca 
were obtained from Blades Biological Ltd. (Kent, UK) in October 2009. All animals 
were maintained in the same conditions as Chapter 2, the reader is referred to 
section 2.2.2 of this thesis. 
 
4.2.3 Interaction of pharmaceuticals with leaf material 
To understand the association of pharmaceuticals on CPOM, the uptake of 5-
fluorouracil, carbamazepine, carvedilol, diazepam, fluoxetine and moclobemide onto 
non-inoculated leaf discs and C. herbarum inoculated leaf discs was investigated. 
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Three replicates of either sterilised leaf discs or C. herbarum inoculated leaf discs 
were exposed for 72 hours to 200 mL of solutions of each of the test compounds in 
APW. All leaf discs were exposed to 0.8, 0.4, 0.2, 0.4, 0.3 and 0.4 µmol L-1 (or 0.1 
mg L-1) of 5-fluorouracil, carbamazepine, carvedilol, diazepam, fluoxetine and 
moclobemide respectively. A static exposure was used for all pharmaceuticals 
except for fluoxetine where a static renewal exposure was employed as preliminary 
studies showed that fluoxetine adsorbed to the glassware. The static renewal 
approach for fluoxetine consisted of transferring the organisms in each beaker into 
fresh test solution every 24 hours. A sample of water (1 mL) was taken to determine 
the exposure concentration once the water had been renewed. 
The leaf material was exposed at 20 °C with a dark/light cycle of 12 hours light: 12 
hours dark. Following exposure, the concentration of the study pharmaceuticals in 
the water and leaf materials was determined by liquid scintillation counting (LSC). 
Water samples were transferred to scintillation vials and 10 mL of Ecoscint A 
(National Diagnostics) was then added. The sample was shaken to mix, left to settle 
and the radioactivity measured in the dark by LSC. LSC analysis was performed 
using a Beckham LS6000 TA Liquid Scintillation Counter (Beckham Instruments Inc. 
USA). Samples were counted three times for 5 minutes. Sample counts were 
corrected for background activity by using blank controls. Counting efficiency and 
colour quenching were corrected using the external standard ratio method. 
Prior to analysis, leaf disc samples were rinsed with deionised water to remove any 
pharmaceutical residue from the surface. The leaf discs were then dissolved using 2 
mL of Soluene 350 (Perkin Elmer, UK) a strong organic base, formulated with 
toluene, which has an excellent capacity for the solubilization of wet tissue. The 
tissue was also bleached with 100 µL of hydrogen peroxide, which was used to 
remove the tannins from the leaf tissue to prevent colour quenching during analysis. 
The rate of solubilization with Soluene 350 was increased by warming over 24 hours 
in a water bath at 60 °C to ensure that all the tissue had fully dissolved. Following 
solubilization and bleaching, the extracts were mixed with 10 mL Hionic Fluor 
scintillation cocktail (Perkin Elmer, UK) and the concentration of pharmaceuticals 
determined by LSC.  
To understand the rates of adsorption/uptake and desorption/elimination of 
pharmaceuticals in detrital material, C. herbarum inoculated leaf discs were exposed 
at 20 C in 200 ml of solutions of the study pharmaceuticals in APW. Concentrations 
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of the pharmaceuticals ranged from 230 (carvedilol) to 714 (5-fluorouracil) pmol mL-
1. There were twelve leaf discs in each replicate and three replicates per 
pharmaceutical. To assess the rate of sorption/uptake, one leaf disc was taken at 
either 0, 3, 6, 24, 48 or 72 hours after the start of the exposure. This left six leaf 
discs in each replicate at the end of the uptake study which were then transferred 
into clean APW in order to determine the rates of depuration. In the depuration 
study, samples of leaf material were obtained 0, 3, 6, 24, 48 and 72 h after transfer 
to the clean APW. The radioactivity in the water at each sampling time point and in 
the collected leaf samples was measured using the extraction and LSC method 
described above. 
 
4.2.4 Uptake into aquatic invertebrates via water and food 
Carvedilol and fluoxetine were selected for use in the uptake studies with 
invertebrates due to their accumulative behaviour on the leaf discs experiments. The 
experiments were carried out using components of a simple food chain namely 
inoculated leaf discs, G. pulex and N. glauca. In this food chain, G. pulex uses leaf 
material as its food source and N. glauca feeds on G. pulex. A systematic approach 
was used to assess the relative importance of water exposure and ‘food’ exposure 
in terms of uptake through the food chain. The studies therefore involved a) 
exposure of each component of the food chain to only APW containing the test 
pharmaceutical; b) exposure of each component of the food chain to ‘food’ 
containing the study pharmaceutical and clean APW; and c) combined exposure 
experiments where uptake was assessed from both the water phase and the ‘food’ 
phase.  
For the water-only studies, inoculated leaf discs, G. pulex and N. glauca were 
exposed individually to 200 ml of either 2.5 or 21 pmol mL-1 (1 µg L-1) of carvedilol 
and fluoxetine in APW. For G. pulex and N. glauca there were two sets of three 
replicates containing single animals. For the leaf discs there were eight replicates 
containing ten leaf discs – two leaf discs were used from each replicate to assess 
water uptake and the remainder were used in the ‘food’ uptake studies described 
below. Organisms were exposed at 12 C for 72 hours. For the leaf discs, samples 
were taken immediately after exposure for analysis while for the G. pulex and N. 
glauca, only one set of replicates was taken. The other set were transferred to clean 
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water for either 6 h (G. pulex) or 12 h (N. glauca) to establish whether the study 
compounds are depurated during the gut purging times used in the ‘food’ only 
studies described below. Water samples (1 ml) were also taken at the end of the 
exposure period for analysis. 
Dietary exposure was assessed in G. pulex and N. glauca. Three replicates of eight 
G. pulex in 500 mL of clean APW were fed eight of contaminated leaf discs obtained 
from the water-only uptake studies. Following 72 hours, one animal was removed 
from each replicate and frozen prior to analysis. A second animal from each 
replicate was transferred to clean APW for 6 hours to allow the animal gut to purge, 
after this time the animal and a water sample (1 ml) were taken and frozen for 
analysis. The remaining six animals were used as the ‘food’ source in the dietary 
and combined exposure studies with N. glauca. Six, single animal replicates of N. 
glauca were prepared in 200 mL of clean APW. Each of these N. glauca was fed 
with 3 of the G. pulex that had previously been exposed to the contaminated food. 
After 72 hours the animals were removed and water samples were obtained, three 
N. glauca were frozen for analysis and three animals were transferred into clean 
APW for 12 h to allow gut purging. Additional water samples were taken for analysis 
at the end of the purging period. 
To determine the total uptake of pharmaceuticals from both dietary and water 
exposure into G. pulex and N. glauca, animals were exposed to both contaminated 
food and contaminated water. The water concentrations were the same as used in 
the water-only uptake studies and the food was prepared in the same way as for the 
‘food’ uptake studies. Animals were exposed for 72 h and samples were taken for 
analysis with and without gut purging. 
All samples were analysed by LSC using the methods described above. The 
extraction methods used for G. pulex and N. glauca were the same as used in the 
leaf experiments.  
  
Chapter 4 
153 
 
4.2.5 Data analysis 
4.2.5.1 Determination of variance between inoculated and non-inoculated leaf 
discs 
A Levene’s test for Equality of Variance was used to determine whether there was 
equal variance between the concentrations of pharmaceuticals in the inoculated and 
non-inoculated leaf discs. If equal variance was found, the significance (at the 5% 
level) of the differences between these samples was determined using an 
independent t-test. A Mann Whitney U test was performed in instances where the 
variance between the samples was found to be unequal. All statistics were 
completed using SPSS Statistic V17.0. 
4.2.5.2 Derivation of rate constants and food accumulation factors (FAF) 
A first-order one-compartment toxicokinetic model was fitted to the total 
concentration on the leaf discs to estimate the parameters for uptake and 
elimination (Ashauer et al., 2006, Ashauer et al., 2010). All simulations and 
parameter estimations were carried out using OpenModel (version 9th Dec 2009, 
http://www.nottingham.ac.uk/environmental-modelling/OpenModel.htm) in 
accordance with Section 2.2.7 of this thesis. 
 
4.2.5.3 Determination of trophic transfer efficiency 
Transfer efficiencies between trophic layers were calculated using an adaptation of 
the method of Brooks et al. (2009). Transfer efficiencies are expressed as the 
percentage of pharmaceutical transferred from the food to the consumer using 
equation 4.1, where p is the body burden of the consumer after exposure and b is 
the concentration in the food. 
Equation 4.1        
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4.2.5.4 Determination of variance between exposure routes 
A two-way analysis of variance (ANOVA) was performed on the G. pulex and N. 
glauca data to show any significant differences between the tissue concentration in 
the animals between the exposure routes and between chemicals. Further to this a 
least significant difference (LSD) test was performed on the route of exposure data 
to show which exposure routes were significantly different from one another. All 
statistics were completed using SPSS Statistic V17.0. 
 
4.2.5.5 Comparison of predicted and measured uptake from the water  
The concentration of pharmaceutical in the organism was predicted using previously 
derived uptake and elimination rate constants from Chapter 2 (table 2.5). Predicted 
concentrations and their 95 percent confidence intervals were calculated by setting 
Cwater equal to either 2.5 or 21 pmol L
-1 for carvedilol and fluoxetine and running the 
model for 72 hours for all combinations of the parameter sample (Ashauer et al., 
2010). All simulations and parameter estimations were carried according to Section 
0. 
 
4.3 Results and discussion 
Understanding the accumulation of contaminants from the food is critical for 
explaining the trophic transfer of contaminants through food chains. The present 
study therefore used a systematic approach to assess the routes of uptake of 
pharmaceuticals into the component species of a simple food chain comprising 
CPOM, G. pulex and N. glauca.  
 
4.3.1 Association of pharmaceuticals with leaf material 
As CPOM is a key component at the base of aquatic food webs, initial studies 
focused on understanding the association of pharmaceuticals from water to non-
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inoculated and fungi-inoculated leaf material. Analysis of the exposure solutions in 
these studies showed that for 5-fluorouracil, carbamazepine, carvedilol, diazepam 
fluoxetine and moclobemide showed that leaf discs were exposed to mean 
concentrations of 714, 418, 230, 345, 292 and 389 pmol mL-1 of 5-fluorouracil, 
carbamazepine, carvedilol, diazepam, fluoxetine and moclobemide (figure 4.1). In 
the fluoxetine studies, concentrations declined rapidly over time so therefore a semi 
static approached was required to maintain the exposure concentration. The 
dissipation of fluoxetine over time was primarily due to sorption to test vessels 
(Appendix A). Water quality parameters remained constant throughout the 
experiments (table 4.1). 
Following 72 hours of exposure to the pharmaceuticals, the leaf discs inoculated 
with Cladosporium fungus were found to take up more pharmaceutical compared to 
the leaf discs without fungus (figure 4.2). The observed differences were only 
statistically significant for 5-fluorouracil, carbamazepine and moclobemide. Mean 
concentrations for the inoculated leaf discs ranged from 9700 – 149,000 pmol g-1 
and for the non-inoculated leaf discs ranged from 1173 – 108,000 pmol g-1. The leaf 
disc concentration for both inoculated and non-inoculated systems, increased in the 
order 5-fluorouracil < carbamazepine < moclobemide < diazepam < carvedilol < 
fluoxetine. 
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Figure 4.1 Mean measured water concentrations of the study pharmaceuticals 
(± standard deviation) for inoculated leaf disc uptake/sorption experiments 
over 72 hours exposure (n=3). Nominal concentration for pharmaceuticals 
were 0.8, 0.4, 0.2, 0.4, 0.3 and 0.4 µmol L-1 (or 0.1 mg L-1) of 5-fluorouracil, 
carbamazepine, carvedilol, diazepam, fluoxetine and moclobemide 
respectively 
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Figure 4.2 Mean sorption/accumulation (± standard deviation, n=3) of 
pharmaceuticals on leaf discs prepared with and without fungus. Nominal 
exposure concentration for pharmaceuticals was or 0.1 mg L-1 for 72 hours 
  
 
Table 4.1 Mean water quality parameters for experiments with Gammarus pulex, Notonecta glauca, and Cladosporium herbarum 
Experiment Species Pharmaceutical Dissolved O2 [mgL
-1
] pH Temperature [°C] 
Leaf sorption/uptake 
Leaf disc inoculated with C. 
herbarum 
5-fluorouracil 9.5 7.10 23.6 
carbamazepine 9.2 7.06 23.3 
carvedilol 7.1 7.76 23.3 
diazepam 7.8 7.72 22.9 
fluoxetine 9.2 7.45 22.9 
moclobemide 9.1 7.10 23.1 
Water exposure 
G. pulex 
carvedilol 8.6 7.44 20.4 
fluoxetine 8.7 7.51 21.0 
N. glauca 
carvedilol 9.3 7.81 20.7 
fluoxetine 8.6 7.55 20.6 
Food exposure 
G. pulex 
carvedilol 9.1 7.23 20.6 
fluoxetine 9.0 7.50 20.9 
N. glauca 
carvedilol 8.6 7.54 20.5 
fluoxetine 8.0 7.12 21.1 
Food & water exposure 
G. pulex 
carvedilol 9.2 7.51 20.3 
fluoxetine 9.2 7.65 21.0 
N. glauca 
carvedilol 8.8 7.47 20.4 
fluoxetine 9.0 7.52 21.0 
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The observed association of the pharmaceuticals with the leaf material may be due 
to adsorption onto the leaf and fungal surfaces or uptake into the biological material. 
The sorptive/accumulation potential of heavy metals and pesticides onto detrital 
material has been shown previously by Odum and Drifmeyer (1978). Filamentous 
fungi such as C. herbarum are known to have several potential accumulation sites 
for chemical contaminants, including carboxyl, sulphydryl, phosphate and hydroxyl 
groups on their cell walls as well as other ligands including the wall constituent, 
chitin (Rome and Gadd, 1987). Fungi also provide a larger surface area for the 
pharmaceuticals to adsorb to (Bolan, 1991). Surface area is thought to be one of the 
factors explaining higher bioaccumulation in other primary producers such as algae 
(Ellgehausen et al., 1980). The presence of fungi can also affect the pH of a system, 
resulting in changes in the speciation and behaviour of chemicals compared to 
systems containing non fungi. These pH effects may be particularly important for 
pharmaceuticals, many of which are ionisable compounds.  
The rate of sorption/uptake and depuration/desorption of the pharmaceuticals in 
inoculated leaf discs over time was also explored. Like the previous study, analysis 
of the exposure water showed that concentrations of all pharmaceuticals except 
fluoxetine remained within 10 % of the starting concentration over the study (figure 
4.1). A first order – one compartment kinetic model was successfully fitted to the 
uptake/sorption and depuration/desorption measurements (figure 4.3 to figure 4.8). 
The rate constants and the resulting food accumulation factors (FAF) are provided in 
table 4.2. FAFs ranged from 24 – 1755 and increased in the order 5-fluorouracil < 
carbamazepine < diazepam < moclobemide < carvedilol < fluoxetine. As well as 
accumulating the most on the leaves, carvedilol and fluoxetine both showed lower 
desorption/depuration than the other compounds with modeled 
depuration/desorption constants of 0.18 and 0.22 d-1 respectively. Studies with 
aquatic organisms indicate that difference in uptake of pharmaceuticals can be 
explained by differences in the lipophilicity of the chemicals (Chapter 2). To explore 
whether this also holds true for leaf material, the relationship between accumulation 
into leaf material and Log Kow and Log Dlipw (the pH-corrected liposome-water 
partition coefficient) was explored and positive relationships were obtained (figure 
4.9 and 4.10). 
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Figure 4.3 Measured internal wet weight concentrations of leaf discs exposed 
to 0.1 mg L-1 of 5-fluorouracil (n=3, May 2009), providing an uptake and 
depuration curve over time. Black diamonds are the measured concentration 
of individual replicates, the blue line is the model fit and the red lines 
represent 95 % confidence intervals. The dashed line represents change from 
exposure solution to freshwater. 
 
Figure 4.4 Measured internal wet weight concentrations of leaf discs exposed 
to 0.1 mg L-1 of carbamazepine (n=3, May 2009), providing an uptake and 
depuration curve over time. Black diamonds are the measured concentration 
of individual replicates, the blue line is the model fit and the red lines 
represent 95 % confidence intervals. The dashed line represents change from 
exposure solution to freshwater.  
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Figure 4.5 Measured internal wet weight concentrations of leaf discs exposed 
to 0.1 mg L-1 of carvedilol (n=3, May 2009), providing an uptake and depuration 
curve over time. Black diamonds are the measured concentration of individual 
replicates, the blue line is the model fit and the red lines represent 95 % 
confidence intervals. The dashed line represents change from exposure 
solution to freshwater. 
 
Figure 4.6 Measured internal wet weight concentrations of leaf discs exposed 
to 0.1 mg L-1 of diazepam (n=3, May 2009), providing an uptake and depuration 
curve over time. Black diamonds are the measured concentration of individual 
replicates, the blue line is the model fit and the red lines represent 95 % 
confidence intervals. The dashed line represents change from exposure 
solution to freshwater.  
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Figure 4.7 Measured internal wet weight concentrations of leaf discs exposed 
to 0.1 mg L-1 of fluoxetine (n=3, May 2009), providing an uptake and depuration 
curve over time. Black diamonds are the measured concentration of individual 
replicates, the blue line is the model fit and the red lines represent 95 % 
confidence intervals. The dashed line represents change from exposure 
solution to freshwater. 
 
Figure 4.8 Measured internal wet weight concentrations of leaf discs exposed 
to 0.1 mg L-1 of moclobemide (n=3, May 2009), providing an uptake and 
depuration curve over time. Black diamonds are the measured concentration 
of individual replicates, the blue line is the model fit and the red lines 
represent 95 % confidence intervals. The dashed line represents change from 
exposure solution to freshwater. 
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Table 4.2 Modeled uptake/sorption and depuration/desorption rate constants, 
modeled uptake and depuration constants, FAF values and goodness of fit 
data for the accumulation/sorption of pharmaceuticals in fungus leaf discs 
Chemical  Cw (pmol mL
-1
) 
kint (mL g-1 d-1) 
mean ± SD 
kout (d-1) 
mean ± SD 
FAF (L kg-1) [95th 
percentiles] 
5 - fluorouracil 625.11 ± 11.69 5.48 ± 1.13 0.27 ± 0.12 24 [20 - 34] 
carbamazepine 335.45 ± 14.29 30.46 ± 6.25 0.57 ± 0.16 63 [51 - 87] 
carvedilol 144.02 ± 3.73 122.47 ± 30.47 0.18 ± 0.11 947 [766 - 1323] 
diazepam 245.61 ± 3.04 60.58 ± 11.51 0.44 ± 0.12 166 [137 - 229] 
fluoxetine 321.57 ± 26.21 258.73 ± 94.65 0.22 ± 0.2 1755 [1335 - 2845] 
moclobemide 292.39 ± 4.11 47.85 ± 8.85 0.32 ± 0.10 176 [145 - 237] 
 
Table 4.3 shows the significance of the linear relationships. Although both Log Kow 
and Log Dlipw show good predictive power for FAFs, Log Dlipw has a more significant 
relationship and the regression model has a better fit. The relationship between Log 
Dlipw and FAF was highly significant (table 4.3). This type of model could be used to 
estimate the inputs of pharmaceuticals to the lowest trophic levels of aquatic food 
chains. In the future, these relationships may prove invaluable for environmental risk 
assessment and biological safety in identifying pharmaceuticals which are likely to 
pose the greatest concern in aquatic systems.  
 
4.3.2 Uptake of pharmaceuticals into aquatic invertebrates from water and 
food  
The relative importance of the route of uptake of chemicals from either food or water 
is unknown in most animals and little is known about the factors that can influence 
accumulation. However, this information is important for modelling the fate of 
chemicals in the environment (Munger and Hare, 1997). Studying the accumulation 
of contaminants from the food is especially critical for understanding trophic transfer 
in food chains (Wang and Fisher, 1999).  
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Carvedilol and fluoxetine were therefore chosen for use in studies to determine the 
relative importance of food uptake into invertebrates, as they showed the most 
association and the least desorption/depuration from the leaf discs in the uptake and 
depuration experiment. The invertebrate uptake studies involved water-only 
exposure, food-only exposures and combined water and food exposures.  
 
 
 
Figure 4.9 Relationships between food accumulation factors (± 95th percentile) 
and Log Kow obtained from leaf discs sorption/uptake experiment with test 
pharmaceuticals; 5-fluorouracil, carbamazepine, carvedilol, diazepam, 
fluoxetine and moclobemide. Diamonds are data points and the line is linear 
regression 
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Figure 4.10 Relationships between food accumulation factors (± 95th 
percentile) and Log Dlipw obtained from leaf discs sorption/uptake experiment 
with test pharmaceuticals; 5-fluorouracil, carbamazepine, carvedilol, 
diazepam, fluoxetine and moclobemide. Diamonds are data points and the line 
is linear regression 
 
Table 4.3 Linear regression analysis of the relationships between Food 
Accumulation Factors (FAF) and lipophilicity of the test pharmaceuticals; 5-
fluorouracil, carbamazepine, carvedilol, diazepam, fluoxetine and 
moclobemide. 
Parameter for Predicting FAF R
2 
Equation P value Figure 
Log Kow 0.76 FAF= 0.33 x Log Kow + 1.60 0.02 4.09 
Log Dlipw 0.85 FAF= 0.39 x Log Dlipw + 1.35 0.009 4.10 
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In order to avoid artifacts from the presence of food-associated pharmaceuticals in 
the gut of the animals, animals were allowed to depurate their gut contents for 6 h 
(G. pulex) or 24 h (N. glauca) prior to analysis. To assess whether this depuration 
period would have any effect on body residues of the compounds, animals were 
exposed to the study pharmaceuticals via water - half of these were analysed 
immediately after exposure and the other half were analysed following 6 h in clean 
water. No significant differences in the tissue concentrations of the depurated and 
non-depurated organisms were observed for both compounds in G. pulex and for 
carvedilol in N. glauca (for p values see supporting information). For fluoxetine in N. 
glauca, were significantly lower (≈ 56%) in the depurated organisms than the non-
depurated organisms (p = 0.05). These observations are in agreement with the 
findings of Chapter 2 which showed that that G. pulex depurates fluoxetine and 
carvedilol very slowly and N. glauca depurates carvedilol slowly. The data presented 
below are therefore based on measurements following gut depuration. 
Analysis of exposure solutions during the uptake studies showed that in the water 
only exposures, G. pulex were exposed to 2.72 ± 0.10 pmol mL-1 carvedilol and 
21.80 ± 0.44 pmol mL-1 fluoxetine and there was no significant change in the 
concentration over 72 h (p = 0.85 and 0.2 respectively). In the N. glauca water-only 
studies, organisms were exposed to measured concentrations of 2.54 ± 0.09 pmol 
mL-1 carvedilol and 21.04 ± 0.51 pmol mL-1 and again there was no significant 
change in concentration over the 72 h test period (p =0.3 and 0.3 respectively). In 
the food-only exposures, both compounds were not detected in the aqueous phase 
at the start of the study for both test organisms but after 72 h, the concentrations for 
carvedilol of 0.09 pmol mL-1 and for fluoxetine of 1.51 pmol mL-1 were measured in 
the G. pulex studies and concentrations of 0.01 pmol mL-1 for carvedilol and 0.37 
pmol mL-1 for fluoxetine were measured in the N. glauca studies. These 
observations are probably explained by depuration/desorption of the study 
compounds from the leaf discs or the invertebrates themselves.  
Data on concentrations within the study organisms are summarized in figure 4.11. 
For both test chemicals, concentrations within the organisms decreased up the food 
chain (figure 4.12). In G. pulex, the simultaneous exposure through the food and the 
water resulted in a significantly higher concentration of both test compounds than 
the water only and food only exposures (p < 0.004; see Appendix C.2.3). Uptake 
from the water phase was significantly greater than uptake from the food phase (p < 
0.05; see Appendix C.2.3). In N. glauca, simultaneous exposure to food and water 
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also resulted in higher mean tissue concentrations for both compounds than the 
water only or food only exposures but this was not significantly different (p > 0.07; 
see Appendix C.2.4). For carvedilol, uptake from water appeared to be more 
important than from food, whereas, for fluoxetine, uptake from food appeared to be 
more important than uptake from water.  
From the food-only uptake results, it is possible to estimate assimilation factors 
(Table 4.4). G. pulex assimilated 3 % of the total carvedilol in the food compared to 
6 % for fluoxetine and N. glauca assimilated 1.66 % of the total carvedilol and 5.52 
% of the total fluoxetine. The assimilation efficiency of both organisms was much 
lower for these pharmaceuticals compared to assimilation efficiencies for neutral 
compounds. For example another aquatic amphipod Diporeia sp assimilated 7 – 33 
% when exposed to benzo[a]pyrene in the food (Harkey et al., 1994).G. pulex has 
also been shown to assimilate 82 % of 4 – Nonylphenol when fed dosed horse – 
chestnut leaves (Gross-Sorokin et al., 2003). The results indicate that uptake of 
dissolved chemicals from the water may be dominant route for accumulation of the 
study compounds in G. pulex. This is possibly due to the respiration strategy of G. 
pulex and its reliance on dissolved oxygen. The gill ventilation rate of Gammarids is 
reported to be 6.0 x 10-3 L d-1 compared to the ingestion rate of 1.9 x 10-5 kg d-1 
resulting in a larger amount of compound being passed over the gills compared to 
that of the gut (Morrison et al., 1997).  
The dietary exposure route is evident when in combination with the aqueous 
exposure because the accumulation in the tissue was significantly higher than the 
accumulation when solely exposed from the water. Consequently water only 
exposure would under estimate accumulation of pharmaceuticals in G. pulex if 
exposed from both aqueous and dietary routes discussed in section 4.3.3 of this 
thesis. This has been found before in G. pulex when exposed to zinc. A 
simultaneous exposure of zinc in the food and the water resulted in higher internal 
zinc concentrations than when exposed only in the water (Wilding and Maltby, 
2006). 
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Figure 4.11 Mean whole body concentrations (wet weight ± standard 
deviation) of fluoxetine (white bars) and carvedilol (black bars) in a) 
Gammarus pulex (n=3) and b) Notonecta glauca (n=3) when exposed in the 
food, the water, and the food and water combined (exposure concentration 1 
µg L-1). 
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Figure 4.12 Mean whole body concentrations (wet weight ± standard 
deviation) of a) fluoxetine and b) carvedilol (exposure concentration of 1 µg L-
1) in a simple aquatic food chain with Leaf disc inoculated with Cladosporium 
herbarum (n=8), Gammarus pulex (n=3) and Notonecta glauca (n=3) 
  
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
leaf disc gammarus notonecta
C
o
n
c
e
n
tr
a
ti
o
n
 [
p
m
o
l 
g
-1
]
a 
0
100
200
300
400
500
600
700
800
900
leaf disc gammarus notonecta
C
o
n
c
e
n
tr
a
ti
o
n
 [
p
m
o
l 
g
-1
]
b 
Chapter 4 
170 
 
Table 4.4 Percentage assimilation of carvedilol and fluoxetine from the food 
source for Gammarus pulex and Notonecta glauca 
Assimilation from the food [%] 
 G. pulex N. glauca 
carvedilol 15.4 1.7 
fluoxetine 6.5 5.5 
 
N. glauca is a predator which pierces its prey, injecting it with paralytic enzymes, 
and sucking out the contents of the prey body (Peckarsky, 1982, Brooks et al., 
2009). Hence piercer predators will only be exposed to pharmaceutical accumulated 
in the internal tissues of the prey and any compound bound to the exoskeleton is 
discarded (Brooks et al., 2009). Therefore the distribution of the contaminant in the 
food organism will influence the concentration accumulated in the predator (Arukwe 
et al., 2000, Liu et al., 2002, Heiden et al., 2005, Gaskell et al., 2007, Brooks et al., 
2009). Other types of feeding behaviours such as engulfers that consume the whole 
prey organism maybe exposed to larger concentrations. 
N. glauca took up less from the water compared to that assimilated from the food. 
Uptake of pharmaceuticals from the water has been shown to be minimal compared 
to other species such as G. pulex in the present study and previous studies 
(Chapter 2). This is believed to be due to a combination of factors such as 
respiration strategy as N. glauca are not exposed to solutes as they rely on 
atmospheric oxygen for respiration (Matthews and Seymour, 2010). The present 
study shows that the food route of exposure to contaminants may be of more 
importance for some species than for others such as N. glauca.  
This study also shows that pharmaceuticals can be transferred through a simple 
aquatic trophic chain. A previous study by Vernouillet et al. (2010) that 
carbamazepine can be taken up from water (10.2 mg L-1) by algae and transferred 
through three trophic levels. However the top trophic level (Hydra attenuata) only 
showed trace concentrations of pharmaceutical in the tissues. In the case of the 
simple food chain tested in this study non biomagnification was observed despite 
the high bioaccumulative potential of the chosen compounds. Both Vernouillet et al. 
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(2010) and the current study show that certain species maybe indirectly exposed to 
pharmaceutical compounds through trophic interaction. Further study is warranted 
as little is known about what mechanisms maybe driving the uptake from the food. 
The kinetics of the uptake from the food would be needed to be studied to determine 
whether it is the rate of uptake or the extent that drives accumulation in predators. 
There are many factors that can affect the rate of diffusion across the gut such as 
conditions in the gut (Gaskell et al., 2007) and chemical state (Cunningham, 2004). 
However distribution of the compound in the food item as well as the desorption 
efficiency from the food particle are important factors influencing the bioavailability of 
the compound to be absorbed (Liu et al., 2002, Gaskell et al., 2007). Also, 
contaminants bound to cell walls and membranes of the food item may not be 
available for accumulation in the predator (Reinfelder et al., 1998).  
 
4.3.3 Comparison of measured and predicted uptake in aquatic invertebrates  
An attempt was made to assess the applicability of rate constants measured at 
higher exposure concentrations in the water to predict the uptake in organisms 
exposed at environmentally relevant concentrations. The rates constants provided 
from previous exposure scenarios (table 2.5; 0.1 mg L-1 of carvedilol and fluoxetine; 
see section 0) were therefore used to estimate the concentration in G. pulex and N. 
glauca after 72 hours at a lower concentration (1 µg L-1 of carvedilol and fluoxetine). 
The whole body internal measured concentrations of pharmaceutical for G. pulex 
and N. glauca when exposed to 1 µg L-1 of carvedilol and fluoxetine has limited 
replication (n=3) and cannot be statistically compared to the predicted results from 
the one compartment model (the model for 1 µg L-1 ran 1000 iterations based on 
rate constants from Chapter 2). Despite the limitations of the data, the preliminary 
results indicate that the rate constants for uptake and depuration obtained in chapter 
2 have the potential to be applicable for use at the lower water exposure 
concentration (1 µg L-1). The data suggests that the predicted internal 
concentrations for both compounds are similar to the measured data in both G. 
pulex and N. glauca (figure 4.13 and 4.14).  
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Figure 4.13 Mean whole body concentrations (wet weight ± standard 
deviation) in a) Gammarus pulex and b) Notonecta glauca when exposed to 
carvedilol in the water and in the food and water combined (exposure 
concentration 1 µg L-1). Filled bars are measured values and open bars are the 
predicted values from a one compartment model and mean predicted 
concentration (see chapter 2; with 95th percentiles) 
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Figure 4.14 Mean whole body concentrations (wet weight ± standard 
deviation) in a) Gammarus pulex and b) Notonecta glauca when exposed to 
fluoxetine in the water and in the food and water combined (exposure 
concentration 1 µg L-1). Filled bars are measured values and open bars are the 
predicted values from a one compartment model and mean predicted 
concentration (see chapter 2; with 95th percentiles)  
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However, the model does not account for exposure of organism to the 
pharmaceutical from the food and water combined. In both G. pulex and N. glauca, 
the internal measured concentrations of carvedilol and fluoxetine were higher than 
those predicted internal concentrations by the one compartment model.  
This data suggests that the one-compartment model rate constants obtained in 
chapter 2 could provide a means to predict pharmaceutical concentrations in the 
aquatic invertebrate tested at lower concentrations. However, more replication is 
needed to determine the robustness of these findings and more research is needed 
to predict the uptake by invertebrates of pharmaceuticals from contaminated food. 
 
4.4 Conclusions 
The route of uptake has been previously shown to be an important factor that 
influences the extent of accumulation (Kraal et al., 1995, Liu et al., 2002, Mafra Jr et 
al., 2010). There are many factors that can influence the accumulation of 
contaminants. For the food route factors include interspecies differences such as 
habitat, behaviour, feeding rate, gut passage time, desorption efficiency from the 
food, absorption efficiency of the gut, metabolism and elimination (Kaag et al., 1997, 
Egeler et al., 2001, Liu et al., 2002, Gaskell et al., 2007, Brooks et al., 2009, Mafra 
Jr et al., 2010). Also the distribution of the contaminant in the food item (Arukwe et 
al., 2000, Brooks et al., 2009) and the chemicals properties can effect accumulation 
in the predator (Kaag et al., 1997, Egeler et al., 2001, Mafra Jr et al., 2010). Many of 
these factors also influence uptake from the water but aqueous exposure is 
dominated by exchange between the respiratory surface (Barber, 2003, Barber, 
2008, Powell et al., 2009) and thus factors such as respiratory strategy play a vital 
role in accumulation (Chapter 2, Buchwalter et al., 2002, Rubach et al., 2010). 
The present study has shown that: 
 Pharmaceuticals can accumulate on particulate matter and the accumulation 
is influenced by microorganisms present on the leaf 
 The physicochemical properties of the pharmaceuticals affect the extent of 
the accumulation with the more lipophilic compounds accumulating the most 
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 The accumulation of pharmaceuticals in aquatic invertebrates may be 
influenced by the route of exposure and contaminated food may be an 
important route of exposure for some species 
 Combining pharmaceutical exposure in both food and water, results in more 
accumulation than the water alone for both N. glauca and G. pulex. 
Therefore the inclusion of pharmaceutical uptake from the food may improve 
predictions of bioaccumulation and provide a more realistic exposure 
scenario 
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Chapter 5 General discussion and recommendations for 
future work 
 
In the past five years there has been increasing scientific research into the 
occurrence of pharmaceuticals in the tissues of aquatic species and a number of 
studies have been published reporting uptake of pharmaceuticals into aquatic 
organisms (Daughton and Brooks, 2011). The majority of the studies to date have 
focused on fish (Brooks et al., 2005, Brown et al., 2007, Chu and Metcalfe, 2007, 
Nakamura et al., 2008, Paterson and Metcalfe, 2008, Gelsleichter, 2009, Ramirez et 
al., 2009, Fick et al., 2010, Kallio et al., 2010, Schultz et al., 2010, Zhang et al., 
2010); few studies exist concerning the fate of pharmaceuticals in aquatic 
invertebrates. It is important that we begin to understand the uptake of 
pharmaceuticals in aquatic invertebrates as these organisms play a very important 
role in aquatic food webs (Allan, 1996, Brooks et al., 2009). At present, information 
is very limited and is generally restricted to pharmaceuticals that have been used in 
aquaculture (James, 1990b, James, 1990a, James and Boyle, 1998); however the 
limited data available indicate that aquatic invertebrates can accumulate 
pharmaceuticals (Vernouillet et al., 2010). Therefore, this research explores those 
factors and processes affecting the uptake of human pharmaceuticals in aquatic 
invertebrates and an overview of the results can be found in table 5.1. 
The core hypotheses investigated were: 
 The uptake and depuration of pharmaceuticals in aquatic invertebrates are 
determined by the traits of an aquatic invertebrate, the degree of metabolism 
within an organism and by the properties of the pharmaceutical; 
 Pharmaceuticals have the potential to biomagnify through aquatic food 
chains; and 
 The bioconcentration of pharmaceuticals into aquatic invertebrates is 
predictable based on the physicochemical properties of the pharmaceutical, 
knowledge of pharmacological behavior in humans and from the individual 
traits of the organism 
Each of the hypotheses investigated will be discussed in detail in the following 
section. 
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5.1 Discussion 
Laboratory studies into the uptake and depuration of a variety of pharmaceuticals, 
covering a range of physico-chemical properties and therapeutic modes of action, 
showed that pharmaceuticals do have the potential to accumulate in aquatic 
invertebrates. Uptake and depuration data was modeled using a one compartment 
model to provide rate constants and BCFs. These BCFs were used to establish the 
accumulative potential of these compounds in invertebrates (table 5.1).  
All of the compounds with the exception of fluoxetine would not be bioaccumulative 
under the European Medical Agency (EMEA) guidelines (EMEA, 2007). However 
fluoxetine would be prioritized for further screening due to the large Log BCF of 5.3. 
The BCF in G. pulex was 2 – 5 orders of magnitude higher than those found by 
other researchers (Nakamura et al., 2008, Paterson and Metcalfe, 2008, Zhang et 
al., 2011). The large BCF in G. pulex is probably due to the limited depuration in the 
animal (kout of 0.00076 d-1). Published data on the uptake of pharmaceuticals are 
limited; however data are available on fluoxetine in fish (Japanese madaka O. 
latipes and Rainbow trout, O. mykiss) which provides some data for comparison. 
Nakumara et al., (2008) reported BCFs of 8.8 – 3100 and Patterson and Metcalfe 
(2008) reported BCFs of 74 – 80 and Zhang et al. (2010) reported BCFs of 143 – 
22. Environmental monitoring studies have also shown concentrations of fluoxetine 
in fish to be significantly higher than concentrations in the surrounding water column 
(Lajeunesse et al., 2009; Schultz et al., 2010) also indicating potential for 
bioaccumulation. 
BCFs for all compounds for the different species varied; G. pulex accumulated the 
most followed N. glauca. For carvedilol, P. corneus accumulated more than N. 
glauca but less than G. pulex. The results indicated that species traits such as 
respiration strategy, bahaviour and metabolism may play an important role in the 
accumulation patterns of compounds in  organisms. These findings are in 
accordance with the published literature where the bioconcentration of compounds 
can be species dependent and influenced by the specific traits of an organism 
(Davies and Dobbs, 1984, Barron, 1990, Rubach et al., 2010, Rubach et al., 2010a, 
Rubach et al., 2011). Studies have shown that bioconcentration of a compound can 
be predicted from the size and lipid content of an organism (Geyer et al., 2000, 
Hendriks and Heikens, 2001, Ashauer et al., 2010, Zhang et al., 2010). However, 
this thesis and work completed by Rubach et al. (2010b) indicate that respiration 
strategy could potentially be more influential on bioconcentration, than size or lipid 
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content. Several other studies corroborate this hypothesis and show that aquatic 
organisms with large gas exchange epitheliums (such as G. pulex) will have larger 
BCFs when exposed to environmental contaminants in the surrounding media 
(Buchwalter et al., 2002, Buchwalter et al., 2003, Buchwalter et al., 2004, 
Buchwalter et al., 2008). However, in this thesis only one compound (carvedilol) was 
tested with all three species, therefore a firm conclusion with regards to the 
influence of species traits (such as respiration) on bioconcentration of 
pharmaceuticals cannot be drawn from this limited data set. Further research will be 
needed on a broader range of organisms and pharmaceuticals to determine the 
specific traits that are of most importance for the process of bioconcentartion. 
Ultimately this information could be used to develop relationships that can be 
combined with physicochemical properties in order to understand that internal 
exposure within an organism. 
Extensive information on metabolism in humans is collected for preclinical and 
clinical trials for the marketing of pharmaceuticals (Winter et al., 2010) however little 
is known about the metabolism in non-target organisms. This thesis explored the 
influence of metabolism in G. pulex on bioconcentration for all of the study 
pharmaceuticals and attempted to predict likely metabolic pathways from human 
data. Metabolism of diazepam was observed in G. pulex, and by using known 
metabolic pathways of diazepam for humans, nordiazepam (the major metabolite of 
diazepam in humans) was identified in the organism. Much of the current knowledge 
of metabolism is derived from fish studies which have shown that pharmaceuticals 
such as fluoxetine (Nakamura et al., 2008, Paterson and Metcalfe, 2008, Smith et 
al., 2010) and diclofenac (Kallio et al., 2010) can be metabolized in non-target 
organisms.  
  
 
Table 5.1 Synthesis of data obtained for six model compounds, 5-fluorouracil, carbamazepine, carvedilol, diazepam, fluoxetine and 
moclobemide –how the bioaccumulation factors (BCF) and biomagnification factors (BMF) correlate to EMEA ‘Persistant, 
Bioaccumulative and Toxic’ (PBT) assessment in Gammarus pulex, Notonecta glauca and Planabarius corneus 
Compound G. pulex BCF N. glauca BCF P. corneus BCF C. herbarum FAF 
Metabolism in 
G. pulex 
Trophic 
transfer 
G. pulex BMF N. glauca BMF 
5-fluorouracil 6.5 0.1 - 24 N - -  
carbemazepine 7.0 0.2 - 63 N - -  
carvedilol 270.8 1.6 57.3 947 N Y 
No 
biomagnification 
No 
biomagnification 
diazepam 37.5 1.0 - 166 Y - -  
fluoxetine 185900
a 
1.4 - 1755 N Y 
No 
biomagnification 
No 
biomagnification 
moclobemide 4.55 0.3 - 176 N - -  
a
Very Bioaccumulative under EMEA PBT assessment; Y = Yes; N= No 
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The work in the current thesis is the first to identify human use pharmaceuticals in 
an aquatic invertebrates, however metabolites of the veterinary medicines 
erythromycin and sulfadimethoxine have been observed in invertebrate species 
important for aquaculture (James, 1990b, James, 1990a, James and Boyle, 1998). 
Diazepam was the only study pharmaceutical to be metabolized in G. pulex and the 
concentrations of nordiazepam were low, therefore the metabolism of 
pharmaceuticals in G. pulex was minimal and would not influence the 
bioconcentration of diazeoam. Therefore it can be concluded that the BCFs 
determined in Chapter 2 were reflective of the bioconcentration of the parent 
pharmaceuticals. 
In the literature it has been shown that physicochemical properties of 
pharmaceuticals can influence BCFs, therefore the BCFs from the current thesis 
were compared to the physicochemical properties of the study pharmaceuticals. A 
summary of the data can be found in table 2.2 (Chapter 2, page 83). Although no 
significant linear relationships were found for G. pulex, Log Kow provided the model 
of best fit, however for N. glauca Log Dlipw was shownto be the best model for this 
organism. The data in this thesis supports the current thinking that lipophilicity of the 
compound will influence it uptake and bioconcentration (Borgå et al., 2004, Giulio 
and Hinton, 2008, Powell et al., 2009). The literature suggests the relationship 
between log Kow and bioconcentration is not straight forward. Compounds such as 
pharmaceuticals with ionization potential, can be dissociated to variable degrees 
according to their disassociation constant at ambient pH (Escher and 
Schwarzenbach, 2002). The relationship between log Kow and bioconcentration is 
further complicated as log Kow does not perfectly mimic the properties of the site of 
uptake – the biological membrane (Verhaar et al., 1992, Verhaar et al., 1996). 
Therefore researchers are starting to use Log Dlipw (a more realistic descriptor of lipid 
membranes) in quantitative structure activity relationships (QSARs) for ionisable 
compounds instead of log Kow with good results (Escher and Schwarzenbach, 2002, 
Escher and Hermens, 2004, Escher et al., 2009).  
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Table 5.2 Synthesis of significant relationships found between 
physicochemical properties and BCF in Gammarus pulex and Notonecta 
glauca 
Parameters tested G. pulex N. glauca 
Log Kow No Yes 
Log Dlipw No Yes 
MW No Yes 
PSA No Yes 
 
To test the merit of using the physicochemical properties for predicting BCF, the 
model developed with the best fit in this thesis for G. pulex (Log Kow; Equation 5.1) 
and N. glauca (Log Dlipw; Equation 5.2) are compared with BCFs predicted for fish in 
risk assessment using the Equation 5.3, taken from the technical guidance 
document (TGD; EC, 2003), and an equivalent BCF for fish (Equation 5.4; Log 
Pblood:water) predicted by the FPM (Huggett et al., 2003b), a model for invertebrates 
presented by Arnot et al. (2006) (BCFARNOT; Equation 5.5) and the BCFs from the 
experimental data (table 5.3). 
 
Equation 5.1                                 
Equation 5.2                                    
Equation 5.3                               
Equation 5.4                                    
Equation 5.5                                  
 
 
The predicted BCFs from the different models for BCF as well as the experimental 
data are synthesized in Table 5.3. The BCFs predicted by the FPM (Log Pblood:water 
equivalent BCF) underestimated the bioconcentration in G. pulex for all compounds. 
Therefore the FPM would not be appropriate to use for these invertebrates. For 5-
fluorouracil, all the models for G. pulex and N. glauca including those based on the 
experimental data underestimated the bioconcentration of the compound. For 
carbamazepine, all the models (with the exception of the Log Pblood:water equivalent 
BCF) overestimated the experiment BCFs for both organisms. For carvedilol, the 
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model proposed in this thesis using Log Kow predicted the concentration in G. pulex 
accurately but the other models underestimated the BCF. When looking at N. glauca 
all models overestimated the experimental BCF for carvedilol, with the exception of 
the model proposed in thesis using Log Dlipw where an underestimation was 
obtained. For diazepam, the BCF predicted from the TGD guidelines was accurate 
and the model proposed in this thesis overestimated the BCF in G. pulex and the 
model proposed by Arnot et al. (2006) underestimated the BCF. In N. glauca all the 
models overestimated the bioconcentration observed for diazepam. For 
moclobemide all of the models with the exception of the model proposed in this 
thesis for G. pulex underestimated the BCF, there were similar findings for N. 
glauca. Fluoxetine BCF was overestimated for N. glauca by all models however the 
models all underestimated the BCF for fluoxetine in G. pulex. This thesis has shown 
the difficulty in using a single parameter such as a physicochemical property to 
predict bioconcentration and it is likely that many factors will influence the BCF. An 
accurate model will need various parameters including those that are 
physicochemical as well as those that are biological to produce reliable results. 
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Table 5.3 Predicted bioconcentration factors using Technical Guidance document (BCFTGD), Fish Plasma Model (Log Pblood:water), Arnot 
et al. (2006) (BCFARNOT) the models based on physicochemical properties with best fit from this thesis (BCFlogkow and BCFlogDlipw) and 
experimental data (BCFEXP) using Gammarus pulex, Notonecta glauca and Planabarus corneus 
Compound Log BCFTGD Log Pblood:water 
Log BCFarnot Log BCFlogkow 
G. pulex 
Log BCFlogDlipw 
N. glauca 
Log BCFEXP 
(G. pulex) 
Log BCFEXP 
(N. glauca) 
Log BCFEXP 
(P. corneus) 
5-fluorouracil -1.39 -1.47 -2.09 -0.33 -0.99 0.81 -0.89  
carbamazepine 1.21 0.76 1.04 1.97 -0.31 0.85 -0.62  
carvedilol 1.89 1.35 1.85 2.57 -0.02 2.43 0.20 1.76 
diazepam 1.60 1.09 1.49 2.31 -0.08 1.57 -0.01  
fluoxetine 3.25 2.51 3.48 3.77 0.16 5.27 0.14  
moclobemide 0.29 -0.03 -0.08 1.15 -0.43 0.66 -0.48  
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As fluoxetine and carvedilol were the most bioaccumulative compared to all the 
other study compounds, a series of laboratory studies explored the potential for 
trophic transfer and biomagnification in a simple aquatic food chain. With such a 
large BCF (5.3) obtained for fluoxetine in G. pulex it was thought that there could be 
potential biomagnification. This hypothesis was formulated because compounds 
such as DDT and it metabolites are well-known for biomagnification and they have 
BCFs in the range of 4.2-4.6 in aquatic invertebrates (Lotufo et al., 2000).  
The mean whole body concentrations measured in food chain studies from Chapter 
4 were applied to the secondary poisoning assessment in the TGD. The secondary 
poisoning assessment derives a biomagnification factor (BMF); in order to 
determine whether a compound would have potential for biomagnification in an 
aquatic food chain. The BMF is is defined as the relative concentration in a 
predatory animal compared to the concentration in its prey (Equation 5.6; EC, 
2003).  
 
Equation 5.6      
          
     
 
 
Where Cpredator is the concentration in the predator and Cprey is the concentration in 
the prey.  
The experimental BMFs calculated from the data in Chapter 4 were < 0.1, therefore 
the study compounds would not be of concern for secondary poisoning in aquatic 
food chains. This was in agreement with the experimental results where no 
biomagnification was observed (EC, 2003). These results are in concurrence with 
the limited literature on trophic transfer of pharmaceuticals where little or no trophic 
transfer has been observed in some studies (Vernouillet et al., 2010). Although little 
information is available for pharmaceuticals, these results agree with studies with 
other compound groups (such as pesticides) and show that biomagnification does 
not occur for compounds with a Log Kow < 5.5 (Russell et al., 1999). 
Although the BMF calculated suggested there is no potential risk for secondary 
poisoning, Chapter 4 identifies that biological traits and feeding strategy played an 
important role in accumulation patterns, which is in agreement with studies 
undertaken of neutral compounds where feeding relationships and behaviours have 
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been shown to control the exposure of chemicals in food chains (Russell et al., 
1999, Fisk et al., 2001, Brooks et al., 2009).  
 
5.2 Effects assessment 
For pharmaceuticals there a lot of data regarding their efficacy and potency from 
pharmacological safety information (Brooks et al., 2005, Williams, 2005, Brown et 
al., 2007). The FPM has been proposed for use in risk assessment of 
pharmaceuticals to determine potential for effects occurring in fish (Huggett et al., 
2003b, Huggett et al., 2004). The principle of the model is that plasma 
concentrations needed to cause a therapeutic effect in humans, would be similar to 
the concentrations needed to cause an effect in fish. By using the physicochemical 
properties of the pharmaceutical and predicted environmental concentrations for 
surface water (PECsw) the model calculates the steady state plasma concentration 
in the fish (Log Pblood:water). 
PECsw values were calculated for the study pharmaceuticals with equation 5.7 taken 
from the EMEA guidelines for the environmental risk assessment of medicinal 
products for human use (EMEA, 2007). The usage data required in this equation 
was taken from the National Health Service statistics for 2011 (NHS, 2011). 
 
Equation 5.7                   
           
                    
 
 
Where DOSEai [mg inhabitants
-1 day-1] is the amount of pharmaceutical prescribed 
per person per day, Fpen is fraction of market penetration [default value], 
WASTEWinhab [L inh
-1d-1] is the volume of waste water per inhabitant per day and 
DILUTION is the dilution factor applied.  
The PECsw values for the test pharmaceuticals can be found in table 5.4. The 
PECSW calculated for the study compounds were very low (< 10 ng L
-1) when using 
the EMEA guidelines (table 5.4). Using the PECsw values for the test 
pharmaceuticals and the Log Pblood:water (equation 5.4), the steady state plasma 
concentration in fish (FssPC) can be determined (equation 5.8). 
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Equation 5.8                                 
 
Table 5.4 Predicted Environmental Concentration for surface water PECSW for 
the study pharmaceuticals 
Chemical PECSW [µg L
-1
] 
5-fluorouracil 0.00000006 
carbamazepine 0.01 
carvedilol 0.0001 
diazepam 0.0002 
fluoxetine 0.001 
moclobemide 0.0001 
 
The FPM can be adapted for aquatic invertebrates and used to predict the steady 
state concentration of a pharmaceutical in an organism. In accordance with the 
FPM, the experimentally derived BCFs from Chapter 2 (table 5.1) can be multiplied 
by the PECsw (Table 5.4) to determine the steady state plasma concentration in the 
aquatic invertebrate (AISSPC) at environmentally relevant concentrations (equation 
5.9). 
 
Equation 5.9                     
 
The predicted AISSPC can then be compared the concentration known to produce a 
therapeutic effect in humans (HTPC) to give an effect ratio (Equation 5.9) to 
estimate the probability of therapeutic effects occurring in the organisms (Huggett et 
al., 2003b). 
 
Equation 5.9        
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At low ER values, the drug concentration in the aquatic invertebrate plasma is close 
to the level in human plasma required to give a therapeutic effect, thus effects in 
aquatic invertebrates are likely, provided the drug target is conserved in the 
invertebrate. At high ER values, the risk of target interactions is smaller. This model 
assumes that the pharmaceutical is evenly distributed in the plasma of the aquatic 
invertebrate and that the plasma of an aquatic invertebrate has similar properties to 
plasma in humans. 
When comparing HTPC and AISSPC in G. pulex, N. glauca and P. corneus in the 
effect ratios were > 1, with the exception of fluoxetine for G. pulex. The effects ratios 
show that these compounds may not pose a risk to aquatic invertebrates at 
environmental concentrations. However, the effect ratio for fluoxetine was < 1, 
showing that plasma concentrations in G. pulex could potentially be large enough 
for effects to occur in the environment, providing that the drug receptors are present 
in the organism. Fluoxetine has been detected in surface waters at mean 
concentrations of 0.05 µgL-1 (greater than those predicted from the EMEA guidance; 
table 5.4), therefore a smaller effect ratio would be expected at these higher 
environmental concentrations (Monteiro and Boxall, 2009). 
 
  
 
Table 5.5 Predicted Aquatic Invertebrate plasma concentration (AIssPC), experimental internal concentration (Cint) in Gammarus 
pulex, Notonecta glauca and Planabarus corneus with human therapeutic plasma concentration (HTPC) and effects ratios (ER) 
Compound 
AISSPC  
G. pulex [ng g
-1
] 
AISSPC  
N. glauca [ng g
-1
] 
AISSPC  
P. corneus 
[ng g
-1
] 
HTPC 
[ng ml
-1
 ] 
ER 
[AISSPC] 
G. pulex 
ER 
[AISSPC] 
N. glauca 
ER 
[AISSPC] 
P. corneus 
5-fluorouracil <0.01 <0.01 N/A 1.5 3446092 223996000 N/A 
carbamazepine 0.07 <0.01 N/A 9300 133445 4670560 N/A 
carvedilol 0.02 0.00 <0.01 105 5394 912899 25491.1 
diazepam 0.01 <0.01 N/A 300-400 51613-68817 1935488-2580651 N/A 
fluoxetine 200.11 <0.001 N/A 200-531 0.99-2.65 132711-352348 N/A 
moclobemide <0.01 <0.01 N/A 54-161 20218-603508 3070019-9153207 N/A  
HTPC were all obtained from (Thummel and Shen, 2001) 
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These data show the importance of being able to measure or predict reliable 
internal concentrations in order to identify pharmaceuticals that may cause effects in 
the environment. It is important for risk assessment to know the mode of action of 
compounds to determine potential effects; for pharmaceuticals this information can 
be available from clinical data (Williams, 2005, Escher et al., 2009). For example, 
fluoxetine is an SSRI that effects by inhibiting serotonin reuptake at presynaptic 
neuronal membranes in humans. In fish serotonin can regulate a wide range of 
behaviours including feeding activity, reproductive behavior and establishment of 
social hierarchies (Brooks et al., 2003, Brooks et al., 2005, Gaworecki and Klaine, 
2008). Due to conservation of evolutionary lines it may be possible to predict likely 
effects occurring, by using human pharmacological data from clinical trials (Brooks 
et al., 2005, Brown et al., 2007, Owen et al., 2009). However, in primary producers 
and invertebrates, mechanistic responses to pharmaceuticals and their metabolites 
are not well understood (Brooks et al., 2003, Brooks et al., 2005). Further research 
should be undertaken to identify common receptors in vertebrates and invertebrates 
to establish likely effects of pharmaceuticals in the environment, in order to prioritise 
compounds for risk assessment. 
 
5.3 Implications for risk assessment 
The EMEA guideline for environmental risk assessment of human pharmaceuticals 
(EMEA, 2007) refers to the TGD, and has set criteria to determine whether a 
substance is ‘Persistent Bioaccumulative and Toxic’ (PBT). If a substance; 
 is highly adsorptive 
 belongs to a class of substances known to have a potential to accumulate in 
living organisms 
 has indications from structural features 
 has no mitigating property such as hydrolysis (half-life less than 12 hours); 
there is an indication of bioaccumulation potential (EC, 2003). 
EMEA (2007) specifically requires a pharmaceutical to be screened for persistence, 
bioaccumulation and toxicity if it has a logKow above 4.5 (EMEA, 2007). Therefore 
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pharmaceuticals with a Log Kow < 4.5 will not be screened. Under the current 
regulations, pharmaceuticals such as those studied in this research would not be 
screened for bioaccumulation; however results from this thesis indicate that aquatic 
invertebrates can uptake and accumulate these compounds. 
In risk assessment the most important and widely accepted indicator for 
bioaccumulation potential is the Log Kow (EC, 2003). There are however limitations 
to predicting BCF from models with Log Kow as the main parameter. These models 
do not consider factors such as active transport, metabolism and the accumulation 
potential of any metabolites and special structural properties (e.g. ionization 
potential) (EC, 2003). The studies presented in this thesis reiterate that Log Kow may 
not be the best predictor for uptake and bioconcentration in aquatic invertebrates, 
as some of the pharmaceuticals tested have potential for uptake and 
bioconcentration. 
OECD No 305 is the current European guidance for characterising the 
bioconcentration potential of substances in aquatic species. It is a flow – through 
fish test. There is currently no guidance for experimentally determining 
bioconcentration in aquatic invertebrates (OECD, 1996). The data from this 
research shows that invertebrates have the potential to uptake pharmaceuticals to 
high concentrations. The use of fish data provide a simple ERA but may not be 
sufficient for safe-guarding against long-term effects on many other aquatic 
organisms, therefore a more diverse range of organisms should be used to 
determine bioconcentration. Being more inclusive and protecting a wider range of 
organisms would help fulfill the objectives of the water framework directives where a 
general requirement for ecological protection, and a general minimum chemical 
standard, was introduced to cover all surface waters (Kallis and Butler, 2001). An 
alternative route for risk assessment could involve investigating the mechanistic 
basis of species variability (Escher et al., 2009). Applying knowledge about 
biological traits in combination with physicochemical properties (such as the Log 
Kow) to prediction algorithms, may increase the reliability and robustness of models 
for a wider range species. 
The findings of this thesis indicate that certain compounds such as fluoxetine may 
be high priority for risk assessment in aquatic invertebrates; however it is not 
considered an environmental risk under the current guidelines (EC, 2003, EMEA, 
2007). To demonstrate the applicability of the models developed in chapter 2 of this 
thesis for risk assessment, the model for G. pulex will be applied to the top 50 
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pharmaceuticals in the UK (based on usage data NHS, 2011) to determine which 
pharmaceuticals could be of potential risk to aquatic invertebrates. The top 50 
pharmaceuticals were ranked by their PECsw and then ranked by BCF, predicted 
using the G. pulex model.  
The prioritization exercise shows that of the top 50 used pharmaceuticals in the UK, 
simvastatin; diclofenac; ibuprofen; flucloxacillin and naproxen would be the top 5 
priority pharmaceuticals for risk assessment for aquatic invertebrates. Out of these 
top 5, simvastatin would be described as ‘very bioaccumulative’ and diclofenac 
would be described as ‘bioaccumulative’ under EMEA. As diclofenac has a LogKow 
of 4.0 it would not be required to have a PBT assessment and further more a 
predicted BCF of 2.7 under the current system using the TGD (equation 5.3; page 
180) would labelled it as non-bioaccumulative (EC, 2003, EMEA, 2007). 
Considering the known effects of diclofenac in fish and birds (Hilton and Thomas, 
2003, Green et al., 2004, Schwaiger et al., 2004, Green et al., 2007), and the 
incurred diclofenac residues in wild fish samples (Brown et al., 2007, Fick et al., 
2010) this compound may warrant further investigation. 
 
  
 
Table 5.6  Prioritisation approach using models based on physicochemical properties with best fit from this thesis for Gammarus 
pulex (BCFlogkow), top 50 pharmaceuticals ranked first by Predicted surface water concentration (PECSW) and then by BCF 
Rank Pharmaceutical Theraputic class Usage (kg) PECSWµgL
-1
 Log kow BCFlogkow G. pulex 
1 Simvastatin Statin 43661 0.010 5.2 4.2 
2 Diclofenac NSAID 151297 0.034 4.0 3.3 
3 Ibuprofen NSAID 262553 0.058 3.8 3.1 
4 Flucloxacillin Penicillinase-resistant penicillins 42929 0.010 3.4 2.8 
5 naproxen NSAID 53082 0.012 3.1 2.6 
6 Hydrocortisone Corticosteroid 224823 0.050 1.6 1.5 
7 Acetylsalicylic Acid Salicylate analgesic/antiplatelet 94159 0.021 1.1 1.1 
8 Paracetamol Analgesic 1022268 0.227 0.3 0.5 
9 Quinine Antipyretic, antimalarial, NSAID, Analgesic 33384 0.007 3.3 2.7 
10 Tramadol Opioid analgesic 32577 0.007 3.0 2.5 
11 ketoprofen NSAID 39959 0.009 3.0 2.5 
12 Diltiazem Calcium channel blocker 24699 0.005 2.8 2.4 
13 carbamazepine Anticonvulsant 39069 0.009 2.3 2.0 
14 Gliclazide Sulphonylureas 29614 0.007 2.1 1.9 
15 Penicillin V Antibiotic  26785 0.006 1.9 1.7 
16 Codeine Opiate 39688 0.009 1.3 1.2 
17 Ranitidine H2-receptor antagonist 29791 0.007 0.3 0.5 
18 Atenolol Selective β1 receptor antagonist 27780 0.006 0.0 0.3 
19 Allopurinol Xanthine-oxidase inhibitor 29385 0.007 -0.6 -0.1 
 
 
 
  
 
Table 5.6 Prioritisation approach using models based on physicochemical properties with best fit from this thesis for Gammarus 
pulex (BCFlogkow), top 50 pharmaceuticals ranked first by Predicted surface water concentration (PECSW) and then by BCF 
Rank Pharmaceutical Theraputic class Usage (kg) PECSWµgL
-1
 Log kow 
BCFlogkowG. pulex 
20 Oxytetracycline Antibiotic (tetracycline) 21297 0.005 -2.9 -1.9 
21 Amiodarone Anti-arrhythmics 4247 0.001 8.8 6.9 
22 Orlistat Gastro-intestinal anti-obesity drugs 11434 0.003 8.2 6.4 
23 Clotrimazole Antifungal 4161 0.001 6.3 5.0 
24 Mebeverine Antispasmodic 20130 0.004 5.1 4.1 
25 Verapamil L-type Calcium channel blocker 6247 0.001 4.8 3.9 
26 Fluoxetine SSRI 4640 0.001 4.7 3.8 
27 Dosulepin Tricyclic antidepressant 4417 0.001 4.5 3.7 
28 Losartan Angiotensin-ii receptor antagonists 8612 0.002 4.0 3.3 
29 Clopidogrel Antiplatelet drugs 8493 0.002 3.8 3.1 
30 Citalopram SSRI  6943 0.002 3.7 3.1 
31 Lansoprazole Proton pump inhibitor 11661 0.003 3.7 3.0 
32 Omeprazole Proton pump inhibitor 12808 0.003 3.4 2.8 
33 Ramipril ACE inhibitor 4400 0.001 3.3 2.8 
34 Venlafaxine SNRI  8540 0.002 3.3 2.7 
35 Quetiapine Antipsychotic 5898 0.001 3.2 2.7 
36 Valproic Acid Anticonvulsant 8206 0.002 3.0 2.5 
37 Fexofenadine Antihistamine 6865 0.002 2.8 2.4 
38 Propranolol Beta blocker 7815 0.002 2.6 2.2 
 
  
 
Table 5.6 Prioritisation approach using models based on physicochemical properties with best fit from this thesis for Gammarus 
pulex (BCFlogkow), top 50 pharmaceuticals ranked first by Predicted surface water concentration (PECSW) and then by BCF 
Rank Pharmaceutical Theraputic class Usage (kg) PECSWµgL
-1
 Log kow 
BCFlogkowG. pulex 
39 Nifedipine Dihydropyridine calcium channel blocker 4010 0.001 2.5 2.2 
40 Furosemide Loop diuretic 15210 0.003 2.3 2.0 
41 Salicylic Acid Preparation for psoriasis 3809 0.001 2.2 2.0 
42 Amlodipine Calcium channel blocker 4243 0.001 2.1 1.8 
43 Lidocaine Antiarrhythmic 5712 0.001 1.7 1.5 
44 Dihydrocodeine Opioid analgesic 10529 0.002 1.5 1.4 
45 Lamotrigine Anticonvulsant 6502 0.001 1.0 1.0 
46 trimethoprim Bacteriostatic antibiotic 8836 0.002 0.7 0.8 
47 Isosorbide Mononitrate Nitrate 7800 0.002 -0.3 0.1 
48 Lisinopril ACE inhibitor 4718 0.001 -0.9 -0.4 
49 Levodopa Psychoactive drug 13773 0.003 -2.2 -1.4 
50 Acamprosate Psychoactive drug 3534 0.001 -2.9 -1.9 
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5.4 Conclusions 
 There is increasing scientific research into the occurrence of 
pharmaceuticals in the tissues of fish; however limited studies exist on 
pharmaceuticals in aquatic invertebrates.  
 The study presented in this thesis focuses on the uptake of human 
pharmaceuticals in aquatic invertebrates and the influences of 
physicochemical properties of the compound and the traits of the species.  
 Modeling bioconcentration from physicochemical properties and 
pharmacokinetic parameters in aquatic invertebrates was shown to be 
difficult. However the refined models for predicting BCF for invertebrates 
species in thesis worked well compared to the alternative models available.  
 To obtain precise prediction of bioconcentration in a particular invertebrate 
would either require detailed experimental data or new algorithms to be 
developed which consider the variability in biological, chemical and 
environmental factors. 
 Biomagnifciation did not occur in the food chain tested however it is also 
important to recognise that exposure from contaminated food can contribute 
to uptake of pharmaceuticals in aquatic invertebrates.  
 Accumulation patterns are associated with feeding behavior and feeding 
relationships may play an important role in controlling the exposure of 
pharmaceuticals in the aquatic environment. 
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5.5 Recommendations for future research 
1 The study has only looked at a handful of pharmaceuticals. In order to 
corroborate the relationships between physico-chemical properties and uptake, 
additional pharmaceutical active ingredients should be studied. 
2 This thesis has shown that LogDlipw can be used effectively in predicting 
BCF, however the test conditions were static. Further studies under 
different conditions to validate the QSAR for pH changes. Well 
characterized natural waters should be used to validate the system for 
the real world. 
3 In this thesis only the influence of physicochemical and biological traits 
on BCF were explored. Therefore more research required to elucidate 
the influence of environmental factors such as dissolved organic carbon 
nitrates and suspended solids.  
4 This thesis only assessed BCF using the water compartment. A real 
system would have a sediment compartment. Ultimately we should 
develop combined fate and uptake models for realistic environmental 
systems that can be used to characterise uptake distributions in the real 
environment. 
5 Different patterns of accumulation were observed for G. pulex and N. glauca. 
This research proposes that species traits influence uptake of pharmaceuticals. 
It was thought that species traits including respiration and feeding strategy may 
be contributing factors to observed differences in uptake. Therefore further 
research is needed with more species of different traits to determine which traits 
and mechanisms have the greatest potential to accumulate pharmaceuticals. 
6 In the food chain experiments no biomagnification was observed. The 
differences in uptake from the food were attributed to species traits. It is 
necessary to investigate the trophic transfer of pharmaceuticals with other 
species to confirm that biomagnification will not occur for compounds such as 
fluoxetine.  
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7 Further research is required to establish the difference in metabolism of 
pharmaceutical compounds in invertebrates in order to establish the influence 
on BCF. 
8 Ultimately it would be advantageous to understand the ecological and 
physiological influences on BCF and to be able to integrate these along with the 
physicochemical parameters into modeling 
9 As data from the above studies becomes available the developed knowledge 
should be used to determine new models for predicting uptake in aquatic 
organisms. These models will be invaluable for risk assessment of 
pharmaceuticals in the environment 
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Appendix A Sorption of Fluoxetine  
 
A.1 Introduction 
It has been shown to be hydrolytically and photolytically stable (Kwon and Armbrust, 
2006), however it was observed to dissipate from the test water during the course of 
the study. It is known that fluoxetine adsorbs to soils and sediments (Kwon et al., 
2008, Monteiro, 2008). Its sorption potential varies greatly and is dependent on 
factors such as pH and radox status of the environment (Oakes et al., 2010). 
Therefore sorption to the test vessels could potentially cause the dissipation of 
compound from the test system. To determine the fate of fluoxetine in the test 
system the aim of this preliminary studied was to determine the cause of the 
dissipation of fluoxetine from the test solution by performing a sorption experiment 
with the test beakers with different lighting conditions. 
 
A.2 Materials and methods 
A.2.1 Experimental procedure 
Radiolabelled flouxetine was obtained from American Radiolabeled Chemicals 
Incorporated (Missouri, USA), the physicochemical properites are shown in table 
2.2. 
Test solutions were made up of radioactive fluoxetine (0.3 nmol L-1) in APW. There 
were four treatments with three replicates each. Each replicate was a glass beaker 
containing 500 mL of test solution. Two treatments were kept in the dark by 
wrapping the test vessels in tinfoil. One of these treatments contained the steel 
cages used in Chapter 2 to separate G. pulex. The final two treatments were kept 
under a 12 hour light, 12 hour dark photoperiod one of these treatments also 
contained steel cages. Samples of water (1 mL) were taken from the test vessels at 
0, 1, 2, 3 and 4 days when the exposure period was terminated. 
The concentration of fluoxetine remaining in the water was determined by liquid 
scintillation counting (LSC). Water samples were transferred to scintillation vials and 
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10 mL of Ecoscint A (National Diagnostics) was then added. The sample was 
shaken to mix, left to settle and the radioactivity measured in the dark by LSC.  
Environmental parameters pH and temperature were measured at the start and at 
the end of the exposure period with a Symphony SB80BD bench top meter (VWR 
International LtD, UK). 
 
A.2.2 Data analysis 
The determination of significant differences between the four treatments was 
calculated by an independent t-test with SPSS v.17.0.0. 
 
A.3.1 Results and discussion 
The concentration of fluoxetine in the test solution decreased over the exposure 
period in all four treatments (Figure 6.1). A independent t-test revealed that in three 
treatments (light; dark; light cages) the concentration of fluoxetine in the test solution 
was significantly different at the end of the exposure period compared to the 
concentration at the start (p < 0.05, Figure A.1). This was not the case for the 
treatment in the dark with cages (p = 0.07), however when considering the 
concentration of fluoxetine has significantly decreased after 72 hours compared to 
the start of the experiment (p = 0.02) it can be assumed that fluoxetine 
concentration is in decline in the test system. 
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Figure A.1 Mean concentration (± standard deviation, n=3) of fluoxetine in the 
test solution at day 0, 1, 2, 3 and 4. 
The overall trend in all treatments is that the fluoxetine concentration is declining. 
When considering the differences between the treatments, the data shows that 
fluoxetine is photolytically stable as there is no significant difference between the 
concentration in light and in the dark (p = 0.94). This is consistent with the literature 
as Kwon and Armbrust (2006) found that fluoxetine is nor susceptible to hydrolysis, 
photolysis and microbial degradation. However is it known that fluoxetine is prone to 
sorption in the environment (Kwon and Armbrust, 2006, Oakes et al., 2010). 
Sorption to the cages in the test system could explain the significant difference (P > 
0.01) between those treatments with and without cages. As fluoxetine is declining in 
all treatments it might be concluded that it is adsorbing to the glass beakers as well 
as the cages. Fluoxetine is an amine with a pKa > 9 (Robertson et al., 1988) 
therefore a larger fraction of the molecule will be positively charged (protonated; 
Yamamoto et al., 2009) at the pH of the experiments (pH 8.42 – 8.42). This 
suggests that pH is unlikely influence the sorption behaviour of fluoxetine in this 
experiment.  
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A.4.1 Conclusions 
It can be concluded from this preliminary experiment that fluoxetine is lost from the 
test solution over a four day time period. The exact process or processes that cause 
the loss of fluoxetine from the test solution is unknown, however the results indicate 
that sorption to the test vessels and cages play a more significant roles in fluoxetine 
dissipation than photolysis. For the proceeding experiments it can be concluded that 
a static renewal approach should be used to ensure a constant concentration of 
fluoxetine in the test solution. 
  
 
Appendix B Toxicity of pharmaceuticals to the test organisms 
Species 
EC50 of test pharmaceuticals [µmol L1] 
5-fluorouracil carbamazepine carvedilol diazepam fluoxetine moclobemide 
Gammarus 
pulex >31 >17 >10 >28 >6 >127 
Notonecta 
glauca >8 >4 >3 >4 >3 >4 
Lymnea 
stagnalis   >3    
In all situations the EC50 values were above the highest concentration tested. 
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Appendix C Statistical Analysis 
C.1 Statistical information for Chapter 2: Linear regression analysis using 
SPSS v17.0 
 
C.1.1 LogKow and LogBCF for Gammarus pulex 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .801
a
 .641 .551 1.18190 
a. Predictors: (Constant), LogKow 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .641 7.142 1 4 .056 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 9.977 1 9.977 7.142 .056
a
 
Residual 5.588 4 1.397   
Total 15.564 5    
a. Predictors: (Constant), LogKow 
b. Dependent Variable: BCFgam 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) .278 .785  .355 .741 
LogKow .764 .286 .801 2.672 .056 
a. Dependent Variable: BCFgam 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -1.901 2.457 
LogKow -.030 1.557 
a. Dependent Variable: BCFgam 
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C.1.2 LogDlipw and LogBCF for Gammarus pulex 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .706
a
 .498 .372 1.39793 
a. Predictors: (Constant), LogDlipw 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .498 3.964 1 4 .117 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 7.747 1 7.747 3.964 .117
a
 
Residual 7.817 4 1.954   
Total 15.564 5    
a. Predictors: (Constant), LogDlipw 
b. Dependent Variable: BCFgam 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) .285 1.005  .283 .791 
LogDlipw .764 .384 .706 1.991 .117 
a. Dependent Variable: BCFgam 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -2.507 3.076 
LogDlipw -.301 1.830 
a. Dependent Variable: BCFgam 
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C.1.3 Molecular weight and LogBCF for Gammarus pulex 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .486
a
 .236 .045 1.72435 
a. Predictors: (Constant), MolecularW 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .236 1.235 1 4 .329 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 3.671 1 3.671 1.235 .329
a
 
Residual 11.894 4 2.973   
Total 15.564 5    
a. Predictors: (Constant), MolecularW 
b. Dependent Variable: BCFgam 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) -.647 2.426  -.267 .803 
MolecularW .009 .009 .486 1.111 .329 
a. Dependent Variable: BCFgam 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -7.383 6.089 
MolecularW -.014 .033 
a. Dependent Variable: BCFgam 
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C.1.4 Polar surface area and LogBCF for Gammarus pulex 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .818
a
 .669 .558 1.29847 
a. Predictors: (Constant), PolarSA 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .669 6.053 1 3 .091 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 10.206 1 10.206 6.053 .091
a
 
Residual 5.058 3 1.686   
Total 15.264 4    
a. Predictors: (Constant), PolarSA 
b. Dependent Variable: BCFGamlessCARV 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) 6.413 1.950  3.289 .046 
PolarSA -.114 .047 -.818 -2.460 .091 
a. Dependent Variable: BCFGamlessCARV 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) .207 12.619 
PolarSA -.263 .034 
a. Dependent Variable: BCFGamlessCARV 
This regression analysis excludes carvedilol and may only be appropriate for 
compounds with low PSAs. 
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C.1.5 Volume Distribution and LogBCF for Gammarus pulex 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .896
a
 .803 .753 .87630 
a. Predictors: (Constant), LOGVD 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .803 16.268 1 4 .016 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 12.493 1 12.493 16.268 .016
a
 
Residual 3.072 4 .768   
Total 15.564 5    
a. Predictors: (Constant), LOGVD 
b. Dependent Variable: LOGBCFGAM 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) 1.389 .382  3.632 .022 
LOGVD 2.249 .557 .896 4.033 .016 
a. Dependent Variable: LOGBCFGAM 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) .327 2.450 
LOGVD .701 3.796 
a. Dependent Variable: LOGBCFGAM 
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C.1.6 Comparision between linear and exponential relations between LogKow 
and Log BCF for Gammarus pulex 
Model Summary and Parameter Estimates 
Dependent Variable:BCFgam 
Equation 
Model Summary Parameter Estimates 
R Square F df1 df2 Sig. Constant b1 
Linear .641 7.142 1 4 .056 .278 .764 
Exponential .702 9.403 1 4 .037 .661 .361 
The independent variable is LogKow. 
 
Figure C.1 Exponential and linear regression for the relationship between LogKow 
and Log BCF  
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C.1.7 Volume Distribution and LogBCF for Notonecta glauca 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .651
a
 .423 .279 .38159 
a. Predictors: (Constant), LOGVD 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .423 2.937 1 4 .162 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .428 1 .428 2.937 .162
a
 
Residual .582 4 .146   
Total 1.010 5    
a. Predictors: (Constant), LOGVD 
b. Dependent Variable: LOGBCFNOT 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) -.375 .166  -2.255 .087 
LOGVD .416 .243 .651 1.714 .162 
a. Dependent Variable: LOGBCFNOT 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -.838 .087 
LOGVD -.258 1.090 
a. Dependent Variable: LOGBCFNOT 
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C.1.8 LogKow and LogBCF for Notonecta glauca 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .866
a
 .750 .688 .25109 
a. Predictors: (Constant), LogKow 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .750 12.022 1 4 .026 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .758 1 .758 12.022 .026
a
 
Residual .252 4 .063   
Total 1.010 5    
a. Predictors: (Constant), LogKow 
b. Dependent Variable: BCFnot 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) -.731 .167  -4.383 .012 
LogKow .210 .061 .866 3.467 .026 
a. Dependent Variable: BCFnot 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -1.194 -.268 
LogKow .042 .379 
a. Dependent Variable: BCFnot 
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C.1.9 Molecular weight and LogBCF for Notonecta glauca 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .899
a
 .809 .761 .21973 
a. Predictors: (Constant), MolecularW 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .809 16.921 1 4 .015 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .817 1 .817 16.921 .015
a
 
Residual .193 4 .048   
Total 1.010 5    
a. Predictors: (Constant), MolecularW 
b. Dependent Variable: BCFnot 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) -1.492 .309  -4.826 .008 
MolecularW .004 .001 .899 4.114 .015 
a. Dependent Variable: BCFnot 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -2.350 -.633 
MolecularW .001 .007 
a. Dependent Variable: BCFnot 
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C.1.10 Log Dlipw and LogBCF for Notonecta glauca 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .914
a
 .835 .793 .20442 
a. Predictors: (Constant), Log Dlipw 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .835 20.171 1 4 .011 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .843 1 .843 20.171 .011
a
 
Residual .167 4 .042   
Total 1.010 5    
a. Predictors: (Constant), Log Dlipw 
b. Dependent Variable: BCFnot 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) -.818 .147  -5.567 .005 
Dlipw .252 .056 .914 4.491 .011 
a. Dependent Variable: BCFnot 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) -1.227 -.410 
Dlipw .096 .408 
a. Dependent Variable: BCFnot 
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C.1.11 Polar surface area and LogBCF for Gammarus pulex 
Model Summary 
Model 
 
R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .979
a
 .958 .944 .10168 
a. Predictors: (Constant), PolarSA 
Model Summary 
Model 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .958 68.071 1 3 .004 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression .704 1 .704 68.071 .004
a
 
Residual .031 3 .010   
Total .735 4    
a. Predictors: (Constant), PolarSA 
b. Dependent Variable: BCFNotLessCARV 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) .832 .153  5.449 .012 
PolarSA -.030 .004 -.979 -8.251 .004 
a. Dependent Variable: BCFNotLessCARV 
Coefficients
a
 
Model 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
1 (Constant) .346 1.318 
PolarSA -.042 -.018 
a. Dependent Variable: BCFNotLessCARV 
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C.2 Statistical Analysis for Chapter 4 using SPSS V17.0 
C.2.1 Linear regression of FAF and Log Kow 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .871
a
 .758 .698 .38469 
a. Predictors: (Constant), LOGKOW 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 1.859 1 1.859 12.559 .024
a
 
Residual .592 4 .148   
Total 2.450 5    
a. Predictors: (Constant), LOGKOW 
b. Dependent Variable: LOGFAF 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) 1.598 .255  6.254 .003 
LOGKOW .330 .093 .871 3.544 .024 
a. Dependent Variable: LOGFAF 
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C.2.2 Linear regression of FAF and Log Dlipw 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .923
a
 .852 .815 .30124 
a. Predictors: (Constant), LOGDLIPW 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 2.088 1 2.088 23.005 .009
a
 
Residual .363 4 .091   
Total 2.450 5    
a. Predictors: (Constant), LOGDLIPW 
b. Dependent Variable: LOGFAF 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients  
B Std. Error Beta t Sig. 
1 (Constant) 1.350 .235  5.738 .005 
LOGDLIPW .393 .082 .923 4.796 .009 
a. Dependent Variable: LOGFAF 
 
  
C.2.3 Statistical information for comparison of uptake/sorption of pharmaceuticals for fungus and non-fungus leaf discs:  
Levene’s test and independent t-test for all test pharmaceuticals 
Independent Samples Test 
  Levene's Test for Equality of Variances t-test for Equality of Means 
    95% Confidence Interval of the Difference 
  F Sig. t df Sig. (2-tailed) Mean Difference Std. Error Difference Lower Upper 
data_flu Equal variances assumed 5.451 .042 5.700 10 .000 8109.64812 1422.84825 4939.34466 11279.95158 
Equal variances not assumed   5.700 5.655 .002 8109.64812 1422.84825 4575.94791 11643.34834 
data_carb Equal variances assumed .293 .600 2.689 10 .023 5779.09738 2148.89101 991.06983 10567.12492 
Equal variances not assumed   2.689 7.681 .029 5779.09738 2148.89101 787.71644 10770.47832 
data_carv Equal variances assumed .979 .346 2.116 10 .060 22923.18692 10835.72002 -1220.30185 47066.67569 
Equal variances not assumed   2.116 8.715 .064 22923.18692 10835.72002 -1711.73510 47558.10895 
data_diaz Equal variances assumed 2.766 .127 1.719 10 .116 9086.82736 5287.25112 -2693.90228 20867.55701 
Equal variances not assumed   1.719 8.010 .124 9086.82736 5287.25112 -3102.99661 21276.65134 
data_fluox Equal variances assumed .632 .445 1.076 10 .307 40726.70784 37836.84402 -43579.03435 1.25032E5 
Equal variances not assumed   1.076 9.893 .307 40726.70784 37836.84402 -43702.51980 1.25156E5 
data_moc Equal variances assumed .275 .611 2.742 10 .021 11310.14437 4124.64834 2119.85515 20500.43359 
Equal variances not assumed   2.742 8.400 .024 11310.14437 4124.64834 1876.99440 20743.29433 
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Mann Whitney U test for 5-fluorouracil 
Ranks 
 test N Mean Rank Sum of Ranks 
data_flu fungus 6 9.50 57.00 
nonfungus 6 3.50 21.00 
Total 12   
 
 
Test Statistics
b
 
 data_flu 
Mann-Whitney U .000 
Wilcoxon W 21.000 
Z -2.882 
Asymp. Sig. (2-tailed) .004 
Exact Sig. [2*(1-tailed Sig.)] .002
a
 
a. Not corrected for ties. 
b. Grouping Variable: test 
 
C.2.4 Analysis of variance comparing exposure route of 
pharmaceuticals for Gammarus pulex 
 
Multiple Comparisons 
data 
LSD 
(I) Route (J) Route 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
food water -427.506
*
 104.3633 .001 -654.894 -200.118 
foodwater -1108.372
*
 104.3633 .000 -1335.760 -880.984 
water food 427.506
*
 104.3633 .001 200.118 654.894 
foodwater -680.866
*
 104.3633 .000 -908.254 -453.478 
foodwater food 1108.372
*
 104.3633 .000 880.984 1335.760 
water 680.866
*
 104.3633 .000 453.478 908.254 
Based on observed means. 
 The error term is Mean Square(Error) = 32675.074. 
*. The mean difference is significant at the 0.05 level. 
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C.2.5 Analysis of variance comparing exposure route of 
pharmaceuticals for Notonecta glauca 
 
Multiple Comparisons 
Data_not_directly 
LSD 
(I) 
test_type_ro
ute 
(J) 
test_type_ro
ute 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
food water 15.3876 19.48929 .442 -26.1528 56.9281 
foodwater -31.1501 19.48929 .131 -72.6906 10.3903 
water food -15.3876 19.48929 .442 -56.9281 26.1528 
foodwater -46.5378
*
 19.48929 .071 -88.0782 -4.9973 
foodwater food 31.1501 19.48929 .131 -10.3903 72.6906 
water 46.5378
*
 19.48929 .071 4.9973 88.0782 
Based on observed means. 
 The error term is Mean Square(Error) = 1139.497. 
*. The mean difference is significant at the 0.05 level. 
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C.3 Statistical information for fluoxetine sorption test: T-test analysis using 
SPSS v17.0 
C.3.1 Independent students t-test 
Independent Samples Test 
  t-test for Equality of Means 
   
  
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
Light_dark Equal variances assumed .944 -.00074 .00989 
Equal variances not assumed .945 -.00074 .00989 
Light_lightcages Equal variances assumed .011 .04768 .01065 
Equal variances not assumed .011 .04768 .01065 
Dark_lightcages Equal variances assumed .006 .04841 .00923 
Equal variances not assumed .007 .04841 .00923 
Light_Darkcages Equal variances assumed .020 .04009 .01062 
Equal variances not assumed .020 .04009 .01062 
dark_darkcages Equal variances assumed .011 .04082 .00920 
Equal variances not assumed .012 .04082 .00920 
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the 
Difference 
  Lower Upper 
Light_dark Equal variances assumed -.02821 .02673 
Equal variances not assumed -.02913 .02766 
Light_lightcages Equal variances assumed .01811 .07724 
Equal variances not assumed .01796 .07739 
Dark_lightcages Equal variances assumed .02279 .07403 
Equal variances not assumed .02245 .07437 
Light_Darkcages Equal variances assumed .01059 .06958 
Equal variances not assumed .01043 .06974 
dark_darkcages Equal variances assumed .01529 .06636 
Equal variances not assumed .01497 .06668 
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Abbreviations 
AA   Analgesics and Anti-inflammatories 
AB  Anti-biotics 
AC  Anti-cancer 
ACE  Angiotensin-Converting Enzyme 
AD   Anti-depressants 
AE  Anti –epileptics 
AHP   Anti – hypertensives 
AP  Anti – psychotic 
API  Active Pharmaceutical Ingredient 
APW  Artificial Pond Water 
ASE  Accelarated Solvent Extraction 
BB   Beta-blockers 
BCF  Bioconcentration Factor 
BAF  Bioaccumulation Factor 
BMF  Biomagnification Factor 
Bq  Becquerel 
BWW  Bishop Wilton Beck Water 
C-14  Carbon 14 isotope 
Cinternal  Internal Concentration  
Cmax  Maximum Concentration 
CO2  Carbon Dioxide 
Cwater  Water Concentration 
CYP – 450 Cytochrome P450 enzymes 
Dlipw  Partition coefficient for liposome-water partition coefficient 
Dow   Partition coefficient for Octanol and Water corrected for pH 
EC50  Effective Concentration with 50 % mortality 
fion  The fraction of the ionic species 
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fneutral  The fraction of the neutral species 
FPM  Fish Plasma Model 
H  Hormones 
H-3  Tritium isotope 
HPLC  High Pressure Liquid Chromatograpy 
HSS  High Strength Silica 
i-Fit  Isotope fit 
IT-MS  Ion Trap Mass Spectormetry 
Kint  Uptake rate constant 
Kout  Depuration rate constant 
Kow   Partition coefficient for Octanol and Water 
LOD  Limit of Detection 
LOQ  Limit of Quantification 
LSC  Liquid Scintillation Counting 
LR  Lipid Regulators 
MCMC  Monte-Carlo Markov-Chain 
MW  Molecular Weight 
ND  Not Detected 
NGR  National Grid Reference 
NHS  National health Service 
NICE   National Institute for Clinical Excellence 
NO2  Nitrogen Dioxide 
NSAID  Non-Steroidal Anti-Inflammatory Drug 
PAH  Polycyclic Aromatic Hydrocarbons 
PBT  Persistent Bioaccumulative and Toxic  
PCB  Polychlorinated Biphenyls 
PECFW  Predicted Environmental Concentration for Fresh Water 
pKa  Partition Coefficient 
PSA  Polar Surface Area 
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PTFE  Polytetrafluoroethylene 
QqQ-MS Tandem Quadrupole Mass Spectrometry 
QTof-MS QuadrupoleTime of flight Mass Spectrometry 
QTof-MS/MS QuadrupoleTime of flight Tandem Mass Spectrometry 
REACH Registration, Evaluation and Authorisation of Chemicals 
RPM  Revolutions Per Minute 
RT  Retention Time 
SA   Specific Activity 
SNRI  Serotonin – Norepinephrine Reuptake Inhibitors 
SO2  Sulphur Dioxide 
SSRI  Selective Serotonin Reuptake Inhibitors 
STW   Sewage Treatment Works 
Tof-MS Time of flight Mass Spectrometry 
UPLC  Ultra Performance Liquid Chromatography 
UK  United Kingdom 
USA  United States of America 
VD  Volume Distribution 
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Glossary 
Absorption the movement of a substance, such as a liquid or 
solute, across a cell membrane by means of diffusion 
or osmosis 
Active transport a mechanism generally for endogenous compounds 
such as nutrients that involves transport by a specific 
membrane carrier for which metabolic energy is 
required 
Adipose tissue tissue containing stored fat that serves as a source of 
energy 
Benthic relating to the benthic zone, which is the ecological 
region at the lowest level of a body of water such as an 
ocean or a lake, including the sediment surface and 
some sub-surface layers 
Bioaccumulation a process by which a substance is absorbed by an 
organism through all routes of exposure, i.e. through 
diet and ambient exposure 
Bioconcentration a process by which a substance is absorbed by an 
organism from the ambient environment only through 
its respiratory and dermal surfaces, i.e. diet is not 
included 
Biomagnification a process by which the thermodynamic activity of a 
substance in an organism exceeds that of its diet 
Biotransformation a series of chemical alterations of a substance within 
the body 
Catabolism destructive reactions, i.e. the breakdown of sugar to 
carbon dioxide and water 
Co-variance a measure of how two random variables change 
together 
Electrospray a type of ionisation that creates ions at atmospheric 
pressure 
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Elimination a process of removal or of extrusion, especially of drug 
expulsion from the body 
Enterohepatic circulation refers to the circulation of bile from the liver 
Epibenthic the area of water overlying the sediment 
Depuration to eliminate substances or impurities from the body 
Facilitated diffusion a mechanism as it occurs across a concentration 
gradient for which no energy is required 
Filtration Small molecules passing through pores in membranes 
formed by protein molecules 
Hepatopancreas is an organ of the digestive tract of arthropods, mollucs 
and fish. It provides the functions which in mammals 
are provided separately by the liver and pancreas 
Hydrophobic tending to repel water 
Hyperosmotic pertaining to a solution that has a higher solute 
concentration than another solution 
Ion an atom or a group of atoms that has acquired a net 
electric charge by gaining or losing one or more 
electrons 
Ionic relating to or occurring in the form of ions 
Ionised a process where substance is converted totally or 
partly into ions 
Ionisable a substance that have a net electric charge by adding 
or removing one or more electrons 
Isotope atoms that contain the same number of protons but a 
different number of neutrons 
Lentic a body of still water, i.e. a pond or a lake 
Lipophilic having an affinity for lipids 
Lotic a body of moving water, i.e. a river or a stream 
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Metabolism a process involving a set of chemical reactions that 
modifies a molecule into another for storage, or for 
immediate use in another reaction or as a by product 
Microsome vesicles in the endoplasmic reticulum 
Neutral relating to a substance that has neither positive nor 
negative electric charge 
Oxidation a process in which a portion of electronegative 
substituent is increased i.e., the increased portion of 
oxygen 
Passive diffusion a first order process that describes movement of 
lipophilic compounds across a membrane down a 
concentration gradient 
Phagocytosis  invagination of the membrane to engulf particles, a 
mechanism where insoluble compounds can be 
absorbed 
Pharmacodynamics event consequent on interaction of the pharmaceutical 
with its receptor or site of action 
Pharmacokinetic the relationship between the time course of the 
pharmaceutical concentrations attained in different 
regions of an organism during and after dosing 
Pharmacological relating to the pharmacology of a compound 
Pinocytosis invagination of the membrane to engulf fluid together 
with its contents, a mechanism where insoluble 
compounds can be absorbed 
Potable safe to drink or drinkable 
Predation a biological interaction where a predator (an organism 
that is hunting) feeds on its prey (the organism that is 
attacked) 
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Quenching a process that interferes with the transmission of light 
from a solution, i.e. colour, refraction of photons by 
chemical 
Reduction a process in which a portion of electronegative 
substituent is deceased i.e., the increased portion of 
hydrogen to decrease the partition of oxygen 
Solvation which there is some chemical association between the 
molecules of a solute and those of the solvent 
Sorption absorption and adsorption considered as a single 
process 
Steric factors relates to spatial arrangement of atoms in a molecule 
Target site a specific site of action for a substance, i.e. a receptor, 
ion channel or enzyme 
Trophic transfer  the transfer of chemicals (xenobiotics or nutrients) from 
one organism to another through the biological levels 
of a food chain 
Xenobiotic a substance which is found in an organism or nature 
but which is not normally produced or expected to be 
present in it 
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